<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> therapy with parenteral amiodarone ( 2300 mg in 3 days ) and other measures <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> dosage <extra_id_5> 2300 mg <extra_id_1> <extra_id_0> route <extra_id_5> parenteral <extra_id_1> <extra_id_0> duration <extra_id_5> 3 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 3 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> congestive heart failure <extra_id_1> <extra_id_0> effect <extra_id_5> jaundice , marked increase in serum transaminase levels and fall in prothrombin time , and histologic changes of severe centrilobular necrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> taking <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> 30 - year history of rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> low dose methotrexate weekly over a 10 - month period <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> low dose <extra_id_1> <extra_id_0> duration <extra_id_5> 10 - month <extra_id_1> <extra_id_0> frequency <extra_id_5> weekly <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 10 - month <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> 30 - year history of rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> non - Hodgkin lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> prevent <extra_id_0> subject <extra_id_5> patients with renal impairment <extra_id_1> <extra_id_0> subject disorder <extra_id_5> renal impairment <extra_id_1> <extra_id_0> treatment <extra_id_5> cautious use of alum irrigation <extra_id_1> <extra_id_0> drug <extra_id_5> alum <extra_id_1> <extra_id_0> route <extra_id_5> irrigation <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> renal impairment <extra_id_1> <extra_id_0> effect <extra_id_5> excessive accumulation and toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> A 44 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 44 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic low back pain <extra_id_1> <extra_id_0> treatment <extra_id_5> naproxen <extra_id_1> <extra_id_0> treatment <extra_id_5> oxaprozin <extra_id_1> <extra_id_0> drug <extra_id_5> naproxen <extra_id_1> <extra_id_0> drug <extra_id_5> oxaprozin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic low back pain <extra_id_1> <extra_id_0> effect <extra_id_5> tense bullae and cutaneous fragility on the face and the back of the hands <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurring <extra_id_0> subject <extra_id_5> a middle - aged man <extra_id_1> <extra_id_0> age <extra_id_5> middle - aged <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic sinusitis <extra_id_1> <extra_id_0> treatment <extra_id_5> pseudoephedrine <extra_id_1> <extra_id_0> drug <extra_id_5> pseudoephedrine <extra_id_1> <extra_id_0> duration <extra_id_5> one year <extra_id_1> <extra_id_0> frequency <extra_id_5> daily <extra_id_1> <extra_id_0> time elapsed <extra_id_5> one year <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic sinusitis <extra_id_1> <extra_id_0> effect <extra_id_5> intracerebral hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developing <extra_id_0> subject <extra_id_5> a patient with rheumatoid arthritis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> Lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> relationship <extra_id_0> subject <extra_id_5> this patient <extra_id_1> <extra_id_0> treatment <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> drug <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> effect <extra_id_5> AIN <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> exposed <extra_id_0> subject <extra_id_5> fetus <extra_id_1> <extra_id_0> age <extra_id_5> fetus <extra_id_1> <extra_id_0> treatment <extra_id_5> disulfiram <extra_id_1> <extra_id_0> drug <extra_id_5> disulfiram <extra_id_1> <extra_id_0> effect <extra_id_5> potential teratogen <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> subject <extra_id_5> 2 - 16 % of patients <extra_id_1> <extra_id_0> population <extra_id_5> 2 - 16 % <extra_id_1> <extra_id_0> subject disorder <extra_id_5> pediatric neoplasms <extra_id_1> <extra_id_0> treatment <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> pediatric neoplasms <extra_id_1> <extra_id_0> effect <extra_id_5> Pancreatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> statin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> statin <extra_id_1> <extra_id_0> effect <extra_id_5> Myopathy <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> effect <extra_id_5> anaphylaxis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Mitomycin - C <extra_id_1> <extra_id_0> drug <extra_id_5> Mitomycin - C <extra_id_1> <extra_id_0> effect <extra_id_5> hemolytic uremic syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> propylthiouracil ( PTU ) <extra_id_1> <extra_id_0> drug <extra_id_5> propylthiouracil <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hyperthyroidism <extra_id_1> <extra_id_0> effect <extra_id_5> Acute hepatic failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> on <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> chronic diphenylhydantoin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> diphenylhydantoin <extra_id_1> <extra_id_0> effect <extra_id_5> Monoclonal gammopathy and subsequent multiple myeloma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient with systemic lupus erythematosus and tubulointerstitial renal disease <extra_id_1> <extra_id_0> subject disorder <extra_id_5> systemic lupus erythematosus <extra_id_1> <extra_id_0> treatment <extra_id_5> cyclosporine A <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporine A <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> systemic lupus erythematosus <extra_id_1> <extra_id_0> effect <extra_id_5> nephrotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> AZ <extra_id_1> <extra_id_0> drug <extra_id_5> AZ <extra_id_1> <extra_id_0> effect <extra_id_5> acute hemorrhagic gastritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulted <extra_id_0> treatment <extra_id_5> 19 days of treatment with 5 - fluorocytosine and amphotericin B. <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorocytosine <extra_id_1> <extra_id_0> drug <extra_id_5> amphotericin B. <extra_id_1> <extra_id_0> duration <extra_id_5> 19 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 19 days <extra_id_1> <extra_id_0> combination drug <extra_id_5> 5 - fluorocytosine <extra_id_1> <extra_id_0> combination drug <extra_id_5> amphotericin B. <extra_id_1> <extra_id_0> effect <extra_id_5> Toxic epidermal necrolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> relationship <extra_id_0> treatment <extra_id_5> phenylpropanolamine <extra_id_1> <extra_id_0> drug <extra_id_5> phenylpropanolamine <extra_id_1> <extra_id_0> effect <extra_id_5> stroke <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 61 - year - old woman with no apparent risk factors for liver injury <extra_id_1> <extra_id_0> age <extra_id_5> 61 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> onychomycosis <extra_id_1> <extra_id_0> treatment <extra_id_5> one week after the final dose of a long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk ) <extra_id_1> <extra_id_0> drug <extra_id_5> itraconazole <extra_id_1> <extra_id_0> dosage <extra_id_5> 200 mg <extra_id_1> <extra_id_0> route <extra_id_5> orally <extra_id_1> <extra_id_0> duration <extra_id_5> one week <extra_id_1> <extra_id_0> time elapsed <extra_id_5> one week <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> onychomycosis <extra_id_1> <extra_id_0> effect <extra_id_5> acute hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> a patient suffering from acute hemorrhagic gastritis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> acute hemorrhagic gastritis <extra_id_1> <extra_id_0> treatment <extra_id_5> AZ <extra_id_1> <extra_id_0> drug <extra_id_5> AZ <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute hemorrhagic gastritis <extra_id_1> <extra_id_0> effect <extra_id_5> chronic renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> subject <extra_id_5> a pregnant patient with myotonic dystrophy <extra_id_1> <extra_id_0> subject disorder <extra_id_5> myotonic dystrophy <extra_id_1> <extra_id_0> treatment <extra_id_5> tocolysis with oral ritodrine hydrochloride <extra_id_1> <extra_id_0> drug <extra_id_5> ritodrine hydrochloride <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> myotonic dystrophy <extra_id_1> <extra_id_0> effect <extra_id_5> Rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient with a renal tubular defect <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> subject disorder <extra_id_5> renal tubular defect <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> renal tubular defect <extra_id_1> <extra_id_0> effect <extra_id_5> hypoprothrombinemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> toxicity <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> effect <extra_id_5> Painful erosion of psoriatic plaques <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> an acromegalic patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> acromegalic <extra_id_1> <extra_id_0> treatment <extra_id_5> combined treatment with pegvisomant and octreotide long - acting repeatable <extra_id_1> <extra_id_0> drug <extra_id_5> pegvisomant <extra_id_1> <extra_id_0> drug <extra_id_5> octreotide long - acting repeatable <extra_id_1> <extra_id_0> combination drug <extra_id_5> pegvisomant <extra_id_1> <extra_id_0> combination drug <extra_id_5> octreotide long - acting repeatable <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acromegalic <extra_id_1> <extra_id_0> effect <extra_id_5> hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> a patient in a promethazine - induced coma <extra_id_1> <extra_id_0> subject disorder <extra_id_5> promethazine - induced coma <extra_id_1> <extra_id_0> treatment <extra_id_5> treatment with flumazenil <extra_id_1> <extra_id_0> drug <extra_id_5> flumazenil <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> promethazine - induced coma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> patients 1 and 3 <extra_id_1> <extra_id_0> population <extra_id_5> 1 and 3 <extra_id_1> <extra_id_0> treatment <extra_id_5> 1 month after the second ranibizumab injection <extra_id_1> <extra_id_0> treatment <extra_id_5> 1 month after the first ranibizumab <extra_id_1> <extra_id_0> drug <extra_id_5> ranibizumab <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 1 month <extra_id_1> <extra_id_0> effect <extra_id_5> Ocular hypertension <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> drug <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> effect <extra_id_5> Priapism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> association <extra_id_0> treatment <extra_id_5> metronidazole therapy <extra_id_1> <extra_id_0> drug <extra_id_5> metronidazole <extra_id_1> <extra_id_0> effect <extra_id_5> Reversible MR imaging and MR spectroscopy abnormalities <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> treatment <extra_id_5> rifabutin <extra_id_1> <extra_id_0> drug <extra_id_5> rifabutin <extra_id_1> <extra_id_0> effect <extra_id_5> corneal endothelial deposits <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a child <extra_id_1> <extra_id_0> age <extra_id_5> child <extra_id_1> <extra_id_0> treatment <extra_id_5> calcineurin <extra_id_1> <extra_id_0> drug <extra_id_5> calcineurin <extra_id_1> <extra_id_0> effect <extra_id_5> pain syndrome ( CIPS ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulting <extra_id_0> subject <extra_id_5> a male patient with psoriasis and hypertension <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> subject disorder <extra_id_5> psoriasis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> hypertension <extra_id_1> <extra_id_0> treatment <extra_id_5> tacalcitol ointment and thiazide <extra_id_1> <extra_id_0> drug <extra_id_5> tacalcitol <extra_id_1> <extra_id_0> drug <extra_id_5> thiazide <extra_id_1> <extra_id_0> combination drug <extra_id_5> tacalcitol <extra_id_1> <extra_id_0> combination drug <extra_id_5> thiazide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> psoriasis <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hypertension <extra_id_1> <extra_id_0> effect <extra_id_5> hypercalciuria and hypercalcemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> calcium hydroxylapatite injection <extra_id_1> <extra_id_0> drug <extra_id_5> calcium hydroxylapatite <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> granulomatous reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> interaction <extra_id_0> treatment <extra_id_5> MTX and a variety of non - steroidal , anti - inflammatory drugs ( NSAIDs ) <extra_id_1> <extra_id_0> drug <extra_id_5> MTX <extra_id_1> <extra_id_0> drug <extra_id_5> non - steroidal , anti - inflammatory drugs ( NSAIDs ) <extra_id_1> <extra_id_0> combination drug <extra_id_5> MTX <extra_id_1> <extra_id_0> combination drug <extra_id_5> non - steroidal , anti - inflammatory drugs ( NSAIDs ) <extra_id_1> <extra_id_0> effect <extra_id_5> various clinical manifestations including acute renal failure , pancytopenia , vomiting , diarrhea , elevated liver transaminases , jaundice , mucosal ulcerations , and pyrexia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> subject <extra_id_5> a patient with alveolar hydatid disease <extra_id_1> <extra_id_0> subject disorder <extra_id_5> alveolar hydatid disease <extra_id_1> <extra_id_0> treatment <extra_id_5> mebendazole <extra_id_1> <extra_id_0> drug <extra_id_5> mebendazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> alveolar hydatid disease <extra_id_1> <extra_id_0> effect <extra_id_5> side effects of alopecia and granulocytopenia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> causes <extra_id_0> subject <extra_id_5> 0.67 % of patients <extra_id_1> <extra_id_0> population <extra_id_5> 0.67 % <extra_id_1> <extra_id_0> treatment <extra_id_5> Niacin <extra_id_1> <extra_id_0> drug <extra_id_5> Niacin <extra_id_1> <extra_id_0> dosage <extra_id_5> high doses <extra_id_1> <extra_id_0> effect <extra_id_5> reversible toxic cystoid maculopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> develop <extra_id_0> subject <extra_id_5> tuberculosis patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> tuberculosis <extra_id_1> <extra_id_0> treatment <extra_id_5> isoniazid <extra_id_1> <extra_id_0> drug <extra_id_5> isoniazid <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> tuberculosis <extra_id_1> <extra_id_0> effect <extra_id_5> histamine reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> adverse effect <extra_id_0> treatment <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> drug <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> effect <extra_id_5> Priapism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> interaction <extra_id_0> subject <extra_id_5> a patient treated after several thromboembolic events <extra_id_1> <extra_id_0> subject disorder <extra_id_5> thromboembolic events <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> thromboembolic events <extra_id_1> <extra_id_0> effect <extra_id_5> interaction of smokeless tobacco with warfarin <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> three cases <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> treatment <extra_id_5> cyproterone acetate <extra_id_1> <extra_id_0> drug <extra_id_5> cyproterone acetate <extra_id_1> <extra_id_0> effect <extra_id_5> Hepatotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> of <extra_id_0> treatment <extra_id_5> intrathecal methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal <extra_id_1> <extra_id_0> effect <extra_id_5> Neurotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Isonicotinic acid hydrazide <extra_id_1> <extra_id_0> drug <extra_id_5> Isonicotinic acid hydrazide <extra_id_1> <extra_id_0> effect <extra_id_5> anagen effluvium and associated lichenoid eruption <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurring <extra_id_0> subject <extra_id_5> one case <extra_id_1> <extra_id_0> population <extra_id_5> one <extra_id_1> <extra_id_0> subject disorder <extra_id_5> onychomycosis <extra_id_1> <extra_id_0> treatment <extra_id_5> pulse therapy with itraconazole <extra_id_1> <extra_id_0> drug <extra_id_5> itraconazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> onychomycosis <extra_id_1> <extra_id_0> effect <extra_id_5> severe symptomatic hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> by <extra_id_0> treatment <extra_id_5> trazodone <extra_id_1> <extra_id_0> drug <extra_id_5> trazodone <extra_id_1> <extra_id_0> effect <extra_id_5> movement disorder <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> subsequent <extra_id_0> treatment <extra_id_5> high doses of CCNU <extra_id_1> <extra_id_0> drug <extra_id_5> CCNU <extra_id_1> <extra_id_0> dosage <extra_id_5> high doses <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic myeloid leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> Pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> subject <extra_id_5> patients with cancer <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> 5 - fluorouracil ( 5 - FU) - based chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cancer <extra_id_1> <extra_id_0> effect <extra_id_5> potentially lethal adverse reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> administration of parenteral verapamil <extra_id_1> <extra_id_0> drug <extra_id_5> verapamil <extra_id_1> <extra_id_0> route <extra_id_5> parenteral <extra_id_1> <extra_id_0> effect <extra_id_5> sustained hypotension <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> human immunodeficiency viral infection <extra_id_1> <extra_id_0> subject disorder <extra_id_5> opioid abuse <extra_id_1> <extra_id_0> treatment <extra_id_5> Methadone <extra_id_1> <extra_id_0> drug <extra_id_5> Methadone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> opioid abuse <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> from <extra_id_0> subject <extra_id_5> he <extra_id_1> <extra_id_0> gender <extra_id_5> he <extra_id_1> <extra_id_0> treatment <extra_id_5> phytonadione <extra_id_1> <extra_id_0> drug <extra_id_5> phytonadione <extra_id_1> <extra_id_0> duration <extra_id_5> a week <extra_id_1> <extra_id_0> time elapsed <extra_id_5> a week <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> phytonadione <extra_id_1> <extra_id_0> effect <extra_id_5> supratherapeutic <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> A 70 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 70 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> atrial fibrillation <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> atrial fibrillation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> a child with systemic lupus erythematosus <extra_id_1> <extra_id_0> age <extra_id_5> child <extra_id_1> <extra_id_0> subject disorder <extra_id_5> systemic lupus erythematosus <extra_id_1> <extra_id_0> treatment <extra_id_5> prednisolone and azathioprine <extra_id_1> <extra_id_0> drug <extra_id_5> prednisolone <extra_id_1> <extra_id_0> drug <extra_id_5> azathioprine <extra_id_1> <extra_id_0> combination drug <extra_id_5> prednisolone <extra_id_1> <extra_id_0> combination drug <extra_id_5> azathioprine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> systemic lupus erythematosus <extra_id_1> <extra_id_0> effect <extra_id_5> fatal cryptococcal meningitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> a patient with chronic renal failure <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic renal failure <extra_id_1> <extra_id_0> treatment <extra_id_5> acetazolamide <extra_id_1> <extra_id_0> drug <extra_id_5> acetazolamide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic renal failure <extra_id_1> <extra_id_0> effect <extra_id_5> Acute hemorrhagic gastritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> acted <extra_id_0> treatment <extra_id_5> trazodone <extra_id_1> <extra_id_0> drug <extra_id_5> trazodone <extra_id_1> <extra_id_0> effect <extra_id_5> movement disorder <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> precipitate <extra_id_0> treatment <extra_id_5> itraconazole <extra_id_1> <extra_id_0> drug <extra_id_5> itraconazole <extra_id_1> <extra_id_0> effect <extra_id_5> severe and irreversible hepatotoxic events <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> two patients with mycosis fungoides <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> mycosis fungoides <extra_id_1> <extra_id_0> treatment <extra_id_5> psoralens plus long - wave ultraviolet radiation ( PUVA ) <extra_id_1> <extra_id_0> drug <extra_id_5> psoralens <extra_id_1> <extra_id_0> drug <extra_id_5> long - wave ultraviolet radiation ( PUVA ) <extra_id_1> <extra_id_0> combination drug <extra_id_5> psoralens <extra_id_1> <extra_id_0> combination drug <extra_id_5> long - wave ultraviolet radiation ( PUVA ) <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> mycosis fungoides <extra_id_1> <extra_id_0> effect <extra_id_5> squamous cell carcinoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient with acute promyelocytic leukemia <extra_id_1> <extra_id_0> subject disorder <extra_id_5> acute promyelocytic leukemia <extra_id_1> <extra_id_0> treatment <extra_id_5> all - trans retinoic acid <extra_id_1> <extra_id_0> drug <extra_id_5> all - trans retinoic acid <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute promyelocytic leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> Scrotal ulceration <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 61 year - old male patient <extra_id_1> <extra_id_0> age <extra_id_5> 61 year - old <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> treatment <extra_id_5> theophylline <extra_id_1> <extra_id_0> drug <extra_id_5> theophylline <extra_id_1> <extra_id_0> effect <extra_id_5> gynecomastia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> dextran - 40 <extra_id_1> <extra_id_0> drug <extra_id_5> dextran - 40 <extra_id_1> <extra_id_0> effect <extra_id_5> renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> secondary <extra_id_0> subject <extra_id_5> a patient with advanced - stage large cell neuroendocrine carcinoma of the cervix <extra_id_1> <extra_id_0> subject disorder <extra_id_5> advanced - stage large cell neuroendocrine carcinoma of the cervix <extra_id_1> <extra_id_0> treatment <extra_id_5> cisplatin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> cisplatin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> advanced - stage large cell neuroendocrine carcinoma of the cervix <extra_id_1> <extra_id_0> effect <extra_id_5> syndrome of inappropriate antidiuretic hormone ( SIADH ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> taking <extra_id_0> subject <extra_id_5> An 80 - year - old white female <extra_id_1> <extra_id_0> age <extra_id_5> 80 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> race <extra_id_5> white <extra_id_1> <extra_id_0> subject disorder <extra_id_5> paroxysmal atrial fibrillation <extra_id_1> <extra_id_0> treatment <extra_id_5> propafenone 900 mg / d for > 10 years <extra_id_1> <extra_id_0> drug <extra_id_5> propafenone <extra_id_1> <extra_id_0> dosage <extra_id_5> 900 mg / d <extra_id_1> <extra_id_0> duration <extra_id_5> > 10 years <extra_id_1> <extra_id_0> time elapsed <extra_id_5> > 10 years <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> paroxysmal atrial fibrillation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> with <extra_id_0> subject <extra_id_5> 109 patients <extra_id_1> <extra_id_0> population <extra_id_5> 109 <extra_id_1> <extra_id_0> treatment <extra_id_5> omeprazole <extra_id_1> <extra_id_0> treatment <extra_id_5> placebo <extra_id_1> <extra_id_0> drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> drug <extra_id_5> placebo <extra_id_1> <extra_id_0> effect <extra_id_5> cardiovascular event <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> to <extra_id_0> treatment <extra_id_5> zomepirac <extra_id_1> <extra_id_0> drug <extra_id_5> zomepirac <extra_id_1> <extra_id_0> effect <extra_id_5> anaphylactoid reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> etanercept <extra_id_1> <extra_id_0> drug <extra_id_5> etanercept <extra_id_1> <extra_id_0> effect <extra_id_5> CD <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> trigger <extra_id_0> treatment <extra_id_5> bleomycin <extra_id_1> <extra_id_0> drug <extra_id_5> bleomycin <extra_id_1> <extra_id_0> effect <extra_id_5> acral vascular toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> in <extra_id_0> subject <extra_id_5> patients with severe recalcitrant nodular acne <extra_id_1> <extra_id_0> subject disorder <extra_id_5> severe recalcitrant nodular acne <extra_id_1> <extra_id_0> treatment <extra_id_5> isotretinoin - Lidose <extra_id_1> <extra_id_0> drug <extra_id_5> isotretinoin <extra_id_1> <extra_id_0> dosage <extra_id_5> Lidose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> severe recalcitrant nodular acne <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> corticosteroid <extra_id_1> <extra_id_0> drug <extra_id_5> corticosteroid <extra_id_1> <extra_id_0> effect <extra_id_5> vision loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> subject <extra_id_5> this patient <extra_id_1> <extra_id_0> treatment <extra_id_5> parenteral amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> route <extra_id_5> parenteral <extra_id_1> <extra_id_0> effect <extra_id_5> acute hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> appeared <extra_id_0> subject <extra_id_5> his <extra_id_1> <extra_id_0> gender <extra_id_5> his <extra_id_1> <extra_id_0> treatment <extra_id_5> Twenty - four hours after the administration of gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> duration <extra_id_5> Twenty - four hours <extra_id_1> <extra_id_0> time elapsed <extra_id_5> Twenty - four hours <extra_id_1> <extra_id_0> effect <extra_id_5> symmetric , bullous , herpetiform eruption <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reduced <extra_id_0> treatment <extra_id_5> omeprazole <extra_id_1> <extra_id_0> drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> overt upper gastrointestinal bleeding <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> association <extra_id_0> treatment <extra_id_5> phenothiazine overdose <extra_id_1> <extra_id_0> drug <extra_id_5> phenothiazine <extra_id_1> <extra_id_0> dosage <extra_id_5> overdose <extra_id_1> <extra_id_0> effect <extra_id_5> respiratory distress syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> risk <extra_id_0> subject <extra_id_5> Patients from endemic areas referred to transplant centers <extra_id_1> <extra_id_0> subject disorder <extra_id_5> graft - versus - host disease <extra_id_1> <extra_id_0> treatment <extra_id_5> long - term prednisone <extra_id_1> <extra_id_0> drug <extra_id_5> prednisone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> graft - versus - host disease <extra_id_1> <extra_id_0> effect <extra_id_5> disseminated histoplasmosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> tamoxifen <extra_id_1> <extra_id_0> drug <extra_id_5> tamoxifen <extra_id_1> <extra_id_0> effect <extra_id_5> malignant transformation of endometriosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 28 year old white schizophrenic male <extra_id_1> <extra_id_0> age <extra_id_5> 28 year old <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> race <extra_id_5> white <extra_id_1> <extra_id_0> subject disorder <extra_id_5> schizophrenic <extra_id_1> <extra_id_0> treatment <extra_id_5> risperidone monotherapy for about one year <extra_id_1> <extra_id_0> drug <extra_id_5> risperidone <extra_id_1> <extra_id_0> duration <extra_id_5> one year <extra_id_1> <extra_id_0> time elapsed <extra_id_5> one year <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> schizophrenic <extra_id_1> <extra_id_0> effect <extra_id_5> dyskinetic movements <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> less likely <extra_id_0> subject <extra_id_5> Subjects <extra_id_1> <extra_id_0> treatment <extra_id_5> ivacaftor <extra_id_1> <extra_id_0> treatment <extra_id_5> placebo <extra_id_1> <extra_id_0> drug <extra_id_5> ivacaftor <extra_id_1> <extra_id_0> drug <extra_id_5> placebo <extra_id_1> <extra_id_0> duration <extra_id_5> through week 48 ( P<unk>0.001 ) <extra_id_1> <extra_id_0> time elapsed <extra_id_5> through week 48 ( P<unk>0.001 ) <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary exacerbation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> zolmitriptan <extra_id_1> <extra_id_0> drug <extra_id_5> zolmitriptan <extra_id_1> <extra_id_0> effect <extra_id_5> Spinal cord infarction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a 29 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 29 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic myelogenous leukemia <extra_id_1> <extra_id_0> treatment <extra_id_5> a 22 - month use of recombinant interferon alpha - 2b <extra_id_1> <extra_id_0> drug <extra_id_5> recombinant interferon alpha - 2b <extra_id_1> <extra_id_0> duration <extra_id_5> 22 - month <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 22 - month <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic myelogenous leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occur <extra_id_0> treatment <extra_id_5> chlorpropamide <extra_id_1> <extra_id_0> drug <extra_id_5> chlorpropamide <extra_id_1> <extra_id_0> effect <extra_id_5> intrahepatic cholestasis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Risperidone <extra_id_1> <extra_id_0> drug <extra_id_5> Risperidone <extra_id_1> <extra_id_0> effect <extra_id_5> tardive dyskinesia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> pentazocine <extra_id_1> <extra_id_0> drug <extra_id_5> pentazocine <extra_id_1> <extra_id_0> effect <extra_id_5> irreversible drug - induced fibrous myopathy and localized neuropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> observed <extra_id_0> treatment <extra_id_5> 99Tc - dimercaptosuccinic acid <extra_id_1> <extra_id_0> drug <extra_id_5> 99Tc - dimercaptosuccinic acid <extra_id_1> <extra_id_0> effect <extra_id_5> fall of the filtration fraction , the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> maculopathy <extra_id_0> treatment <extra_id_5> Niacin <extra_id_1> <extra_id_0> drug <extra_id_5> Niacin <extra_id_1> <extra_id_0> effect <extra_id_5> maculopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> led <extra_id_0> treatment <extra_id_5> clobazam and etravirine <extra_id_1> <extra_id_0> drug <extra_id_5> clobazam <extra_id_1> <extra_id_0> drug <extra_id_5> etravirine <extra_id_1> <extra_id_0> combination drug <extra_id_5> clobazam <extra_id_1> <extra_id_0> combination drug <extra_id_5> etravirine <extra_id_1> <extra_id_0> effect <extra_id_5> increased concentrations of clobazam and its pharmacologically active metabolite , N - desmethylclobazam <extra_id_1> <extra_id_0> effect <extra_id_5> neurotoxic symptoms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> two other cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> long - term cyclophosphamide treatment <extra_id_1> <extra_id_0> drug <extra_id_5> cyclophosphamide <extra_id_1> <extra_id_0> effect <extra_id_5> hepatic angiosarcoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> in <extra_id_0> treatment <extra_id_5> amphotericin B <extra_id_1> <extra_id_0> drug <extra_id_5> amphotericin B <extra_id_1> <extra_id_0> effect <extra_id_5> cutaneous leucocytoclastic vasculitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> with <extra_id_0> treatment <extra_id_5> olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> effect <extra_id_5> hyperglycemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> the same patient <extra_id_1> <extra_id_0> treatment <extra_id_5> antiretroviral drug <extra_id_1> <extra_id_0> drug <extra_id_5> antiretroviral drug <extra_id_1> <extra_id_0> effect <extra_id_5> two severe adverse reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> thiethylperazine maleate ( thiethylperazine ) <extra_id_1> <extra_id_0> drug <extra_id_5> thiethylperazine maleate <extra_id_1> <extra_id_0> effect <extra_id_5> successive anaphylactic reaction and extra - pyramidal syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> dextran - 40 <extra_id_1> <extra_id_0> drug <extra_id_5> dextran - 40 <extra_id_1> <extra_id_0> effect <extra_id_5> Renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> 5 - fluorouracil and oxaliplatinum combined chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> drug <extra_id_5> oxaliplatinum <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> combination drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> combination drug <extra_id_5> oxaliplatinum <extra_id_1> <extra_id_0> effect <extra_id_5> Acute lung injury <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> heparin <extra_id_1> <extra_id_0> drug <extra_id_5> heparin <extra_id_1> <extra_id_0> effect <extra_id_5> thrombocytopenia ( HIT ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> atovaquone <extra_id_1> <extra_id_0> drug <extra_id_5> atovaquone <extra_id_1> <extra_id_0> effect <extra_id_5> vortex keratopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> bleomycin and methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> bleomycin <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> combination drug <extra_id_5> bleomycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> effect <extra_id_5> Gangrene of the fingertips <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induce <extra_id_0> subject <extra_id_5> children <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> treatment <extra_id_5> CBZ <extra_id_1> <extra_id_0> drug <extra_id_5> CBZ <extra_id_1> <extra_id_0> effect <extra_id_5> simple motor tics <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> propranolol overdose <extra_id_1> <extra_id_0> treatment <extra_id_5> glucagon <extra_id_1> <extra_id_0> drug <extra_id_5> propranolol <extra_id_1> <extra_id_0> drug <extra_id_5> glucagon <extra_id_1> <extra_id_0> dosage <extra_id_5> overdose <extra_id_1> <extra_id_0> effect <extra_id_5> Esophageal spasm <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> diagnosed <extra_id_0> subject <extra_id_5> She <extra_id_1> <extra_id_0> gender <extra_id_5> She <extra_id_1> <extra_id_0> treatment <extra_id_5> AZ <extra_id_1> <extra_id_0> drug <extra_id_5> AZ <extra_id_1> <extra_id_0> effect <extra_id_5> intoxication <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> massive ingestion of oolong tea <extra_id_1> <extra_id_0> drug <extra_id_5> oolong <extra_id_1> <extra_id_0> route <extra_id_5> ingestion <extra_id_1> <extra_id_0> effect <extra_id_5> Severe rhabdomyolysis <extra_id_1> <extra_id_0> effect <extra_id_5> caffeine intoxication with coexisting hyponatremia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> healed <extra_id_0> treatment <extra_id_5> withholding ATRA <extra_id_1> <extra_id_0> drug <extra_id_5> ATRA <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> ulcer <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulting <extra_id_0> treatment <extra_id_5> Gemfibrozil - warfarin drug interaction <extra_id_1> <extra_id_0> drug <extra_id_5> Gemfibrozil <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> combination drug <extra_id_5> Gemfibrozil <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> profound hypoprothrombinemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side effect <extra_id_0> treatment <extra_id_5> clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> clozapine <extra_id_1> <extra_id_0> effect <extra_id_5> Drug - induced eosinophilia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> atovaquone <extra_id_1> <extra_id_0> drug <extra_id_5> atovaquone <extra_id_1> <extra_id_0> effect <extra_id_5> Vortex keratopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> owing <extra_id_0> treatment <extra_id_5> thalidomide treatment <extra_id_1> <extra_id_0> drug <extra_id_5> thalidomide <extra_id_1> <extra_id_0> effect <extra_id_5> Sustained ventricular tachycardia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> substitution of acetohexamide for acetazolamide <extra_id_1> <extra_id_0> drug <extra_id_5> acetohexamide <extra_id_1> <extra_id_0> drug <extra_id_5> acetazolamide <extra_id_1> <extra_id_0> effect <extra_id_5> systemic hypoglycemic reaction resulting in head trauma and confusion <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> association <extra_id_0> treatment <extra_id_5> Ritalin <extra_id_1> <extra_id_0> drug <extra_id_5> Ritalin <extra_id_1> <extra_id_0> effect <extra_id_5> glaucoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> After <extra_id_0> treatment <extra_id_5> two - month interruption of interferon administration <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alpha <extra_id_1> <extra_id_0> duration <extra_id_5> two - month <extra_id_1> <extra_id_0> time elapsed <extra_id_5> two - month <extra_id_1> <extra_id_0> effect <extra_id_5> neurological manifestations <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> interaction between SSRIs and fentanyl <extra_id_1> <extra_id_0> drug <extra_id_5> SSRIs <extra_id_1> <extra_id_0> drug <extra_id_5> fentanyl <extra_id_1> <extra_id_0> combination drug <extra_id_5> SSRIs <extra_id_1> <extra_id_0> combination drug <extra_id_5> fentanyl <extra_id_1> <extra_id_0> effect <extra_id_5> serotonin syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> dextran <extra_id_1> <extra_id_0> drug <extra_id_5> dextran <extra_id_1> <extra_id_0> effect <extra_id_5> renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> secondary <extra_id_0> treatment <extra_id_5> pamidronate <extra_id_1> <extra_id_0> drug <extra_id_5> pamidronate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hypercalcemia <extra_id_1> <extra_id_0> effect <extra_id_5> acute vitamin D intoxication <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> acenocoumarol <extra_id_1> <extra_id_0> drug <extra_id_5> acenocoumarol <extra_id_1> <extra_id_0> effect <extra_id_5> Early overanticoagulation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurring <extra_id_0> treatment <extra_id_5> CHOP chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> CHOP <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> effect <extra_id_5> supravenous hyperpigmentation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> metronidazole treatment <extra_id_1> <extra_id_0> drug <extra_id_5> metronidazole <extra_id_1> <extra_id_0> effect <extra_id_5> persistent lactate elevation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> intravesical alum irrigations <extra_id_1> <extra_id_0> drug <extra_id_5> alum <extra_id_1> <extra_id_0> route <extra_id_5> intravesical <extra_id_1> <extra_id_0> effect <extra_id_5> Encephalopathy and seizures <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> subject <extra_id_5> these patients <extra_id_1> <extra_id_0> treatment <extra_id_5> SSRI - drugs <extra_id_1> <extra_id_0> drug <extra_id_5> SSRI - drugs <extra_id_1> <extra_id_0> effect <extra_id_5> Dermal side reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> prescribed <extra_id_0> subject <extra_id_5> A febrile 36 - year - old seaman from Mumbai ( Bombay ) <extra_id_1> <extra_id_0> age <extra_id_5> 36 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> seaman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> malaria <extra_id_1> <extra_id_0> treatment <extra_id_5> > 5 times the usual dose of chloroquine <extra_id_1> <extra_id_0> drug <extra_id_5> chloroquine <extra_id_1> <extra_id_0> dosage <extra_id_5> > 5 times the usual dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> malaria <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> two instillations of epirubicin <extra_id_1> <extra_id_0> drug <extra_id_5> epirubicin <extra_id_1> <extra_id_0> route <extra_id_5> instillations <extra_id_1> <extra_id_0> effect <extra_id_5> significant morbidity related to primary and secondary perforation of the bladder <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side effect <extra_id_0> treatment <extra_id_5> voriconazole <extra_id_1> <extra_id_0> drug <extra_id_5> voriconazole <extra_id_1> <extra_id_0> effect <extra_id_5> Angio - oedema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reduced <extra_id_0> treatment <extra_id_5> Oxycodone - gabapentin <extra_id_1> <extra_id_0> drug <extra_id_5> Oxycodone <extra_id_1> <extra_id_0> drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> combination drug <extra_id_5> Oxycodone <extra_id_1> <extra_id_0> combination drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> pain score <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> clozapine <extra_id_1> <extra_id_0> effect <extra_id_5> neutropenia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> had <extra_id_0> subject <extra_id_5> Five of 70 patients <extra_id_1> <extra_id_0> population <extra_id_5> Five of 70 <extra_id_1> <extra_id_0> treatment <extra_id_5> leflunomide therapy <extra_id_1> <extra_id_0> drug <extra_id_5> leflunomide <extra_id_1> <extra_id_0> effect <extra_id_5> significant weight loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> link <extra_id_0> subject <extra_id_5> a patient with an AVM <extra_id_1> <extra_id_0> subject disorder <extra_id_5> AVM <extra_id_1> <extra_id_0> treatment <extra_id_5> phenylpropanolamine <extra_id_1> <extra_id_0> drug <extra_id_5> phenylpropanolamine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> AVM <extra_id_1> <extra_id_0> effect <extra_id_5> intracerebral hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> thiethylperazine <extra_id_1> <extra_id_0> drug <extra_id_5> thiethylperazine <extra_id_1> <extra_id_0> effect <extra_id_5> Anaphylactic reaction and unrelated , subsequent , known side effects <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient with severe acyclovir - induced neurotoxicity <extra_id_1> <extra_id_0> treatment <extra_id_5> acyclovir <extra_id_1> <extra_id_0> drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> effect <extra_id_5> neurotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> arise <extra_id_0> treatment <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> effect <extra_id_5> Radiation recall <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> respond <extra_id_0> subject <extra_id_5> Most cases of pancreatitis associated with L - asparaginase toxicity <extra_id_1> <extra_id_0> population <extra_id_5> Most <extra_id_1> <extra_id_0> subject disorder <extra_id_5> L - asparaginase toxicity <extra_id_1> <extra_id_0> treatment <extra_id_5> nasogastric decompression and intravenous hyperalimentation <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> route <extra_id_5> nasogastric decompression <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> L - asparaginase toxicity <extra_id_1> <extra_id_0> effect <extra_id_5> pancreatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> Shortly after commencing the drug <extra_id_1> <extra_id_0> drug <extra_id_5> drug <extra_id_1> <extra_id_0> time elapsed <extra_id_5> Shortly after <extra_id_1> <extra_id_0> effect <extra_id_5> a severe adverse drug reaction manifesting as Drug Reaction ( or Rash ) with Eosinophilia and Systemic Symptoms ( DRESS ) syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> risperidone <extra_id_1> <extra_id_0> drug <extra_id_5> risperidone <extra_id_1> <extra_id_0> effect <extra_id_5> tardive dyskinesia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> described <extra_id_0> subject <extra_id_5> The patient <extra_id_1> <extra_id_0> treatment <extra_id_5> one hour after infusion of the first dose of penicillin <extra_id_1> <extra_id_0> drug <extra_id_5> penicillin <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> time elapsed <extra_id_5> one hour <extra_id_1> <extra_id_0> effect <extra_id_5> cold with worsening headache and chills <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> pentamidine <extra_id_1> <extra_id_0> drug <extra_id_5> pentamidine <extra_id_1> <extra_id_0> effect <extra_id_5> second - degree heart block and sinus bradycardia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> BCNU <extra_id_1> <extra_id_0> drug <extra_id_5> BCNU <extra_id_1> <extra_id_0> effect <extra_id_5> Fatal pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induce <extra_id_0> subject <extra_id_5> patients with normal renal function <extra_id_1> <extra_id_0> treatment <extra_id_5> losartan <extra_id_1> <extra_id_0> drug <extra_id_5> losartan <extra_id_1> <extra_id_0> effect <extra_id_5> late - onset angioedema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> association <extra_id_0> subject <extra_id_5> Two cases <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> treatment <extra_id_5> diltiazem <extra_id_1> <extra_id_0> drug <extra_id_5> diltiazem <extra_id_1> <extra_id_0> effect <extra_id_5> widespread cutaneous vasculitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> secondary <extra_id_0> treatment <extra_id_5> losartan <extra_id_1> <extra_id_0> drug <extra_id_5> losartan <extra_id_1> <extra_id_0> effect <extra_id_5> angioedema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a young man <extra_id_1> <extra_id_0> age <extra_id_5> young <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> 2 weeks after the administration of leflunomide <extra_id_1> <extra_id_0> drug <extra_id_5> leflunomide <extra_id_1> <extra_id_0> duration <extra_id_5> 2 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 2 weeks <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> rapid - onset short - of - breath , hemoptysis , and severe weakness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> chloroquine <extra_id_1> <extra_id_0> drug <extra_id_5> chloroquine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> resistant vivax malaria <extra_id_1> <extra_id_0> effect <extra_id_5> Toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> subject <extra_id_5> Patients with vitamin B12 deficiency <extra_id_1> <extra_id_0> subject disorder <extra_id_5> vitamin B12 deficiency <extra_id_1> <extra_id_0> treatment <extra_id_5> nitrous oxide anesthesia <extra_id_1> <extra_id_0> drug <extra_id_5> nitrous oxide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> vitamin B12 deficiency <extra_id_1> <extra_id_0> effect <extra_id_5> neurologic deterioration <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> subject <extra_id_5> two patients <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> familiar mediterranean fever ( FMF ) <extra_id_1> <extra_id_0> treatment <extra_id_5> high dose colchicine treatment <extra_id_1> <extra_id_0> drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> dosage <extra_id_5> high dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> familiar mediterranean fever ( FMF ) <extra_id_1> <extra_id_0> effect <extra_id_5> PD <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> two patients <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> salazosulfapyridine ( SASP ) <extra_id_1> <extra_id_0> drug <extra_id_5> salazosulfapyridine <extra_id_1> <extra_id_0> effect <extra_id_5> infectious mononucleosis - like syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> high - dose carmustine infusion <extra_id_1> <extra_id_0> drug <extra_id_5> carmustine <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> effect <extra_id_5> Myocardial ischemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> interaction <extra_id_0> subject <extra_id_5> a bone marrow transplant patient harboring CYP2C19 and CYP3A5 heterozygous mutations <extra_id_1> <extra_id_0> subject disorder <extra_id_5> CYP2C19 and CYP3A5 heterozygous mutations <extra_id_1> <extra_id_0> treatment <extra_id_5> tacrolimus and lansoprazole <extra_id_1> <extra_id_0> drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> drug <extra_id_5> lansoprazole <extra_id_1> <extra_id_0> combination drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> combination drug <extra_id_5> lansoprazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> CYP2C19 and CYP3A5 heterozygous mutations <extra_id_1> <extra_id_0> effect <extra_id_5> Hepatic drug interaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presenting <extra_id_0> treatment <extra_id_5> Gabapentin withdrawal <extra_id_1> <extra_id_0> drug <extra_id_5> Gabapentin <extra_id_1> <extra_id_0> effect <extra_id_5> status epilepticus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> effect <extra_id_5> Atypical ventricular tachycardia ( torsade de pointes ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Colchicine <extra_id_1> <extra_id_0> drug <extra_id_5> Colchicine <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> in <extra_id_0> treatment <extra_id_5> benzodiazepine <extra_id_1> <extra_id_0> drug <extra_id_5> benzodiazepine <extra_id_1> <extra_id_0> effect <extra_id_5> Spindle coma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> dextran - 40 <extra_id_1> <extra_id_0> drug <extra_id_5> dextran - 40 <extra_id_1> <extra_id_0> effect <extra_id_5> acute renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> After <extra_id_0> subject <extra_id_5> he <extra_id_1> <extra_id_0> gender <extra_id_5> he <extra_id_1> <extra_id_0> treatment <extra_id_5> infliximab infusion <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> effect <extra_id_5> transient neutropenia ( 0.5 x 10(9)/L ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> for <extra_id_0> treatment <extra_id_5> Lithium <extra_id_1> <extra_id_0> drug <extra_id_5> Lithium <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> irritability in post - traumatic stress disorder <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> subject <extra_id_5> a case of psoriasis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> psoriasis <extra_id_1> <extra_id_0> treatment <extra_id_5> vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics <extra_id_1> <extra_id_0> drug <extra_id_5> vitamin D3 <extra_id_1> <extra_id_0> drug <extra_id_5> thiazide diuretics <extra_id_1> <extra_id_0> combination drug <extra_id_5> thiazide diuretics <extra_id_1> <extra_id_0> combination drug <extra_id_5> vitamin D3 <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> psoriasis <extra_id_1> <extra_id_0> effect <extra_id_5> Iatrogenic hypercalcemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> fluoxetine <extra_id_1> <extra_id_0> drug <extra_id_5> fluoxetine <extra_id_1> <extra_id_0> effect <extra_id_5> mania <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> found <extra_id_0> treatment <extra_id_5> progestin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> progestin <extra_id_1> <extra_id_0> effect <extra_id_5> Extensive squamous metaplasia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> morphine <extra_id_1> <extra_id_0> drug <extra_id_5> morphine <extra_id_1> <extra_id_0> effect <extra_id_5> Acute generalized exanthematous pustulosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> Eleven days after initiation of therapy with amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> duration <extra_id_5> Eleven days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> Eleven days <extra_id_1> <extra_id_0> effect <extra_id_5> syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> lead <extra_id_0> subject <extra_id_5> patients with ET <extra_id_1> <extra_id_0> subject disorder <extra_id_5> ET <extra_id_1> <extra_id_0> treatment <extra_id_5> Prolonged used of hydroxyurea <extra_id_1> <extra_id_0> drug <extra_id_5> hydroxyurea <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> ET <extra_id_1> <extra_id_0> effect <extra_id_5> acute leukemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> BCG vaccination <extra_id_1> <extra_id_0> drug <extra_id_5> BCG <extra_id_1> <extra_id_0> effect <extra_id_5> Metastatic osteomyelitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> valproic acid <extra_id_1> <extra_id_0> drug <extra_id_5> valproic acid <extra_id_1> <extra_id_0> effect <extra_id_5> coma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> two patients <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> effect <extra_id_5> painful erosions of their psoriasis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Methysergide <extra_id_1> <extra_id_0> drug <extra_id_5> Methysergide <extra_id_1> <extra_id_0> effect <extra_id_5> retroperitoneal fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> 2 children with cerebral palsy <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> population <extra_id_5> 2 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cerebral palsy <extra_id_1> <extra_id_0> treatment <extra_id_5> hyperbaric oxygen <extra_id_1> <extra_id_0> drug <extra_id_5> hyperbaric oxygen <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cerebral palsy <extra_id_1> <extra_id_0> effect <extra_id_5> significant morbidity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A patient is described with polycythemia vera <extra_id_1> <extra_id_0> subject disorder <extra_id_5> polycythemia vera <extra_id_1> <extra_id_0> treatment <extra_id_5> anticoagulants <extra_id_1> <extra_id_0> drug <extra_id_5> anticoagulants <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> polycythemia vera <extra_id_1> <extra_id_0> effect <extra_id_5> spontaneous retropharyngeal hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side effects <extra_id_0> treatment <extra_id_5> fludarabine phosphate <extra_id_1> <extra_id_0> drug <extra_id_5> fludarabine phosphate <extra_id_1> <extra_id_0> effect <extra_id_5> CD4 T - lymphocyte depletion , myelosuppression , and subsequent severe infections <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Penicillin <extra_id_1> <extra_id_0> drug <extra_id_5> Penicillin <extra_id_1> <extra_id_0> effect <extra_id_5> Jarisch - Herxheimer reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> increase <extra_id_0> subject <extra_id_5> patients with schizophrenia <extra_id_1> <extra_id_0> subject disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> treatment <extra_id_5> risperidone <extra_id_1> <extra_id_0> drug <extra_id_5> risperidone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> effect <extra_id_5> affect <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> a patient with progressive renal impairment <extra_id_1> <extra_id_0> subject disorder <extra_id_5> progressive renal impairment <extra_id_1> <extra_id_0> treatment <extra_id_5> chronic cibenzoline <extra_id_1> <extra_id_0> drug <extra_id_5> cibenzoline <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> progressive renal impairment <extra_id_1> <extra_id_0> effect <extra_id_5> blurred vision , QRS broadening and cardiac failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> subject <extra_id_5> postoperative patient with pre - existent myasthenia gravis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> myasthenia gravis <extra_id_1> <extra_id_0> treatment <extra_id_5> oral verapamil <extra_id_1> <extra_id_0> drug <extra_id_5> verapamil <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> myasthenia gravis <extra_id_1> <extra_id_0> effect <extra_id_5> marked exacerbation in myasthenic weakness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> subject <extra_id_5> patient <extra_id_1> <extra_id_0> treatment <extra_id_5> penicillin <extra_id_1> <extra_id_0> drug <extra_id_5> penicillin <extra_id_1> <extra_id_0> effect <extra_id_5> JHR <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> acquired <extra_id_0> subject <extra_id_5> A 34 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 34 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> diabetic macular edema <extra_id_1> <extra_id_0> treatment <extra_id_5> intravitreal injection of triamcinolone <extra_id_1> <extra_id_0> drug <extra_id_5> triamcinolone <extra_id_1> <extra_id_0> route <extra_id_5> intravitreal injection <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> diabetic macular edema <extra_id_1> <extra_id_0> effect <extra_id_5> visual field defects and severe vision loss in both eyes <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulting <extra_id_0> treatment <extra_id_5> Simvastatin - amiodarone interaction <extra_id_1> <extra_id_0> drug <extra_id_5> Simvastatin <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> combination drug <extra_id_5> Simvastatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis , azotemia , and possible hepatotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 73 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 73 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> bipolar disorder <extra_id_1> <extra_id_0> treatment <extra_id_5> high - dosage olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dosage <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> bipolar disorder <extra_id_1> <extra_id_0> effect <extra_id_5> parkinsonism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> paclitaxel <extra_id_1> <extra_id_0> drug <extra_id_5> paclitaxel <extra_id_1> <extra_id_0> effect <extra_id_5> Fatal pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Raltegravir <extra_id_1> <extra_id_0> drug <extra_id_5> Raltegravir <extra_id_1> <extra_id_0> effect <extra_id_5> Eosinophilia and Systemic Symptoms ( DRESS ) syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> manifested <extra_id_0> subject <extra_id_5> A 10 - year - old boy with osteosarcoma and normal renal function <extra_id_1> <extra_id_0> age <extra_id_5> 10 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> boy <extra_id_1> <extra_id_0> subject disorder <extra_id_5> osteosarcoma <extra_id_1> <extra_id_0> treatment <extra_id_5> 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( MTX ) ( 12 g / m2 ) <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> 12 g / m2 <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 2 hours <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> osteosarcoma <extra_id_1> <extra_id_0> effect <extra_id_5> impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase <extra_id_1> <extra_id_0> effect <extra_id_5> acute renal failure with life - threatening hyperkalemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> three depressed patients <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> subject disorder <extra_id_5> depressed <extra_id_1> <extra_id_0> treatment <extra_id_5> trazodone <extra_id_1> <extra_id_0> drug <extra_id_5> trazodone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> depressed <extra_id_1> <extra_id_0> effect <extra_id_5> hypomanic symptoms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> praziquantel <extra_id_1> <extra_id_0> drug <extra_id_5> praziquantel <extra_id_1> <extra_id_0> effect <extra_id_5> disseminated muscular cysticercosis followed by myositis ( fever , diffuse myalgia , weakness of the lower limbs , and inflammatory reaction around dying cysticerci ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> diltiazem therapy <extra_id_1> <extra_id_0> drug <extra_id_5> diltiazem <extra_id_1> <extra_id_0> effect <extra_id_5> fever <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reverse <extra_id_0> treatment <extra_id_5> Hemodialysis <extra_id_1> <extra_id_0> drug <extra_id_5> Hemodialysis <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> ifosfamide - related neurotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> appeared <extra_id_0> treatment <extra_id_5> amphotericin B treatment <extra_id_1> <extra_id_0> drug <extra_id_5> amphotericin B <extra_id_1> <extra_id_0> duration <extra_id_5> 55th day <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 55th day <extra_id_1> <extra_id_0> effect <extra_id_5> Palpable purpuric skin lesions on the anterior surface of both legs <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> cisplatinum , vinblastine , and bleomycin <extra_id_1> <extra_id_0> drug <extra_id_5> cisplatinum <extra_id_1> <extra_id_0> drug <extra_id_5> vinblastine <extra_id_1> <extra_id_0> drug <extra_id_5> bleomycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> cisplatinum <extra_id_1> <extra_id_0> combination drug <extra_id_5> vinblastine <extra_id_1> <extra_id_0> combination drug <extra_id_5> bleomycin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> testicular carcinoma <extra_id_1> <extra_id_0> effect <extra_id_5> Transient left homonymous hemianopsia and encephalopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a 46 - yr - old woman with ovarian carcinoma <extra_id_1> <extra_id_0> age <extra_id_5> 46 - yr - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> ovarian carcinoma <extra_id_1> <extra_id_0> treatment <extra_id_5> cisplatin and cyclophosphamide <extra_id_1> <extra_id_0> drug <extra_id_5> cisplatin <extra_id_1> <extra_id_0> drug <extra_id_5> cyclophosphamide <extra_id_1> <extra_id_0> combination drug <extra_id_5> cisplatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> cyclophosphamide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> ovarian carcinoma <extra_id_1> <extra_id_0> effect <extra_id_5> porphyria cutanea tarda <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulted <extra_id_0> subject <extra_id_5> one child <extra_id_1> <extra_id_0> age <extra_id_5> child <extra_id_1> <extra_id_0> population <extra_id_5> one <extra_id_1> <extra_id_0> treatment <extra_id_5> a second course of carbamazepine <extra_id_1> <extra_id_0> drug <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> effect <extra_id_5> dystonia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> increase <extra_id_0> treatment <extra_id_5> acyclovir <extra_id_1> <extra_id_0> drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> effect <extra_id_5> serum lithium levels <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> revisited <extra_id_0> treatment <extra_id_5> Sulfadiazine <extra_id_1> <extra_id_0> drug <extra_id_5> Sulfadiazine <extra_id_1> <extra_id_0> effect <extra_id_5> crystalluria <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induce <extra_id_0> subject <extra_id_5> subarachnoid haemorrhage ( SAH ) patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> subarachnoid haemorrhage ( SAH ) <extra_id_1> <extra_id_0> treatment <extra_id_5> sumatriptan <extra_id_1> <extra_id_0> drug <extra_id_5> sumatriptan <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> subarachnoid haemorrhage ( SAH ) <extra_id_1> <extra_id_0> effect <extra_id_5> symptomatic cerebral vasospasm with potentially dangerous consequences <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> subject <extra_id_5> Six of 13 outpatients with schizophrenia <extra_id_1> <extra_id_0> population <extra_id_5> Six of 13 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> treatment <extra_id_5> ten - week open trial of risperidone <extra_id_1> <extra_id_0> drug <extra_id_5> risperidone <extra_id_1> <extra_id_0> duration <extra_id_5> ten - week <extra_id_1> <extra_id_0> time elapsed <extra_id_5> ten - week <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> effect <extra_id_5> intolerable affect , including feelings of agitation and depression and periods of crying and insomnia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> subject <extra_id_5> a patient with pulmonary hypertension and limited scleroderma <extra_id_1> <extra_id_0> subject disorder <extra_id_5> pulmonary hypertension and limited scleroderma <extra_id_1> <extra_id_0> treatment <extra_id_5> acute infusion of epoprostenol <extra_id_1> <extra_id_0> drug <extra_id_5> epoprostenol <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> pulmonary hypertension and limited scleroderma <extra_id_1> <extra_id_0> effect <extra_id_5> Pulmonary edema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> antiemetic effect <extra_id_0> treatment <extra_id_5> Decadron ( dexamethasone ; Merck Sharp & Dohme , West Point , Pa ) <extra_id_1> <extra_id_0> drug <extra_id_5> Decadron <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cisplatin - induced vomiting <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> long - term treatment with the dopamine agonist pergolide <extra_id_1> <extra_id_0> drug <extra_id_5> pergolide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Parkinson Disease <extra_id_1> <extra_id_0> effect <extra_id_5> Pleuropulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> An infertile patient with amenorrhea - galactorrhea syndrome <extra_id_1> <extra_id_0> subject disorder <extra_id_5> amenorrhea - galactorrhea syndrome <extra_id_1> <extra_id_0> treatment <extra_id_5> Bromocryptine treatment <extra_id_1> <extra_id_0> drug <extra_id_5> Bromocryptine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> amenorrhea - galactorrhea syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> lost vision <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> treatment <extra_id_5> a delay of 24 to 48 hours after acyclovir peak serum concentrations <extra_id_1> <extra_id_0> drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> duration <extra_id_5> 24 to 48 hours <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 24 to 48 hours <extra_id_1> <extra_id_0> effect <extra_id_5> neurotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> Two cases <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> treatment <extra_id_5> mequitazine <extra_id_1> <extra_id_0> drug <extra_id_5> mequitazine <extra_id_1> <extra_id_0> effect <extra_id_5> photosensitivity reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> a patient with decreased calcium - dependent potassium permeability of cell membranes <extra_id_1> <extra_id_0> subject disorder <extra_id_5> decreased calcium - dependent potassium permeability of cell membranes <extra_id_1> <extra_id_0> treatment <extra_id_5> clozapine treatment <extra_id_1> <extra_id_0> drug <extra_id_5> clozapine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> decreased calcium - dependent potassium permeability of cell membranes <extra_id_1> <extra_id_0> effect <extra_id_5> Rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 47 year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 47 year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> intramuscular pentazocine injections in the lower extremities <extra_id_1> <extra_id_0> drug <extra_id_5> pentazocine <extra_id_1> <extra_id_0> route <extra_id_5> intramuscular <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 4 - year <extra_id_1> <extra_id_0> effect <extra_id_5> gradual stiffness and weakness of the lower extremities <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> subject <extra_id_5> a patient with water intoxication <extra_id_1> <extra_id_0> subject disorder <extra_id_5> water intoxication <extra_id_1> <extra_id_0> treatment <extra_id_5> massive ingestion of caffeine - containing beverages <extra_id_1> <extra_id_0> drug <extra_id_5> caffeine <extra_id_1> <extra_id_0> route <extra_id_5> ingestion <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> water intoxication <extra_id_1> <extra_id_0> effect <extra_id_5> severe rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 25 - year - old postpartum white woman <extra_id_1> <extra_id_0> age <extra_id_5> 25 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> race <extra_id_5> white <extra_id_1> <extra_id_0> subject disorder <extra_id_5> bacterial vaginosis <extra_id_1> <extra_id_0> treatment <extra_id_5> clindamycin vaginal cream <extra_id_1> <extra_id_0> drug <extra_id_5> clindamycin <extra_id_1> <extra_id_0> route <extra_id_5> vaginal cream <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> bacterial vaginosis <extra_id_1> <extra_id_0> effect <extra_id_5> multiple watery stools and abdominal cramping <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> three case reports <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> treatment <extra_id_5> olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> effect <extra_id_5> leukopenia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> became <extra_id_0> subject <extra_id_5> He <extra_id_1> <extra_id_0> gender <extra_id_5> He <extra_id_1> <extra_id_0> treatment <extra_id_5> 2 weeks after administration of levodopa <extra_id_1> <extra_id_0> drug <extra_id_5> levodopa <extra_id_1> <extra_id_0> duration <extra_id_5> 2 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 2 weeks <extra_id_1> <extra_id_0> effect <extra_id_5> completely premorbid <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> darifenacin <extra_id_1> <extra_id_0> drug <extra_id_5> darifenacin <extra_id_1> <extra_id_0> effect <extra_id_5> interstitial granulomatous dermatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induce <extra_id_0> subject <extra_id_5> this patient <extra_id_1> <extra_id_0> gender <extra_id_5> she <extra_id_1> <extra_id_0> treatment <extra_id_5> 200 mg / day six days per week for six months <extra_id_1> <extra_id_0> drug <extra_id_5> Amiodarone <extra_id_1> <extra_id_0> dosage <extra_id_5> 200 mg / day <extra_id_1> <extra_id_0> duration <extra_id_5> six months <extra_id_1> <extra_id_0> frequency <extra_id_5> six days per week <extra_id_1> <extra_id_0> time elapsed <extra_id_5> six months <extra_id_1> <extra_id_0> effect <extra_id_5> AVT <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A young diamond dealer <extra_id_1> <extra_id_0> age <extra_id_5> young <extra_id_1> <extra_id_0> gender <extra_id_5> dealer <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cisplatin - associated nausea <extra_id_1> <extra_id_0> treatment <extra_id_5> four courses of intermittent Decadron <extra_id_1> <extra_id_0> drug <extra_id_5> Decadron <extra_id_1> <extra_id_0> duration <extra_id_5> four courses <extra_id_1> <extra_id_0> time elapsed <extra_id_5> four courses <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cisplatin - associated nausea <extra_id_1> <extra_id_0> effect <extra_id_5> visual impairment attributed to bilateral posterior subcapsular cataracts <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> losartan <extra_id_1> <extra_id_0> drug <extra_id_5> losartan <extra_id_1> <extra_id_0> effect <extra_id_5> angioedema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> 3 months after the transurethral injection of calcium hydroxylapatite <extra_id_1> <extra_id_0> drug <extra_id_5> calcium hydroxylapatite <extra_id_1> <extra_id_0> route <extra_id_5> transurethral injection <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 3 months <extra_id_1> <extra_id_0> effect <extra_id_5> granulomatous reaction leading to urethral prolapse <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> a patient with rheumatoid arthritis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> methotrexate and rofecoxib <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> rofecoxib <extra_id_1> <extra_id_0> combination drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> combination drug <extra_id_5> rofecoxib <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> Epstein - Barr virus - associated lymphoproliferative disorder <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> promoted <extra_id_0> treatment <extra_id_5> aspirin <extra_id_1> <extra_id_0> drug <extra_id_5> aspirin <extra_id_1> <extra_id_0> effect <extra_id_5> spontaneous hemorrhage from meningioma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> increased <extra_id_0> treatment <extra_id_5> omeprazole <extra_id_1> <extra_id_0> drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> effect <extra_id_5> diarrhea <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> Treatment <extra_id_0> subject <extra_id_5> a patient with severe digitoxin intoxication <extra_id_1> <extra_id_0> subject disorder <extra_id_5> digitoxin intoxication <extra_id_1> <extra_id_0> treatment <extra_id_5> Fab fragments of anti - digitalis antibodies <extra_id_1> <extra_id_0> drug <extra_id_5> anti - digitalis antibodies <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> digitoxin intoxication <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> cyclophosphamide <extra_id_1> <extra_id_0> drug <extra_id_5> cyclophosphamide <extra_id_1> <extra_id_0> effect <extra_id_5> porphyria cutanea tarda <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a premature infant <extra_id_1> <extra_id_0> age <extra_id_5> premature infant <extra_id_1> <extra_id_0> treatment <extra_id_5> intraventricular administration of nafcillin <extra_id_1> <extra_id_0> drug <extra_id_5> nafcillin <extra_id_1> <extra_id_0> route <extra_id_5> intraventricular <extra_id_1> <extra_id_0> effect <extra_id_5> seizures <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> drug <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> effect <extra_id_5> priapism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurring <extra_id_0> subject <extra_id_5> a case <extra_id_1> <extra_id_0> subject disorder <extra_id_5> locally advanced pancreatic cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> gemcitabine monotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> duration <extra_id_5> five months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> five months <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> locally advanced pancreatic cancer <extra_id_1> <extra_id_0> effect <extra_id_5> radiation recall dermatitis and myositis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> gold sodium thiomalate <extra_id_1> <extra_id_0> drug <extra_id_5> gold sodium thiomalate <extra_id_1> <extra_id_0> effect <extra_id_5> Stroke - like syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> MTX <extra_id_1> <extra_id_0> drug <extra_id_5> MTX <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> leukemia , gestational disease and during treatment of psoriasis and rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> hepatic injury and liver enzyme elevations <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> fluoxetine <extra_id_1> <extra_id_0> drug <extra_id_5> fluoxetine <extra_id_1> <extra_id_0> effect <extra_id_5> adverse drug reaction ( ADR ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> etanercept <extra_id_1> <extra_id_0> drug <extra_id_5> etanercept <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> active ankylosing spondylitis <extra_id_1> <extra_id_0> effect <extra_id_5> Crohn 's disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> long - term pulse itraconazole treatment <extra_id_1> <extra_id_0> drug <extra_id_5> itraconazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> onychomycosis <extra_id_1> <extra_id_0> effect <extra_id_5> Fatal hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> outcome <extra_id_0> treatment <extra_id_5> intravesical formalin instillation <extra_id_1> <extra_id_0> drug <extra_id_5> formalin <extra_id_1> <extra_id_0> route <extra_id_5> intravesical <extra_id_1> <extra_id_0> effect <extra_id_5> changes mimicking renal tuberculosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> anti - emetic drug <extra_id_1> <extra_id_0> treatment <extra_id_5> clemastine fumarate <extra_id_1> <extra_id_0> drug <extra_id_5> clemastine fumarate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> anaphylactic reaction <extra_id_1> <extra_id_0> effect <extra_id_5> Both reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> treatment <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> systemic lupus erythematosus with thrombocytopenia <extra_id_1> <extra_id_0> effect <extra_id_5> Reversible posterior leukoencephalopathy syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reduced <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> aspirin and clopidogrel <extra_id_1> <extra_id_0> drug <extra_id_5> aspirin <extra_id_1> <extra_id_0> drug <extra_id_5> clopidogrel <extra_id_1> <extra_id_0> combination drug <extra_id_5> aspirin <extra_id_1> <extra_id_0> combination drug <extra_id_5> clopidogrel <extra_id_1> <extra_id_0> effect <extra_id_5> upper gastrointestinal bleeding <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> in <extra_id_0> subject <extra_id_5> a pediatric bone marrow transplant recipient <extra_id_1> <extra_id_0> age <extra_id_5> pediatric <extra_id_1> <extra_id_0> treatment <extra_id_5> Clofazimine <extra_id_1> <extra_id_0> drug <extra_id_5> Clofazimine <extra_id_1> <extra_id_0> effect <extra_id_5> enteropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> from <extra_id_0> treatment <extra_id_5> transdermal scopolamine <extra_id_1> <extra_id_0> drug <extra_id_5> scopolamine <extra_id_1> <extra_id_0> route <extra_id_5> transdermal <extra_id_1> <extra_id_0> effect <extra_id_5> Anisocoria <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> he <extra_id_1> <extra_id_0> gender <extra_id_5> he <extra_id_1> <extra_id_0> subject disorder <extra_id_5> fever <extra_id_1> <extra_id_0> treatment <extra_id_5> chloroquine <extra_id_1> <extra_id_0> drug <extra_id_5> chloroquine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> fever <extra_id_1> <extra_id_0> effect <extra_id_5> symptoms consistent with those of chloroquine toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 36 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 36 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> testicular carcinoma <extra_id_1> <extra_id_0> treatment <extra_id_5> cisplatinum , vinblastine , and bleomycin <extra_id_1> <extra_id_0> drug <extra_id_5> cisplatinum <extra_id_1> <extra_id_0> drug <extra_id_5> vinblastine <extra_id_1> <extra_id_0> drug <extra_id_5> bleomycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> cisplatinum <extra_id_1> <extra_id_0> combination drug <extra_id_5> vinblastine <extra_id_1> <extra_id_0> combination drug <extra_id_5> bleomycin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> testicular carcinoma <extra_id_1> <extra_id_0> effect <extra_id_5> dense left homonymous hemianopsia , encephalopathy , and a partial nondominant parietal lobe syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> produced <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> a statin and a protease inhibitor <extra_id_1> <extra_id_0> drug <extra_id_5> statin <extra_id_1> <extra_id_0> drug <extra_id_5> protease inhibitor <extra_id_1> <extra_id_0> combination drug <extra_id_5> statin <extra_id_1> <extra_id_0> combination drug <extra_id_5> protease inhibitor <extra_id_1> <extra_id_0> effect <extra_id_5> death associated with rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> several recent reports of Epstein - Barr virus ( EBV) - associated polyclonal B cell lymphoproliferative disorder <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Epstein - Barr virus ( EBV) - associated polyclonal B cell lymphoproliferative disorder <extra_id_1> <extra_id_0> treatment <extra_id_5> MTX <extra_id_1> <extra_id_0> drug <extra_id_5> MTX <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Epstein - Barr virus ( EBV) - associated polyclonal B cell lymphoproliferative disorder <extra_id_1> <extra_id_0> effect <extra_id_5> polyclonal B cell lymphoproliferative disorder <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> azathioprine <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> azathioprine <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> combination drug <extra_id_5> azathioprine <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> resistance <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> paclitaxel therapy <extra_id_1> <extra_id_0> treatment <extra_id_5> despite treatments with corticosteroids <extra_id_1> <extra_id_0> drug <extra_id_5> paclitaxel <extra_id_1> <extra_id_0> drug <extra_id_5> corticosteroids <extra_id_1> <extra_id_0> combination drug <extra_id_5> corticosteroids <extra_id_1> <extra_id_0> combination drug <extra_id_5> paclitaxel <extra_id_1> <extra_id_0> effect <extra_id_5> Pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> Two patients with adrenal carcinoma <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> adrenal carcinoma <extra_id_1> <extra_id_0> treatment <extra_id_5> 2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane ( o , p' - DDD ) <extra_id_1> <extra_id_0> drug <extra_id_5> 2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> adrenal carcinoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> acyclovir overdose <extra_id_1> <extra_id_0> drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> dosage <extra_id_5> overdose <extra_id_1> <extra_id_0> effect <extra_id_5> coma and nonoliguric renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> An 8 - year - old girl <extra_id_1> <extra_id_0> age <extra_id_5> 8 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> girl <extra_id_1> <extra_id_0> treatment <extra_id_5> vaccinated with BCG <extra_id_1> <extra_id_0> drug <extra_id_5> BCG <extra_id_1> <extra_id_0> duration <extra_id_5> 7 months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 7 months <extra_id_1> <extra_id_0> effect <extra_id_5> osteomyelitis in the left calcaneus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> persisted <extra_id_0> treatment <extra_id_5> FAB <extra_id_1> <extra_id_0> drug <extra_id_5> FAB <extra_id_1> <extra_id_0> effect <extra_id_5> cardiac DGTX toxicity ( total AV - block ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> in <extra_id_0> treatment <extra_id_5> quinine <extra_id_1> <extra_id_0> drug <extra_id_5> quinine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> quinine amblyopia <extra_id_1> <extra_id_0> effect <extra_id_5> Abnormalities of the pupil and visual - evoked potential <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulted <extra_id_0> subject <extra_id_5> A case <extra_id_1> <extra_id_0> subject disorder <extra_id_5> toxemia of pregnancy <extra_id_1> <extra_id_0> treatment <extra_id_5> magnesium sulfate <extra_id_1> <extra_id_0> drug <extra_id_5> magnesium sulfate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> toxemia of pregnancy <extra_id_1> <extra_id_0> effect <extra_id_5> severe hypocalcemia , with a low plasma parathyroid hormone ( PTH ) concentration <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side - effect <extra_id_0> treatment <extra_id_5> low - dose methotrexate therapy <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> low - dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> Concurrent acute megaloblastic anaemia and pneumonitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> risk <extra_id_0> subject <extra_id_5> Patients <extra_id_1> <extra_id_0> treatment <extra_id_5> dexamethasone <extra_id_1> <extra_id_0> drug <extra_id_5> dexamethasone <extra_id_1> <extra_id_0> effect <extra_id_5> osteonecrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient with inoperable pancreatic cancer <extra_id_1> <extra_id_0> subject disorder <extra_id_5> inoperable pancreatic cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> radiation - recall related to gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> inoperable pancreatic cancer <extra_id_1> <extra_id_0> effect <extra_id_5> gastrointestinal bleeding <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> a 14 - year - old male with nephrotic syndrome <extra_id_1> <extra_id_0> age <extra_id_5> 14 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> subject disorder <extra_id_5> nephrotic syndrome <extra_id_1> <extra_id_0> treatment <extra_id_5> oral prednisolone for 6 weeks <extra_id_1> <extra_id_0> drug <extra_id_5> prednisolone <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> duration <extra_id_5> 6 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 6 weeks <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> nephrotic syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> SJS <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 45 - year - old woman with thyrotoxicosis <extra_id_1> <extra_id_0> age <extra_id_5> 45 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> thyrotoxicosis <extra_id_1> <extra_id_0> treatment <extra_id_5> propylthiouracil <extra_id_1> <extra_id_0> drug <extra_id_5> propylthiouracil <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> thyrotoxicosis <extra_id_1> <extra_id_0> effect <extra_id_5> agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side effects <extra_id_0> treatment <extra_id_5> prolonged ACTH therapy <extra_id_1> <extra_id_0> drug <extra_id_5> ACTH <extra_id_1> <extra_id_0> effect <extra_id_5> hyperkalemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complicating <extra_id_0> treatment <extra_id_5> long - term mitomycin C and 5 - fluorouracil therapy <extra_id_1> <extra_id_0> drug <extra_id_5> mitomycin C <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> combination drug <extra_id_5> mitomycin C <extra_id_1> <extra_id_0> combination drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> gastric carcinoma <extra_id_1> <extra_id_0> effect <extra_id_5> Haemolytic - uraemic syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> result <extra_id_0> treatment <extra_id_5> selective serotonin reuptake inhibitors ( SSRI ) and fentanyl <extra_id_1> <extra_id_0> drug <extra_id_5> selective serotonin reuptake inhibitors <extra_id_1> <extra_id_0> drug <extra_id_5> fentanyl <extra_id_1> <extra_id_0> combination drug <extra_id_5> selective serotonin reuptake inhibitors <extra_id_1> <extra_id_0> combination drug <extra_id_5> fentanyl <extra_id_1> <extra_id_0> effect <extra_id_5> serotonin syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> a 61 - year - old diabetic patient <extra_id_1> <extra_id_0> age <extra_id_5> 61 - year - old <extra_id_1> <extra_id_0> subject disorder <extra_id_5> diabetic <extra_id_1> <extra_id_0> treatment <extra_id_5> glibenclamide <extra_id_1> <extra_id_0> drug <extra_id_5> glibenclamide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> diabetic <extra_id_1> <extra_id_0> effect <extra_id_5> Intrahepatic cholestasis and cutaneous bullae <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> responsible <extra_id_0> treatment <extra_id_5> cloxacillin <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> cloxacillin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> combination drug <extra_id_5> cloxacillin <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> enhanced INR <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> sumatriptan <extra_id_1> <extra_id_0> drug <extra_id_5> sumatriptan <extra_id_1> <extra_id_0> effect <extra_id_5> Cardiac arrest <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> receiving <extra_id_0> subject <extra_id_5> one patient <extra_id_1> <extra_id_0> population <extra_id_5> one <extra_id_1> <extra_id_0> treatment <extra_id_5> continuous bladder irrigations with alum <extra_id_1> <extra_id_0> drug <extra_id_5> alum <extra_id_1> <extra_id_0> route <extra_id_5> continuous bladder irrigations <extra_id_1> <extra_id_0> effect <extra_id_5> encephalopathy <extra_id_1> <extra_id_0> effect <extra_id_5> seizures <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> Nine azotemic patients <extra_id_1> <extra_id_0> population <extra_id_5> Nine <extra_id_1> <extra_id_0> subject disorder <extra_id_5> azotemic <extra_id_1> <extra_id_0> treatment <extra_id_5> cephalosporin or moxalactam antibiotics <extra_id_1> <extra_id_0> drug <extra_id_5> cephalosporin <extra_id_1> <extra_id_0> drug <extra_id_5> moxalactam antibiotics <extra_id_1> <extra_id_0> combination drug <extra_id_5> cephalosporin <extra_id_1> <extra_id_0> combination drug <extra_id_5> moxalactam antibiotics <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> azotemic <extra_id_1> <extra_id_0> effect <extra_id_5> coagulopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> exposed <extra_id_0> subject <extra_id_5> fetuses <extra_id_1> <extra_id_0> age <extra_id_5> fetuses <extra_id_1> <extra_id_0> treatment <extra_id_5> disulfiram <extra_id_1> <extra_id_0> drug <extra_id_5> disulfiram <extra_id_1> <extra_id_0> duration <extra_id_5> the first trimester <extra_id_1> <extra_id_0> time elapsed <extra_id_5> the first trimester <extra_id_1> <extra_id_0> effect <extra_id_5> poor prognosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> result <extra_id_0> treatment <extra_id_5> caffeine toxicity <extra_id_1> <extra_id_0> drug <extra_id_5> caffeine <extra_id_1> <extra_id_0> effect <extra_id_5> unusually severe rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> an 81 - year - old - man <extra_id_1> <extra_id_0> age <extra_id_5> 81 - year - old - man <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> treatment <extra_id_5> erlotinib <extra_id_1> <extra_id_0> drug <extra_id_5> erlotinib <extra_id_1> <extra_id_0> effect <extra_id_5> rosaceiform eruption <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> An 11 - year - old boy <extra_id_1> <extra_id_0> age <extra_id_5> 11 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> boy <extra_id_1> <extra_id_0> subject disorder <extra_id_5> graft - versus - host disease <extra_id_1> <extra_id_0> treatment <extra_id_5> 2 years after initiation of clofazimine treatment <extra_id_1> <extra_id_0> drug <extra_id_5> clofazimine <extra_id_1> <extra_id_0> duration <extra_id_5> 2 years <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 2 years <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> graft - versus - host disease <extra_id_1> <extra_id_0> effect <extra_id_5> severe enteropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experience <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> high doses of oral niacin <extra_id_1> <extra_id_0> drug <extra_id_5> niacin <extra_id_1> <extra_id_0> dosage <extra_id_5> high doses <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> effect <extra_id_5> visual symptoms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> in <extra_id_0> subject <extra_id_5> renal transplanted patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> renal transplanted <extra_id_1> <extra_id_0> treatment <extra_id_5> immunosuppression with tacrolimus <extra_id_1> <extra_id_0> drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> renal transplanted <extra_id_1> <extra_id_0> effect <extra_id_5> Reflex sympathetic dystrophy syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> an 11 - year - old female <extra_id_1> <extra_id_0> age <extra_id_5> 11 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> subject disorder <extra_id_5> mediastinal T - cell lymphoma <extra_id_1> <extra_id_0> treatment <extra_id_5> the second cycle of high - dose methotrexate ( HDMTX ) <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> mediastinal T - cell lymphoma <extra_id_1> <extra_id_0> effect <extra_id_5> renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> three cases <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> treatment <extra_id_5> olanzapine treatment <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> effect <extra_id_5> leukopenia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> the combined use of simvastatin and colchicine <extra_id_1> <extra_id_0> drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> combination drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> effect <extra_id_5> Rapid onset of muscle weakness ( rhabdomyolysis ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 35 - year - old man with seropositive rheumatoid arthritis <extra_id_1> <extra_id_0> age <extra_id_5> 35 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> seropositive rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> fenclofenac <extra_id_1> <extra_id_0> drug <extra_id_5> fenclofenac <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> seropositive rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> selective IgA deficiency <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> demonstrated <extra_id_0> subject <extra_id_5> two newborns with congenital heart anomalies <extra_id_1> <extra_id_0> age <extra_id_5> newborns <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> congenital heart anomalies <extra_id_1> <extra_id_0> treatment <extra_id_5> the dose of systemic prostaglandin E1 <extra_id_1> <extra_id_0> drug <extra_id_5> prostaglandin E1 <extra_id_1> <extra_id_0> route <extra_id_5> systemic <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> congenital heart anomalies <extra_id_1> <extra_id_0> effect <extra_id_5> harlequin color change <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> described <extra_id_0> subject <extra_id_5> infants of women <extra_id_1> <extra_id_0> age <extra_id_5> infants <extra_id_1> <extra_id_0> gender <extra_id_5> women <extra_id_1> <extra_id_0> treatment <extra_id_5> disulfiram <extra_id_1> <extra_id_0> drug <extra_id_5> disulfiram <extra_id_1> <extra_id_0> duration <extra_id_5> the first trimester <extra_id_1> <extra_id_0> time elapsed <extra_id_5> the first trimester <extra_id_1> <extra_id_0> effect <extra_id_5> Nonspecific but significant abnormalities <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> triggered <extra_id_0> treatment <extra_id_5> infliximab <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> effect <extra_id_5> production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> under <extra_id_0> subject <extra_id_5> a postmenopausal woman <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> breast cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> tamoxifen therapy <extra_id_1> <extra_id_0> drug <extra_id_5> tamoxifen <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> breast cancer <extra_id_1> <extra_id_0> effect <extra_id_5> Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Tacrolimus <extra_id_1> <extra_id_0> drug <extra_id_5> Tacrolimus <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> nephrotic syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> HUS <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a woman with cryptococcal meningitis and no previous cardiac disease <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cryptococcal meningitis <extra_id_1> <extra_id_0> treatment <extra_id_5> an acute overdose of amphotericin B <extra_id_1> <extra_id_0> drug <extra_id_5> amphotericin B <extra_id_1> <extra_id_0> dosage <extra_id_5> acute overdose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cryptococcal meningitis <extra_id_1> <extra_id_0> effect <extra_id_5> fatal cardiac arrhythmia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> intake of captopril <extra_id_1> <extra_id_0> drug <extra_id_5> captopril <extra_id_1> <extra_id_0> effect <extra_id_5> bullous lichenoid eruption <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> overcome <extra_id_0> treatment <extra_id_5> increasing steroid replacement therapy <extra_id_1> <extra_id_0> drug <extra_id_5> steroid <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hypoadrenalism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Interferon alpha - 2b <extra_id_1> <extra_id_0> drug <extra_id_5> Interferon alpha - 2b <extra_id_1> <extra_id_0> effect <extra_id_5> cardiomyopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> systemic tissue plasminogen activator <extra_id_1> <extra_id_0> drug <extra_id_5> plasminogen activator <extra_id_1> <extra_id_0> route <extra_id_5> systemic tissue plasminogen activator <extra_id_1> <extra_id_0> effect <extra_id_5> Choroidal hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient with chronic schizophrenia with suicidal tendencies <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic schizophrenia with suicidal tendencies <extra_id_1> <extra_id_0> treatment <extra_id_5> Clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> Clozapine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic schizophrenia with suicidal tendencies <extra_id_1> <extra_id_0> effect <extra_id_5> eosinophilia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> long - term therapy with the addition of citalopram <extra_id_1> <extra_id_0> drug <extra_id_5> propafenone <extra_id_1> <extra_id_0> drug <extra_id_5> citalopram <extra_id_1> <extra_id_0> combination drug <extra_id_5> propafenone <extra_id_1> <extra_id_0> combination drug <extra_id_5> citalopram <extra_id_1> <extra_id_0> effect <extra_id_5> Adverse effects <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> an adult <extra_id_1> <extra_id_0> age <extra_id_5> adult <extra_id_1> <extra_id_0> treatment <extra_id_5> exposure to cimetidine <extra_id_1> <extra_id_0> drug <extra_id_5> cimetidine <extra_id_1> <extra_id_0> effect <extra_id_5> hepatic dysfunction and an impaired macrophage migration <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> 4 patients <extra_id_1> <extra_id_0> population <extra_id_5> 4 <extra_id_1> <extra_id_0> treatment <extra_id_5> within 2 weeks of starting treatment with a statin drug <extra_id_1> <extra_id_0> drug <extra_id_5> statin <extra_id_1> <extra_id_0> duration <extra_id_5> 2 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 2 weeks <extra_id_1> <extra_id_0> effect <extra_id_5> myasthenia gravis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> After <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> the third dose of pentamidine <extra_id_1> <extra_id_0> drug <extra_id_5> pentamidine <extra_id_1> <extra_id_0> dosage <extra_id_5> third dose <extra_id_1> <extra_id_0> effect <extra_id_5> the patient 's heart rate had decreased to 48 beats / minute <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> A 44 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 44 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> amiodarone , disopyramide , and quinidine <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> disopyramide <extra_id_1> <extra_id_0> drug <extra_id_5> quinidine <extra_id_1> <extra_id_0> combination drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> combination drug <extra_id_5> disopyramide <extra_id_1> <extra_id_0> combination drug <extra_id_5> quinidine <extra_id_1> <extra_id_0> effect <extra_id_5> atypical ventricular tachycardia ( AVT , torsade de pointes ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> causative <extra_id_0> treatment <extra_id_5> Azathioprine <extra_id_1> <extra_id_0> drug <extra_id_5> Azathioprine <extra_id_1> <extra_id_0> effect <extra_id_5> warfarin resistance <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> deter <extra_id_0> subject <extra_id_5> patients with a history of alcohol abuse <extra_id_1> <extra_id_0> subject disorder <extra_id_5> alcohol abuse <extra_id_1> <extra_id_0> treatment <extra_id_5> Disulfiram <extra_id_1> <extra_id_0> drug <extra_id_5> Disulfiram <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> alcohol abuse <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> human immunodeficiency virus ( HIV) - infected patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> immunodeficiency virus ( HIV) <extra_id_1> <extra_id_0> treatment <extra_id_5> Nevirapine <extra_id_1> <extra_id_0> drug <extra_id_5> Nevirapine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> immunodeficiency virus ( HIV) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> ergotamine <extra_id_1> <extra_id_0> drug <extra_id_5> ergotamine <extra_id_1> <extra_id_0> effect <extra_id_5> Vasospasm <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> she <extra_id_1> <extra_id_0> gender <extra_id_5> she <extra_id_1> <extra_id_0> treatment <extra_id_5> six - week course of low - dose cyclosporine A <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporine A <extra_id_1> <extra_id_0> dosage <extra_id_5> low - dose <extra_id_1> <extra_id_0> duration <extra_id_5> six - week <extra_id_1> <extra_id_0> time elapsed <extra_id_5> six - week <extra_id_1> <extra_id_0> effect <extra_id_5> severe but reversible loss of glomerular filtration rate and effective renal plasma flow <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> simvastatin <extra_id_1> <extra_id_0> treatment <extra_id_5> amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> combination drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> combination drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> a 50 - year - old transgender female with HIV infection and recurrent deep vein thrombosis <extra_id_1> <extra_id_0> age <extra_id_5> 50 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV infection and recurrent deep vein thrombosis <extra_id_1> <extra_id_0> treatment <extra_id_5> TRIO study regimen <extra_id_1> <extra_id_0> drug <extra_id_5> TRIO <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> HIV infection and recurrent deep vein thrombosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> inhibition <extra_id_0> treatment <extra_id_5> zafirlukast <extra_id_1> <extra_id_0> drug <extra_id_5> zafirlukast <extra_id_1> <extra_id_0> effect <extra_id_5> inhibition of CYP2C9 <extra_id_1> <extra_id_0> effect <extra_id_5> impaired clearance of S - warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> enhanced anti - thrombotic effects <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> to <extra_id_0> subject <extra_id_5> patients who have asymptomatic meningioma <extra_id_1> <extra_id_0> subject disorder <extra_id_5> asymptomatic meningioma <extra_id_1> <extra_id_0> treatment <extra_id_5> aspirin <extra_id_1> <extra_id_0> drug <extra_id_5> aspirin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> asymptomatic meningioma <extra_id_1> <extra_id_0> effect <extra_id_5> intratumoral hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> IVTA injection <extra_id_1> <extra_id_0> drug <extra_id_5> IVTA <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> ASPPC <extra_id_1> <extra_id_0> effect <extra_id_5> fundus picture <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> action <extra_id_0> treatment <extra_id_5> amiodarone <extra_id_1> <extra_id_0> treatment <extra_id_5> magnesium sulfate <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> magnesium sulfate <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> combination drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> combination drug <extra_id_5> magnesium sulfate <extra_id_1> <extra_id_0> effect <extra_id_5> proarrhythmic action <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> psoriasis <extra_id_1> <extra_id_0> treatment <extra_id_5> imiquimod <extra_id_1> <extra_id_0> treatment <extra_id_5> infliximab <extra_id_1> <extra_id_0> drug <extra_id_5> imiquimod <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> combination drug <extra_id_5> imiquimod <extra_id_1> <extra_id_0> combination drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> psoriasis <extra_id_1> <extra_id_0> effect <extra_id_5> severe , atypical ASRs <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complicated <extra_id_0> treatment <extra_id_5> propranolol <extra_id_1> <extra_id_0> drug <extra_id_5> propranolol <extra_id_1> <extra_id_0> effect <extra_id_5> esophageal spasm <extra_id_1> <extra_id_1> <extra_id_0> potential therapeutic event <extra_id_5> relieved <extra_id_0> treatment <extra_id_5> intravenous glucagon <extra_id_1> <extra_id_0> drug <extra_id_5> glucagon <extra_id_1> <extra_id_0> dosage <extra_id_5> intravenous <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> propranolol overdose <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Fenclofenac <extra_id_1> <extra_id_0> drug <extra_id_5> Fenclofenac <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> selective IgA deficiency <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> pediatric population <extra_id_1> <extra_id_0> age <extra_id_5> pediatric <extra_id_1> <extra_id_0> treatment <extra_id_5> Naproxen <extra_id_1> <extra_id_0> drug <extra_id_5> Naproxen <extra_id_1> <extra_id_0> effect <extra_id_5> dimorphic clinical pattern <extra_id_5> a PCT - like presentation and one simulating erythropoietic protoporphyria <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treat <extra_id_0> treatment <extra_id_5> Zafirlukast <extra_id_1> <extra_id_0> drug <extra_id_5> Zafirlukast <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> allergic and exercise - induced asthma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> effect <extra_id_5> hyperglycemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> diagnosed <extra_id_0> subject <extra_id_5> a 61 - year - old man with a 30 - year history of fistulizing CD <extra_id_1> <extra_id_0> age <extra_id_5> 61 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> fistulizing CD <extra_id_1> <extra_id_0> treatment <extra_id_5> 9 months after treatment with infliximab <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> duration <extra_id_5> 9 months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 9 months <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> fistulizing CD <extra_id_1> <extra_id_0> effect <extra_id_5> B - cell non - Hodgkin 's lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> pediatric oncology patients <extra_id_1> <extra_id_0> age <extra_id_5> pediatric <extra_id_1> <extra_id_0> subject disorder <extra_id_5> pediatric oncology <extra_id_1> <extra_id_0> treatment <extra_id_5> ifosfamide <extra_id_1> <extra_id_0> drug <extra_id_5> ifosfamide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> pediatric oncology <extra_id_1> <extra_id_0> effect <extra_id_5> Fanconi syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient with chronic renal failure and ischemic heart disease <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic renal failure and ischemic heart disease <extra_id_1> <extra_id_0> treatment <extra_id_5> an axillary block with bupivacaine and additional injection of lidocaine in the operative field <extra_id_1> <extra_id_0> drug <extra_id_5> bupivacaine <extra_id_1> <extra_id_0> drug <extra_id_5> lidocaine <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> combination drug <extra_id_5> bupivacaine <extra_id_1> <extra_id_0> combination drug <extra_id_5> lidocaine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic renal failure and ischemic heart disease <extra_id_1> <extra_id_0> effect <extra_id_5> methemoglobinemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Amikacin <extra_id_1> <extra_id_0> drug <extra_id_5> Amikacin <extra_id_1> <extra_id_0> effect <extra_id_5> type 5 Bartter - like syndrome with severe hypocalcemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> effect <extra_id_5> necrotizing pancreatitis <extra_id_1> <extra_id_1> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> treatment <extra_id_5> percutaneous drainage <extra_id_1> <extra_id_0> drug <extra_id_5> percutaneous drainage <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> L - asparaginase - induced severe necrotizing pancreatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient without underlying heart disease <extra_id_1> <extra_id_0> treatment <extra_id_5> insulin <extra_id_1> <extra_id_0> drug <extra_id_5> insulin <extra_id_1> <extra_id_0> effect <extra_id_5> cardiac failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> frequency <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> leflunomide <extra_id_1> <extra_id_0> drug <extra_id_5> leflunomide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> weight loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> INH <extra_id_1> <extra_id_0> drug <extra_id_5> INH <extra_id_1> <extra_id_0> effect <extra_id_5> drug eruptions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> immediate instillations of epirubicin <extra_id_1> <extra_id_0> drug <extra_id_5> epirubicin <extra_id_1> <extra_id_0> route <extra_id_5> instillations <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> superficial urothelial tumours <extra_id_1> <extra_id_0> effect <extra_id_5> primary and secondary perforation of the bladder <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> Ofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> Ofloxacin <extra_id_1> <extra_id_0> effect <extra_id_5> toxic epidermal necrolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> subject <extra_id_5> a 62 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 62 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> advanced ovarian cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> six cycles of paclitaxel and carboplatin as combination chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> paclitaxel <extra_id_1> <extra_id_0> drug <extra_id_5> carboplatin <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> combination drug <extra_id_5> paclitaxel <extra_id_1> <extra_id_0> combination drug <extra_id_5> carboplatin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> advanced ovarian cancer <extra_id_1> <extra_id_0> effect <extra_id_5> Fatal lung fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 21 - year - old patient <extra_id_1> <extra_id_0> age <extra_id_5> 21 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> drug - resistant schizophrenia <extra_id_1> <extra_id_0> treatment <extra_id_5> nineteenth week of treatment with clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> clozapine <extra_id_1> <extra_id_0> duration <extra_id_5> nineteenth week <extra_id_1> <extra_id_0> time elapsed <extra_id_5> nineteenth week <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> drug - resistant schizophrenia <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient with neuroendocrine tumor of the cervix <extra_id_1> <extra_id_0> subject disorder <extra_id_5> neuroendocrine tumor of the cervix <extra_id_1> <extra_id_0> treatment <extra_id_5> Cisplatin <extra_id_1> <extra_id_0> drug <extra_id_5> Cisplatin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> neuroendocrine tumor of the cervix <extra_id_1> <extra_id_0> effect <extra_id_5> syndrome of inappropriate antidiuretic hormone ( SIADH ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> intravenous vasopressin infusion <extra_id_1> <extra_id_0> drug <extra_id_5> vasopressin <extra_id_1> <extra_id_0> route <extra_id_5> intravenous vasopressin infusion <extra_id_1> <extra_id_0> effect <extra_id_5> Myoglobinuria and acute renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> the first case <extra_id_1> <extra_id_0> age <extra_id_5> adult <extra_id_1> <extra_id_0> subject disorder <extra_id_5> hepatitis C <extra_id_1> <extra_id_0> treatment <extra_id_5> pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin <extra_id_1> <extra_id_0> drug <extra_id_5> pegylated interferon alpha - 2a <extra_id_1> <extra_id_0> drug <extra_id_5> ribavirin <extra_id_1> <extra_id_0> combination drug <extra_id_5> ribavirin <extra_id_1> <extra_id_0> combination drug <extra_id_5> pegylated interferon alpha - 2a <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hepatitis C <extra_id_1> <extra_id_0> effect <extra_id_5> fulminant adult respiratory distress syndrome ( ARDS ) <extra_id_1> <extra_id_0> effect <extra_id_5> sepsis and multiorgan failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> disulfiram therapy <extra_id_1> <extra_id_0> drug <extra_id_5> disulfiram <extra_id_1> <extra_id_0> effect <extra_id_5> Catatonia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> with <extra_id_0> treatment <extra_id_5> imiquimod <extra_id_1> <extra_id_0> drug <extra_id_5> imiquimod <extra_id_1> <extra_id_0> effect <extra_id_5> exaggerated ASRs <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Losartan <extra_id_1> <extra_id_0> drug <extra_id_5> Losartan <extra_id_1> <extra_id_0> effect <extra_id_5> angioedema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> mequitazine or other phenothiazine - derivative drugs <extra_id_1> <extra_id_0> drug <extra_id_5> mequitazine <extra_id_1> <extra_id_0> drug <extra_id_5> phenothiazine - derivative drugs <extra_id_1> <extra_id_0> effect <extra_id_5> photosensitivity reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> improved <extra_id_0> treatment <extra_id_5> Oxycodone - gabapentin <extra_id_1> <extra_id_0> drug <extra_id_5> Oxycodone <extra_id_1> <extra_id_0> drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> combination drug <extra_id_5> Oxycodone <extra_id_1> <extra_id_0> combination drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> pain relief <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> contributed <extra_id_0> subject <extra_id_5> 2 of the 3 cases <extra_id_1> <extra_id_0> population <extra_id_5> 2 of the 3 <extra_id_1> <extra_id_0> treatment <extra_id_5> lithium carbonate and beta - blockers <extra_id_1> <extra_id_0> drug <extra_id_5> lithium carbonate <extra_id_1> <extra_id_0> drug <extra_id_5> beta - blockers <extra_id_1> <extra_id_0> combination drug <extra_id_5> lithium carbonate <extra_id_1> <extra_id_0> combination drug <extra_id_5> beta - blockers <extra_id_1> <extra_id_0> effect <extra_id_5> incontinence <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> bis - chloronitrosourea ( BCNU ) therapy <extra_id_1> <extra_id_0> drug <extra_id_5> bis - chloronitrosourea <extra_id_1> <extra_id_0> effect <extra_id_5> Pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> died <extra_id_0> subject <extra_id_5> a 26 - year - old female with diffuse large B - cell lymphoma <extra_id_1> <extra_id_0> age <extra_id_5> 26 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> subject disorder <extra_id_5> diffuse large B - cell lymphoma <extra_id_1> <extra_id_0> treatment <extra_id_5> 81 days after the administration of high - dose BCNU ( 600 mg / m2 ) <extra_id_1> <extra_id_0> drug <extra_id_5> BCNU <extra_id_1> <extra_id_0> dosage <extra_id_5> 600 mg / m2 <extra_id_1> <extra_id_0> duration <extra_id_5> 81 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 81 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> diffuse large B - cell lymphoma <extra_id_1> <extra_id_0> effect <extra_id_5> severe pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> The patient <extra_id_1> <extra_id_0> treatment <extra_id_5> methimazole <extra_id_1> <extra_id_0> treatment <extra_id_5> propylthiouracil <extra_id_1> <extra_id_0> drug <extra_id_5> methimazole <extra_id_1> <extra_id_0> drug <extra_id_5> propylthiouracil <extra_id_1> <extra_id_0> duration <extra_id_5> 10 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 10 weeks <extra_id_1> <extra_id_0> combination drug <extra_id_5> methimazole <extra_id_1> <extra_id_0> combination drug <extra_id_5> propylthiouracil <extra_id_1> <extra_id_0> effect <extra_id_5> agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> she <extra_id_1> <extra_id_0> gender <extra_id_5> she <extra_id_1> <extra_id_0> treatment <extra_id_5> Three months after starting citalopram <extra_id_1> <extra_id_0> drug <extra_id_5> citalopram <extra_id_1> <extra_id_0> duration <extra_id_5> Three months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> Three months <extra_id_1> <extra_id_0> effect <extra_id_5> episodes of chest tightness and dizziness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> subject <extra_id_5> a small number of patients <extra_id_1> <extra_id_0> population <extra_id_5> small number <extra_id_1> <extra_id_0> treatment <extra_id_5> vincristine <extra_id_1> <extra_id_0> drug <extra_id_5> vincristine <extra_id_1> <extra_id_0> effect <extra_id_5> severe visual loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induce <extra_id_0> treatment <extra_id_5> glatiramer acetate <extra_id_1> <extra_id_0> drug <extra_id_5> glatiramer acetate <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> skin necrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> increase <extra_id_0> treatment <extra_id_5> SSRI - drugs <extra_id_1> <extra_id_0> drug <extra_id_5> SSRI - drugs <extra_id_1> <extra_id_0> effect <extra_id_5> serotonin concentrations and are known to have pruritus and other dermal side effects <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> increased <extra_id_0> subject <extra_id_5> patients undergoing total hip and total knee arthroplasty <extra_id_1> <extra_id_0> treatment <extra_id_5> Dabigatran etexilate and concomitant use of non - steroidal anti - inflammatory drugs or acetylsalicylic acid <extra_id_1> <extra_id_0> drug <extra_id_5> Dabigatran etexilate <extra_id_1> <extra_id_0> drug <extra_id_5> non - steroidal anti - inflammatory drugs <extra_id_1> <extra_id_0> drug <extra_id_5> acetylsalicylic acid <extra_id_1> <extra_id_0> combination drug <extra_id_5> Dabigatran etexilate <extra_id_1> <extra_id_0> combination drug <extra_id_5> non - steroidal anti - inflammatory drugs <extra_id_1> <extra_id_0> combination drug <extra_id_5> acetylsalicylic acid <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> total hip and total knee arthroplasty <extra_id_1> <extra_id_0> effect <extra_id_5> no increased risk of bleeding <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> onset <extra_id_0> subject <extra_id_5> six cases <extra_id_1> <extra_id_0> population <extra_id_5> six <extra_id_1> <extra_id_0> subject disorder <extra_id_5> MS <extra_id_1> <extra_id_0> treatment <extra_id_5> IFN - beta <extra_id_1> <extra_id_0> drug <extra_id_5> IFN - beta <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> MS <extra_id_1> <extra_id_0> effect <extra_id_5> inflammatory arthritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> treatment <extra_id_5> 24 hours following an increase in the dose of disopyramide from 300 to 600 mg / day <extra_id_1> <extra_id_0> drug <extra_id_5> disopyramide <extra_id_1> <extra_id_0> dosage <extra_id_5> from 300 to 600 mg / day <extra_id_1> <extra_id_0> duration <extra_id_5> 24 hours <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 24 hours <extra_id_1> <extra_id_0> effect <extra_id_5> AVT with syncope <extra_id_1> <extra_id_1> <extra_id_0> potential therapeutic event <extra_id_5> abolished <extra_id_0> treatment <extra_id_5> isoproterenol <extra_id_1> <extra_id_0> drug <extra_id_5> isoproterenol <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> AVT with syncope <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> The patient <extra_id_1> <extra_id_0> treatment <extra_id_5> hydration and furosemide <extra_id_1> <extra_id_0> drug <extra_id_5> furosemide <extra_id_1> <extra_id_0> drug <extra_id_5> hydration <extra_id_1> <extra_id_0> combination drug <extra_id_5> hydration <extra_id_1> <extra_id_0> combination drug <extra_id_5> furosemide <extra_id_1> <extra_id_0> effect <extra_id_5> congestive heart failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> having <extra_id_0> subject <extra_id_5> an HIV - positive woman <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> treatment <extra_id_5> antiretroviral therapy <extra_id_1> <extra_id_0> drug <extra_id_5> Implanon <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> effect <extra_id_5> tubal pregnancies <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> COX - 2 inhibitor <extra_id_1> <extra_id_0> drug <extra_id_5> COX - 2 inhibitor <extra_id_1> <extra_id_0> effect <extra_id_5> decreased renal elimination of MTX <extra_id_1> <extra_id_0> effect <extra_id_5> enhanced hematopoietic toxicity and immunosuppression <extra_id_1> <extra_id_0> effect <extra_id_5> EBV - associated lymphoproliferative disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Temsirolimus <extra_id_1> <extra_id_0> drug <extra_id_5> Temsirolimus <extra_id_1> <extra_id_0> effect <extra_id_5> glomerulopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> effect <extra_id_5> linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> This patient <extra_id_1> <extra_id_0> treatment <extra_id_5> 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue <extra_id_1> <extra_id_0> drug <extra_id_5> HD - MTX <extra_id_1> <extra_id_0> drug <extra_id_5> leucovorin rescue <extra_id_1> <extra_id_0> dosage <extra_id_5> 8 gm / m2 <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 5 days <extra_id_1> <extra_id_0> combination drug <extra_id_5> HD - MTX <extra_id_1> <extra_id_0> combination drug <extra_id_5> leucovorin rescue <extra_id_1> <extra_id_0> effect <extra_id_5> sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> dependent <extra_id_0> subject <extra_id_5> Adult and adolescent patients ( > or = 12 years old ; n = 141 ) <extra_id_1> <extra_id_0> age <extra_id_5> > or = 12 years old ; n = 141 <extra_id_1> <extra_id_0> population <extra_id_5> n = 141 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> severe , persistent , oral steroid ( prednisone) - dependent asthma <extra_id_1> <extra_id_0> treatment <extra_id_5> oral steroid ( prednisone) <extra_id_1> <extra_id_0> drug <extra_id_5> prednisone <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> severe , persistent , oral steroid ( prednisone) - dependent asthma <extra_id_1> <extra_id_0> effect <extra_id_5> persistent , oral steroid ( prednisone) - dependent asthma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> produce <extra_id_0> subject <extra_id_5> children and in adults with preexisting cardiac disease <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> age <extra_id_5> adults <extra_id_1> <extra_id_0> subject disorder <extra_id_5> preexisting cardiac disease <extra_id_1> <extra_id_0> treatment <extra_id_5> Amphotericin B deoxycholate <extra_id_1> <extra_id_0> drug <extra_id_5> Amphotericin B deoxycholate <extra_id_1> <extra_id_0> dosage <extra_id_5> overdoses <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> preexisting cardiac disease <extra_id_1> <extra_id_0> effect <extra_id_5> significant cardiac toxicity , with ventricular arrhythmias and bradycardia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a male 60 yrs of age <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> subject disorder <extra_id_5> unresectable rectum carcinoma <extra_id_1> <extra_id_0> treatment <extra_id_5> oxaliplatinum and 5 - fluorouracil <extra_id_1> <extra_id_0> drug <extra_id_5> oxaliplatinum <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> combination drug <extra_id_5> oxaliplatinum <extra_id_1> <extra_id_0> combination drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> unresectable rectum carcinoma <extra_id_1> <extra_id_0> effect <extra_id_5> Diarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> piperacillin and cefotiam <extra_id_1> <extra_id_0> drug <extra_id_5> piperacillin <extra_id_1> <extra_id_0> drug <extra_id_5> cefotiam <extra_id_1> <extra_id_0> combination drug <extra_id_5> piperacillin <extra_id_1> <extra_id_0> combination drug <extra_id_5> cefotiam <extra_id_1> <extra_id_0> effect <extra_id_5> tardive seizures <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 55 - yr - old man <extra_id_1> <extra_id_0> age <extra_id_5> 55 - yr - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> treatment <extra_id_5> thiabendazole <extra_id_1> <extra_id_0> drug <extra_id_5> thiabendazole <extra_id_1> <extra_id_0> effect <extra_id_5> prolonged jaundice and sicca complex <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Methylphenidate ( Ritalin) <extra_id_1> <extra_id_0> drug <extra_id_5> Methylphenidate <extra_id_1> <extra_id_0> effect <extra_id_5> cataract and glaucoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> implicated <extra_id_0> treatment <extra_id_5> Simvastatin - nelfinavir interaction <extra_id_1> <extra_id_0> drug <extra_id_5> Simvastatin <extra_id_1> <extra_id_0> drug <extra_id_5> nelfinavir <extra_id_1> <extra_id_0> combination drug <extra_id_5> Simvastatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> nelfinavir <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis and death <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> oxcarbazepine <extra_id_1> <extra_id_0> drug <extra_id_5> oxcarbazepine <extra_id_1> <extra_id_0> effect <extra_id_5> Uncontrolled headache <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> four cases <extra_id_1> <extra_id_0> population <extra_id_5> four <extra_id_1> <extra_id_0> subject disorder <extra_id_5> kidney transplant <extra_id_1> <extra_id_0> treatment <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> kidney transplant <extra_id_1> <extra_id_0> effect <extra_id_5> RSDS <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> high - dose methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> osteogenic sarcoma <extra_id_1> <extra_id_0> effect <extra_id_5> Transient neurological disturbances <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> patients with uncontrolled partial - onset seizures <extra_id_1> <extra_id_0> subject disorder <extra_id_5> uncontrolled partial - onset seizures <extra_id_1> <extra_id_0> treatment <extra_id_5> adjunctive lacosamide <extra_id_1> <extra_id_0> drug <extra_id_5> lacosamide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> uncontrolled partial - onset seizures <extra_id_1> <extra_id_0> effect <extra_id_5> Long - term safety and efficacy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occur <extra_id_0> subject <extra_id_5> adults and children <extra_id_1> <extra_id_0> age <extra_id_5> adults and children <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Tourette 's syndrome <extra_id_1> <extra_id_0> treatment <extra_id_5> carbamazepine ( CBZ ) therapy <extra_id_1> <extra_id_0> drug <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Tourette 's syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> A variety of movement disorders <extra_id_1> <extra_id_0> effect <extra_id_5> development of tics <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> he <extra_id_1> <extra_id_0> gender <extra_id_5> he <extra_id_1> <extra_id_0> subject disorder <extra_id_5> bladder cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> the third of six serial weekly BCG bladder instillations <extra_id_1> <extra_id_0> drug <extra_id_5> BCG <extra_id_1> <extra_id_0> route <extra_id_5> instillations <extra_id_1> <extra_id_0> frequency <extra_id_5> weekly <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> bladder cancer <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> received <extra_id_0> subject <extra_id_5> she <extra_id_1> <extra_id_0> gender <extra_id_5> she <extra_id_1> <extra_id_0> treatment <extra_id_5> quinidine , 1.2 g / day , without interruption for 17 years <extra_id_1> <extra_id_0> drug <extra_id_5> quinidine <extra_id_1> <extra_id_0> dosage <extra_id_5> 1.2 g / day <extra_id_1> <extra_id_0> duration <extra_id_5> 17 years <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 17 years <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> closed mitral valvotomy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> intrabiliary infusion of monooctanoin <extra_id_1> <extra_id_0> drug <extra_id_5> monooctanoin <extra_id_1> <extra_id_0> route <extra_id_5> intrabiliary infusion <extra_id_1> <extra_id_0> effect <extra_id_5> noncardiogenic pulmonary edema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Mitomycin - C <extra_id_1> <extra_id_0> drug <extra_id_5> Mitomycin - C <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> malignancies <extra_id_1> <extra_id_0> effect <extra_id_5> serious dose related adverse effects including the occurrence of hemolytic uremic syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> an adult patient without a history of metabolic disease <extra_id_1> <extra_id_0> age <extra_id_5> adult <extra_id_1> <extra_id_0> treatment <extra_id_5> Valproic acid <extra_id_1> <extra_id_0> drug <extra_id_5> Valproic acid <extra_id_1> <extra_id_0> effect <extra_id_5> coma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> Three patients with no history of asthma or allergy <extra_id_1> <extra_id_0> population <extra_id_5> Three <extra_id_1> <extra_id_0> subject disorder <extra_id_5> hypertension <extra_id_1> <extra_id_0> treatment <extra_id_5> propranolol <extra_id_1> <extra_id_0> drug <extra_id_5> propranolol <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hypertension <extra_id_1> <extra_id_0> effect <extra_id_5> bronchospasm <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulted <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> treatment <extra_id_5> tolterodine <extra_id_1> <extra_id_0> drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> combination drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> prolonged international normalized ratios ( INRs ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> UV exposure <extra_id_1> <extra_id_0> treatment <extra_id_5> mequitazine <extra_id_1> <extra_id_0> drug <extra_id_5> mequitazine <extra_id_1> <extra_id_0> effect <extra_id_5> immediate erythematous macule <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> accelerated <extra_id_0> treatment <extra_id_5> Acetazolamide <extra_id_1> <extra_id_0> drug <extra_id_5> Acetazolamide <extra_id_1> <extra_id_0> effect <extra_id_5> anticonvulsant osteomalacia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> became <extra_id_0> subject <extra_id_5> Both patients <extra_id_1> <extra_id_0> population <extra_id_5> Both <extra_id_1> <extra_id_0> treatment <extra_id_5> injection of chymopapain <extra_id_1> <extra_id_0> drug <extra_id_5> chymopapain <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> hypotensive <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> Large dose of methylphenidate <extra_id_1> <extra_id_0> drug <extra_id_5> methylphenidate <extra_id_1> <extra_id_0> dosage <extra_id_5> Large dose <extra_id_1> <extra_id_0> effect <extra_id_5> cataract and glaucoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a 54 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 54 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> leg cramps <extra_id_1> <extra_id_0> treatment <extra_id_5> quinine sulfate <extra_id_1> <extra_id_0> drug <extra_id_5> quinine sulfate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> leg cramps <extra_id_1> <extra_id_0> effect <extra_id_5> Total blindness with a transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Carbamazepine <extra_id_1> <extra_id_0> drug <extra_id_5> Carbamazepine <extra_id_1> <extra_id_0> effect <extra_id_5> tics <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> Three patients <extra_id_1> <extra_id_0> population <extra_id_5> Three <extra_id_1> <extra_id_0> treatment <extra_id_5> BCNU infusion <extra_id_1> <extra_id_0> drug <extra_id_5> BCNU <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> time elapsed <extra_id_5> immediately <extra_id_1> <extra_id_0> effect <extra_id_5> myocardial ischemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> ranolazine <extra_id_1> <extra_id_0> treatment <extra_id_5> clarithromycin <extra_id_1> <extra_id_0> drug <extra_id_5> clarithromycin <extra_id_1> <extra_id_0> drug <extra_id_5> ranolazine <extra_id_1> <extra_id_0> combination drug <extra_id_5> clarithromycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> ranolazine <extra_id_1> <extra_id_0> effect <extra_id_5> debilitating neurological adverse effect <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> intra - articular hyaluronate injection <extra_id_1> <extra_id_0> drug <extra_id_5> hyaluronate <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> Septic knee arthritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> colchicine and statin <extra_id_1> <extra_id_0> drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> drug <extra_id_5> statin <extra_id_1> <extra_id_0> combination drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> combination drug <extra_id_5> statin <extra_id_1> <extra_id_0> effect <extra_id_5> rapid onset of muscle weakness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> a patient with propylthiouracil - induced acute hepatic failure <extra_id_1> <extra_id_0> subject disorder <extra_id_5> propylthiouracil - induced acute hepatic failure <extra_id_1> <extra_id_0> treatment <extra_id_5> amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> propylthiouracil - induced acute hepatic failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> Olanzapine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> smoking cessation <extra_id_1> <extra_id_0> effect <extra_id_5> parkinsonism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> an 11 - year old male with Budd - Chiari syndrome <extra_id_1> <extra_id_0> age <extra_id_5> 11 - year old <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Budd - Chiari syndrome <extra_id_1> <extra_id_0> treatment <extra_id_5> immunosuppressive therapy was changed from tacrolimus to sirolimus <extra_id_1> <extra_id_0> drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> drug <extra_id_5> sirolimus <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Budd - Chiari syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> profound worsening of chronic aphthous ulcers <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> two patients <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> taking riluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks <extra_id_1> <extra_id_0> drug <extra_id_5> riluzole <extra_id_1> <extra_id_0> dosage <extra_id_5> 100 mg <extra_id_1> <extra_id_0> duration <extra_id_5> 7 and 4 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 7 and 4 weeks <extra_id_1> <extra_id_0> effect <extra_id_5> acute hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulting <extra_id_0> treatment <extra_id_5> interaction between levodopa and enteral nutrition <extra_id_1> <extra_id_0> drug <extra_id_5> levodopa <extra_id_1> <extra_id_0> route <extra_id_5> enteral <extra_id_1> <extra_id_0> combination drug <extra_id_5> levodopa <extra_id_1> <extra_id_0> combination drug <extra_id_5> enteral <extra_id_1> <extra_id_0> effect <extra_id_5> neuroleptic malignant - like syndrome and prolonged ICU stay <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> when <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> tolterodine therapy is initiated in a patient maintained on warfarin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> combination drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> drug interaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> disappeared <extra_id_0> subject <extra_id_5> The itch spread to the arms , abdomen and legs <extra_id_1> <extra_id_0> gender <extra_id_5> patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> itch <extra_id_1> <extra_id_0> treatment <extra_id_5> clemastine <extra_id_1> <extra_id_0> drug <extra_id_5> clemastine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> itch <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> causing <extra_id_0> subject <extra_id_5> a 36 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 36 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> erythromycin and ergotamine at normal doses <extra_id_1> <extra_id_0> drug <extra_id_5> erythromycin <extra_id_1> <extra_id_0> drug <extra_id_5> ergotamine <extra_id_1> <extra_id_0> dosage <extra_id_5> normal doses <extra_id_1> <extra_id_0> combination drug <extra_id_5> erythromycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> ergotamine <extra_id_1> <extra_id_0> effect <extra_id_5> lower extremity ischemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occur <extra_id_0> treatment <extra_id_5> phenothiazines and clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> phenothiazines <extra_id_1> <extra_id_0> combination drug <extra_id_5> clozapine <extra_id_1> <extra_id_0> combination drug <extra_id_5> phenothiazines <extra_id_1> <extra_id_0> effect <extra_id_5> Neutropenia and agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> taking <extra_id_0> subject <extra_id_5> She <extra_id_1> <extra_id_0> gender <extra_id_5> She <extra_id_1> <extra_id_0> subject disorder <extra_id_5> acid - fast bacilli <extra_id_1> <extra_id_0> treatment <extra_id_5> rifampin <extra_id_1> <extra_id_0> drug <extra_id_5> rifampin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acid - fast bacilli <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> pathogenesis <extra_id_0> treatment <extra_id_5> CCNU <extra_id_1> <extra_id_0> drug <extra_id_5> CCNU <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> taking <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> raloxifene <extra_id_1> <extra_id_0> drug <extra_id_5> raloxifene <extra_id_1> <extra_id_0> effect <extra_id_5> Malignant mixed mullerian tumor of the uterus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> quetiapine <extra_id_1> <extra_id_0> drug <extra_id_5> quetiapine <extra_id_1> <extra_id_0> effect <extra_id_5> Fatal overdoses <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> Gemcitabine <extra_id_1> <extra_id_0> effect <extra_id_5> rectus abdominus radiation recall <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> a severely depressed 55 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 55 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> severely depressed <extra_id_1> <extra_id_0> treatment <extra_id_5> combination treatment with antidepressants , atypical antipsychotic drugs , the mood stabilizer lithium and the lipid - lowering drug pravastatin <extra_id_1> <extra_id_0> drug <extra_id_5> antidepressants <extra_id_1> <extra_id_0> drug <extra_id_5> atypical antipsychotic drugs <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> drug <extra_id_5> pravastatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> antidepressants <extra_id_1> <extra_id_0> combination drug <extra_id_5> atypical antipsychotic drugs <extra_id_1> <extra_id_0> combination drug <extra_id_5> lithium <extra_id_1> <extra_id_0> combination drug <extra_id_5> pravastatin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> severely depressed <extra_id_1> <extra_id_0> effect <extra_id_5> erythematous pigmented skin rash on the whole body <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a 20 - year - old woman with Basedow - Graves ' disease <extra_id_1> <extra_id_0> age <extra_id_5> 20 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Basedow - Graves ' disease <extra_id_1> <extra_id_0> treatment <extra_id_5> PTU <extra_id_1> <extra_id_0> drug <extra_id_5> PTU <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Basedow - Graves ' disease <extra_id_1> <extra_id_0> effect <extra_id_5> fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reduce <extra_id_0> subject <extra_id_5> children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> subject disorder <extra_id_5> increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma <extra_id_1> <extra_id_0> treatment <extra_id_5> high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX ) <extra_id_1> <extra_id_0> drug <extra_id_5> cytarabine <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose ( HD ) intravenous ( IV ) <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> combination drug <extra_id_5> cytarabine <extra_id_1> <extra_id_0> combination drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma <extra_id_1> <extra_id_0> effect <extra_id_5> incidence of CNS and systemic relapses <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurs <extra_id_0> treatment <extra_id_5> combination with phenothiazines , primarily thioridazine <extra_id_1> <extra_id_0> drug <extra_id_5> phenothiazines <extra_id_1> <extra_id_0> drug <extra_id_5> thioridazine <extra_id_1> <extra_id_0> combination drug <extra_id_5> phenothiazines <extra_id_1> <extra_id_0> combination drug <extra_id_5> thioridazine <extra_id_1> <extra_id_0> effect <extra_id_5> neuroleptic malignant extrapyramidal syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> lithium toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> treatment <extra_id_5> Trans - catheter hepatic arterial injection of lipiodol soluble anti - cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia <extra_id_1> <extra_id_0> drug <extra_id_5> lipiodol <extra_id_1> <extra_id_0> drug <extra_id_5> ADR <extra_id_1> <extra_id_0> route <extra_id_5> Trans - catheter hepatic arterial injection <extra_id_1> <extra_id_0> combination drug <extra_id_5> lipiodol <extra_id_1> <extra_id_0> combination drug <extra_id_5> ADR <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hepatocellular carcinoma <extra_id_1> <extra_id_0> effect <extra_id_5> arterial embolization and local hyperthermia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> theophylline <extra_id_1> <extra_id_0> drug <extra_id_5> theophylline <extra_id_1> <extra_id_0> effect <extra_id_5> Gynecomastia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> multiple sclerosis patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> multiple sclerosis <extra_id_1> <extra_id_0> treatment <extra_id_5> interferon - beta <extra_id_1> <extra_id_0> drug <extra_id_5> interferon - beta <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> multiple sclerosis <extra_id_1> <extra_id_0> effect <extra_id_5> Arthritis and bursitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> diltiazem hydrochloride <extra_id_1> <extra_id_0> drug <extra_id_5> diltiazem hydrochloride <extra_id_1> <extra_id_0> effect <extra_id_5> fever <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> heparin <extra_id_1> <extra_id_0> drug <extra_id_5> heparin <extra_id_1> <extra_id_0> effect <extra_id_5> thrombocytopenia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> a 41 yr old leprosy patient <extra_id_1> <extra_id_0> age <extra_id_5> 41 yr old <extra_id_1> <extra_id_0> subject disorder <extra_id_5> leprosy <extra_id_1> <extra_id_0> treatment <extra_id_5> 10 yrs with clofazimine <extra_id_1> <extra_id_0> drug <extra_id_5> clofazimine <extra_id_1> <extra_id_0> duration <extra_id_5> 10 yrs <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 10 yrs <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> leprosy <extra_id_1> <extra_id_0> effect <extra_id_5> severe abdominal pain <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side effect <extra_id_0> treatment <extra_id_5> antiemetic treatment with dexamethasone <extra_id_1> <extra_id_0> drug <extra_id_5> dexamethasone <extra_id_1> <extra_id_0> effect <extra_id_5> Osteonecrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> subject <extra_id_5> a patient with acute promyleocytic leukemia ( APL ) <extra_id_1> <extra_id_0> subject disorder <extra_id_5> acute promyleocytic leukemia ( APL ) <extra_id_1> <extra_id_0> treatment <extra_id_5> within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily <extra_id_1> <extra_id_0> drug <extra_id_5> ATRA <extra_id_1> <extra_id_0> dosage <extra_id_5> 40 mg <extra_id_1> <extra_id_0> route <extra_id_5> orally <extra_id_1> <extra_id_0> duration <extra_id_5> 10 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 10 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute promyleocytic leukemia ( APL ) <extra_id_1> <extra_id_0> effect <extra_id_5> scrotal ulcer <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> increased <extra_id_0> treatment <extra_id_5> topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day <extra_id_1> <extra_id_0> drug <extra_id_5> vitamin D3 <extra_id_1> <extra_id_0> dosage <extra_id_5> 20 micro g / g <extra_id_1> <extra_id_0> route <extra_id_5> topical <extra_id_1> <extra_id_0> frequency <extra_id_5> 10 g / day <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> skin lesions <extra_id_1> <extra_id_0> effect <extra_id_5> both the serum level of calcium and urinary excretion of calcium increased gradually <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> Vancomycin <extra_id_1> <extra_id_0> drug <extra_id_5> Vancomycin <extra_id_1> <extra_id_0> effect <extra_id_5> LABD <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> treatment with methylprednisolone <extra_id_1> <extra_id_0> drug <extra_id_5> methylprednisolone <extra_id_1> <extra_id_0> effect <extra_id_5> Vision declined <extra_id_1> <extra_id_0> effect <extra_id_5> progressive outer retinal necrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> showed <extra_id_0> subject <extra_id_5> he <extra_id_1> <extra_id_0> gender <extra_id_5> he <extra_id_1> <extra_id_0> treatment <extra_id_5> Eight days after the end of interferon treatment <extra_id_1> <extra_id_0> drug <extra_id_5> interferon <extra_id_1> <extra_id_0> duration <extra_id_5> Eight days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> Eight days <extra_id_1> <extra_id_0> effect <extra_id_5> inability to sit still for ten seconds and walked around constantly <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> infliximab <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> enteropathic spondyloarthropathy <extra_id_1> <extra_id_0> effect <extra_id_5> agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Aripiprazole <extra_id_1> <extra_id_0> drug <extra_id_5> Aripiprazole <extra_id_1> <extra_id_0> effect <extra_id_5> hiccups <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> normalized <extra_id_0> treatment <extra_id_5> discontinuation of pegvisomant <extra_id_1> <extra_id_0> drug <extra_id_5> pegvisomant <extra_id_1> <extra_id_0> effect <extra_id_5> hepatic enzyme disturbances normalized <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a 58 - year - old female patient with Graves ' disease <extra_id_1> <extra_id_0> age <extra_id_5> 58 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Graves ' disease <extra_id_1> <extra_id_0> treatment <extra_id_5> methimazole ( MMI ) <extra_id_1> <extra_id_0> drug <extra_id_5> methimazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Graves ' disease <extra_id_1> <extra_id_0> effect <extra_id_5> AA <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> effect <extra_id_5> radiation recall in rectus abdominus muscles <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> after <extra_id_0> subject <extra_id_5> One patient was an 80 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 80 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> population <extra_id_5> One <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Staphylococcus aureus knee arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> intraarticular injections of sodium hyaluronate and corticosteroids <extra_id_1> <extra_id_0> drug <extra_id_5> sodium hyaluronate <extra_id_1> <extra_id_0> drug <extra_id_5> corticosteroids <extra_id_1> <extra_id_0> route <extra_id_5> intraarticular injections <extra_id_1> <extra_id_0> combination drug <extra_id_5> sodium hyaluronate <extra_id_1> <extra_id_0> combination drug <extra_id_5> corticosteroids <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Staphylococcus aureus knee arthritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> association <extra_id_0> treatment <extra_id_5> zomepirac <extra_id_1> <extra_id_0> drug <extra_id_5> zomepirac <extra_id_1> <extra_id_0> effect <extra_id_5> renal cortical necrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> gold sodium thiomalate <extra_id_1> <extra_id_0> drug <extra_id_5> gold sodium thiomalate <extra_id_1> <extra_id_0> effect <extra_id_5> Vasomotor reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> Moxifloxacin - acetaminophen - warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> Moxifloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> acetaminophen <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> combination drug <extra_id_5> Moxifloxacin <extra_id_1> <extra_id_0> combination drug <extra_id_5> acetaminophen <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> bladder cancer <extra_id_1> <extra_id_0> effect <extra_id_5> Moxifloxacin - acetaminophen - warfarin interaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> four patients <extra_id_1> <extra_id_0> population <extra_id_5> four <extra_id_1> <extra_id_0> treatment <extra_id_5> intensive chemotherapy containing busulfan <extra_id_1> <extra_id_0> drug <extra_id_5> busulfan <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 2 - 45 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> severe hepatic veno - occlusive disease ( HVOD ) <extra_id_1> <extra_id_0> effect <extra_id_5> thrombosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> An adolescent male <extra_id_1> <extra_id_0> age <extra_id_5> adolescent <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> treatment <extra_id_5> 16 weeks after cessation of intramuscular L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> route <extra_id_5> intramuscular <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 16 weeks <extra_id_1> <extra_id_0> effect <extra_id_5> acute pancreatitis and pseudocyst of the pancreas <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> in <extra_id_0> subject <extra_id_5> patients with cystic fibrosis and the G551D mutation <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cystic fibrosis <extra_id_1> <extra_id_0> treatment <extra_id_5> A CFTR potentiator <extra_id_1> <extra_id_0> drug <extra_id_5> A CFTR potentiator <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cystic fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> lead <extra_id_0> treatment <extra_id_5> Quinapril <extra_id_1> <extra_id_0> drug <extra_id_5> Quinapril <extra_id_1> <extra_id_0> dosage <extra_id_5> overdose <extra_id_1> <extra_id_0> effect <extra_id_5> prolonged hypotension and , less frequently , transient renal impairment <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developing <extra_id_0> subject <extra_id_5> a renal transplant recipient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> renal transplant <extra_id_1> <extra_id_0> treatment <extra_id_5> maintained on cyclosporine and prednisone <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> drug <extra_id_5> prednisone <extra_id_1> <extra_id_0> combination drug <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> combination drug <extra_id_5> prednisone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> renal transplant <extra_id_1> <extra_id_0> effect <extra_id_5> Nocardia Asteroides brain abscess <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> control <extra_id_0> subject <extra_id_5> a patient with PTU - induced fulminant hepatitis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> PTU - induced fulminant hepatitis <extra_id_1> <extra_id_0> treatment <extra_id_5> amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> PTU - induced fulminant hepatitis <extra_id_1> <extra_id_0> effect <extra_id_5> control hyperthyroidism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> the patient 's mother <extra_id_1> <extra_id_0> gender <extra_id_5> mother <extra_id_1> <extra_id_0> treatment <extra_id_5> metamizole <extra_id_1> <extra_id_0> drug <extra_id_5> metamizole <extra_id_1> <extra_id_0> effect <extra_id_5> sepsis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> a patient with a long - standing history of refractory CLL <extra_id_1> <extra_id_0> subject disorder <extra_id_5> refractory CLL <extra_id_1> <extra_id_0> treatment <extra_id_5> fludarabine phosphate <extra_id_1> <extra_id_0> drug <extra_id_5> fludarabine phosphate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> refractory CLL <extra_id_1> <extra_id_0> effect <extra_id_5> respiratory syncytial virus ( RSV ) infection <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> A 77 - year - old woman with no history of epilepsy <extra_id_1> <extra_id_0> age <extra_id_5> 77 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> vertebral metastasis of a malignant lymphoma <extra_id_1> <extra_id_0> treatment <extra_id_5> continuous intravenous morphine <extra_id_1> <extra_id_0> drug <extra_id_5> morphine <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> vertebral metastasis of a malignant lymphoma <extra_id_1> <extra_id_0> effect <extra_id_5> probable nonconvulsive status epilepticus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reduce <extra_id_0> treatment <extra_id_5> replacing OCS with inhaled corticosteroids ( ICS ) <extra_id_1> <extra_id_0> drug <extra_id_5> corticosteroids <extra_id_1> <extra_id_0> route <extra_id_5> inhaled <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> systemic adverse events ( AEs ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> long - term colchicine treatment <extra_id_1> <extra_id_0> drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> effect <extra_id_5> Peyronie 's disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reverse <extra_id_0> subject <extra_id_5> DPD - deficient patients with severe acute 5 - FU reactions <extra_id_1> <extra_id_0> subject disorder <extra_id_5> 5 - FU - induced neurologic symptoms such as encephalopathy and coma <extra_id_1> <extra_id_0> treatment <extra_id_5> thymidine <extra_id_1> <extra_id_0> drug <extra_id_5> thymidine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> 5 - FU - induced neurologic symptoms such as encephalopathy and coma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> a patient with aspirin - induced asthma <extra_id_1> <extra_id_0> subject disorder <extra_id_5> aspirin - induced asthma <extra_id_1> <extra_id_0> treatment <extra_id_5> zafirlukast <extra_id_1> <extra_id_0> drug <extra_id_5> zafirlukast <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> aspirin - induced asthma <extra_id_1> <extra_id_0> effect <extra_id_5> Adverse reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> gold <extra_id_1> <extra_id_0> drug <extra_id_5> gold <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> nephrotic syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complications <extra_id_0> treatment <extra_id_5> nonsteroidal anti - inflammatory agents , especially zomepirac <extra_id_1> <extra_id_0> drug <extra_id_5> zomepirac <extra_id_1> <extra_id_0> effect <extra_id_5> renal complications <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> resolved <extra_id_0> treatment <extra_id_5> discontinuation of metronidazole <extra_id_1> <extra_id_0> drug <extra_id_5> metronidazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Clinical , spectroscopic , and imaging abnormalities <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> started <extra_id_0> subject <extra_id_5> two other patients ( one after OLTX and one with Crohn 's disease ) <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Crohn 's disease <extra_id_1> <extra_id_0> treatment <extra_id_5> raltegravir - based HIV therapy <extra_id_1> <extra_id_0> treatment <extra_id_5> 1 or 2 mg of tacrolimus twice daily <extra_id_1> <extra_id_0> drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> dosage <extra_id_5> 1 or 2 mg <extra_id_1> <extra_id_0> frequency <extra_id_5> twice daily <extra_id_1> <extra_id_0> combination drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> combination drug <extra_id_5> raltegravir <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Crohn 's disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> interferon alpha <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alpha <extra_id_1> <extra_id_0> effect <extra_id_5> Reversible cardiomyopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Metipranolol <extra_id_1> <extra_id_0> drug <extra_id_5> Metipranolol <extra_id_1> <extra_id_0> effect <extra_id_5> granulomatous anterior uveitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> increase <extra_id_0> treatment <extra_id_5> tifacogin <extra_id_1> <extra_id_0> drug <extra_id_5> tifacogin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> high INR <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> low INR <extra_id_1> <extra_id_0> effect <extra_id_5> serious adverse events with bleeding <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> timolol <extra_id_1> <extra_id_0> drug <extra_id_5> timolol <extra_id_1> <extra_id_0> effect <extra_id_5> ocular pemphigoid <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> A 70 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 70 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> itching <extra_id_1> <extra_id_0> treatment <extra_id_5> antihistaminic agent ( homochlorcyclizine hydrochloride ) <extra_id_1> <extra_id_0> drug <extra_id_5> homochlorcyclizine hydrochloride <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> itching <extra_id_1> <extra_id_0> effect <extra_id_5> dyspnea <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> when <extra_id_0> treatment <extra_id_5> antiretroviral regimen including nevirapine <extra_id_1> <extra_id_0> drug <extra_id_5> nevirapine <extra_id_1> <extra_id_0> drug <extra_id_5> Methadone <extra_id_1> <extra_id_0> combination drug <extra_id_5> nevirapine <extra_id_1> <extra_id_0> combination drug <extra_id_5> Methadone <extra_id_1> <extra_id_0> effect <extra_id_5> Methadone withdrawal <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> zonisamide <extra_id_1> <extra_id_0> drug <extra_id_5> zonisamide <extra_id_1> <extra_id_0> effect <extra_id_5> oligohidrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> lung and breast cancer <extra_id_1> <extra_id_0> effect <extra_id_5> Radiation recall <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> risk <extra_id_0> treatment <extra_id_5> clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> clozapine <extra_id_1> <extra_id_0> effect <extra_id_5> neutropenia and agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> human immunodeficiency virus infection <extra_id_1> <extra_id_0> subject disorder <extra_id_5> immunodeficiency virus infection <extra_id_1> <extra_id_0> treatment <extra_id_5> Vicriviroc ( SCH 417690 ) <extra_id_1> <extra_id_0> drug <extra_id_5> Vicriviroc <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> immunodeficiency virus infection <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> subject <extra_id_5> Children <extra_id_1> <extra_id_0> age <extra_id_5> Children <extra_id_1> <extra_id_0> treatment <extra_id_5> zonisamide <extra_id_1> <extra_id_0> drug <extra_id_5> zonisamide <extra_id_1> <extra_id_0> effect <extra_id_5> oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> 2 male patients <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> population <extra_id_5> 2 <extra_id_1> <extra_id_0> treatment <extra_id_5> venlafaxine <extra_id_1> <extra_id_0> drug <extra_id_5> venlafaxine <extra_id_1> <extra_id_0> effect <extra_id_5> incontinence <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> ethambutol and rifampicin <extra_id_1> <extra_id_0> drug <extra_id_5> ethambutol <extra_id_1> <extra_id_0> drug <extra_id_5> rifampicin <extra_id_1> <extra_id_0> combination drug <extra_id_5> ethambutol <extra_id_1> <extra_id_0> combination drug <extra_id_5> rifampicin <extra_id_1> <extra_id_0> effect <extra_id_5> Polyarthritis , hepatitis and anti - native DNA antibodies <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> an HIV - infected woman <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> treatment <extra_id_5> nevirapine <extra_id_1> <extra_id_0> drug <extra_id_5> nevirapine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> effect <extra_id_5> mild leukopenia <extra_id_1> <extra_id_0> effect <extra_id_5> skin and hepatic toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> a geriatric patient <extra_id_1> <extra_id_0> age <extra_id_5> geriatric <extra_id_1> <extra_id_0> treatment <extra_id_5> 3 days after treatment with olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> duration <extra_id_5> 3 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 3 days <extra_id_1> <extra_id_0> effect <extra_id_5> rapidly occurring hyperglycemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Tifacogin <extra_id_1> <extra_id_0> drug <extra_id_5> Tifacogin <extra_id_1> <extra_id_0> effect <extra_id_5> increase in risk of bleeding <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> two epileptic patients <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> epileptic <extra_id_1> <extra_id_0> treatment <extra_id_5> addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin <extra_id_1> <extra_id_0> drug <extra_id_5> fluoresone <extra_id_1> <extra_id_0> drug <extra_id_5> phenobarbital <extra_id_1> <extra_id_0> drug <extra_id_5> phenytoin <extra_id_1> <extra_id_0> dosage <extra_id_5> 750 mg <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> frequency <extra_id_5> daily <extra_id_1> <extra_id_0> combination drug <extra_id_5> phenobarbital <extra_id_1> <extra_id_0> combination drug <extra_id_5> phenytoin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> epileptic <extra_id_1> <extra_id_0> effect <extra_id_5> Gynecomastia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> characterized <extra_id_0> treatment <extra_id_5> combined lithium and haloperidol <extra_id_1> <extra_id_0> drug <extra_id_5> haloperidol <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> combination drug <extra_id_5> lithium <extra_id_1> <extra_id_0> combination drug <extra_id_5> haloperidol <extra_id_1> <extra_id_0> effect <extra_id_5> hyperpyrexia , severe rigidity , mutism , and development of irreversible tardive dyskinesia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> clozapine <extra_id_1> <extra_id_0> effect <extra_id_5> dangerous side effects such as agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> reported <extra_id_0> subject <extra_id_5> Two women and one man <extra_id_1> <extra_id_0> gender <extra_id_5> women <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> population <extra_id_5> One <extra_id_1> <extra_id_0> treatment <extra_id_5> intravenous L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> effect <extra_id_5> pseudocyst of the pancreas <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Ritalin <extra_id_1> <extra_id_0> drug <extra_id_5> Ritalin <extra_id_1> <extra_id_0> effect <extra_id_5> cataract and glaucoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> short - term therapy with Amikacin <extra_id_1> <extra_id_0> drug <extra_id_5> Amikacin <extra_id_1> <extra_id_0> effect <extra_id_5> severe renal tubular dysfunction <extra_id_1> <extra_id_0> effect <extra_id_5> refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> BCNU <extra_id_1> <extra_id_0> drug <extra_id_5> BCNU <extra_id_1> <extra_id_0> effect <extra_id_5> Cardiac toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> prevent <extra_id_0> treatment <extra_id_5> Aprepitant <extra_id_1> <extra_id_0> treatment <extra_id_5> when added to conventional therapy with a corticosteroid and a 5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist <extra_id_1> <extra_id_0> drug <extra_id_5> Aprepitant <extra_id_1> <extra_id_0> drug <extra_id_5> corticosteroid <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist <extra_id_1> <extra_id_0> combination drug <extra_id_5> Aprepitant <extra_id_1> <extra_id_0> combination drug <extra_id_5> corticosteroid <extra_id_1> <extra_id_0> combination drug <extra_id_5> 5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chemotherapy - induced nausea and vomiting <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> nephrotic syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> HUS <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> receiving <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> pentamidine <extra_id_1> <extra_id_0> drug <extra_id_5> pentamidine <extra_id_1> <extra_id_0> effect <extra_id_5> cardiotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> vitamin D3 ointment and thiazide simultaneously <extra_id_1> <extra_id_0> drug <extra_id_5> thiazide <extra_id_1> <extra_id_0> drug <extra_id_5> vitamin D3 ointment <extra_id_1> <extra_id_0> combination drug <extra_id_5> thiazide <extra_id_1> <extra_id_0> combination drug <extra_id_5> vitamin D3 ointment <extra_id_1> <extra_id_0> effect <extra_id_5> hypercalcemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> adverse event <extra_id_0> subject <extra_id_5> patients with rheumatoid arthritis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> leflunomide <extra_id_1> <extra_id_0> drug <extra_id_5> leflunomide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> Significant weight loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> had <extra_id_0> subject <extra_id_5> a man with classic rheumatoid arthritis <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> classic rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> gold or penicillamine therapy <extra_id_1> <extra_id_0> drug <extra_id_5> gold <extra_id_1> <extra_id_0> drug <extra_id_5> penicillamine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> classic rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> membranous nephropathy <extra_id_1> <extra_id_0> effect <extra_id_5> nephrotic syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> HIV - infected patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> subject disorder <extra_id_5> tuberculosis <extra_id_1> <extra_id_0> treatment <extra_id_5> etravirine <extra_id_1> <extra_id_0> treatment <extra_id_5> rifampin <extra_id_1> <extra_id_0> drug <extra_id_5> etravirine <extra_id_1> <extra_id_0> drug <extra_id_5> rifampin <extra_id_1> <extra_id_0> combination drug <extra_id_5> etravirine <extra_id_1> <extra_id_0> combination drug <extra_id_5> rifampin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> tuberculosis <extra_id_1> <extra_id_0> effect <extra_id_5> Pharmacokinetics of etravirine <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> led <extra_id_0> treatment <extra_id_5> an excessive dose of AZ <extra_id_1> <extra_id_0> drug <extra_id_5> AZ <extra_id_1> <extra_id_0> dosage <extra_id_5> excessive dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> bone marrow disorder <extra_id_1> <extra_id_0> effect <extra_id_5> hemorrhagic gastritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Acyclovir <extra_id_1> <extra_id_0> drug <extra_id_5> Acyclovir <extra_id_1> <extra_id_0> dosage <extra_id_5> overdose <extra_id_1> <extra_id_0> effect <extra_id_5> neurotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> a patient with rheumatoid arthritis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> sulphasalazine therapy <extra_id_1> <extra_id_0> drug <extra_id_5> sulphasalazine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> Psoriasis - like skin reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> diagnosed <extra_id_0> subject <extra_id_5> 2 patients with Crohn 's disease ( CD ) <extra_id_1> <extra_id_0> population <extra_id_5> 2 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Crohn 's disease ( CD ) <extra_id_1> <extra_id_0> treatment <extra_id_5> infliximab <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Crohn 's disease ( CD ) <extra_id_1> <extra_id_0> effect <extra_id_5> lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> treatment <extra_id_5> Valproic acid <extra_id_1> <extra_id_0> drug <extra_id_5> Valproic acid <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> idiopathic generalized epilepsies <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> juvenile absence epilepsy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> manifesting <extra_id_0> subject <extra_id_5> a case <extra_id_1> <extra_id_0> treatment <extra_id_5> intrathecal methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal <extra_id_1> <extra_id_0> effect <extra_id_5> left arm weakness and aphasia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> relationship <extra_id_0> treatment <extra_id_5> warfarin - cloxacillin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> cloxacillin <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> combination drug <extra_id_5> cloxacillin <extra_id_1> <extra_id_0> effect <extra_id_5> increased INR value <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> two female patients <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> relapsing - remitting multiple sclerosis ( RRMS ) <extra_id_1> <extra_id_0> treatment <extra_id_5> IFN - beta therapy <extra_id_1> <extra_id_0> drug <extra_id_5> IFN - beta <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> relapsing - remitting multiple sclerosis ( RRMS ) <extra_id_1> <extra_id_0> effect <extra_id_5> inflammatory musculoskeletal manifestations <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> brain - damaged children <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> subject disorder <extra_id_5> brain - damaged <extra_id_1> <extra_id_0> treatment <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> drug <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> brain - damaged <extra_id_1> <extra_id_0> effect <extra_id_5> Dystonia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> with <extra_id_0> subject <extra_id_5> 51 patients <extra_id_1> <extra_id_0> population <extra_id_5> 51 <extra_id_1> <extra_id_0> treatment <extra_id_5> omeprazole <extra_id_1> <extra_id_0> treatment <extra_id_5> placebo <extra_id_1> <extra_id_0> drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> drug <extra_id_5> placebo <extra_id_1> <extra_id_0> duration <extra_id_5> 180 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 180 days <extra_id_1> <extra_id_0> effect <extra_id_5> gastrointestinal event <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> use <extra_id_0> subject <extra_id_5> a case <extra_id_1> <extra_id_0> treatment <extra_id_5> pamidronate <extra_id_1> <extra_id_0> drug <extra_id_5> pamidronate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute vitamin D poisoning <extra_id_1> <extra_id_0> effect <extra_id_5> significant hypercalcemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> in <extra_id_0> treatment <extra_id_5> Clopidogrel with or without omeprazole <extra_id_1> <extra_id_0> drug <extra_id_5> Clopidogrel <extra_id_1> <extra_id_0> drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> combination drug <extra_id_5> Clopidogrel <extra_id_1> <extra_id_0> combination drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> coronary artery disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> contributed <extra_id_0> subject <extra_id_5> patients with dementia <extra_id_1> <extra_id_0> age <extra_id_5> elderly <extra_id_1> <extra_id_0> subject disorder <extra_id_5> dementia <extra_id_1> <extra_id_0> treatment <extra_id_5> risperidone <extra_id_1> <extra_id_0> drug <extra_id_5> risperidone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> dementia <extra_id_1> <extra_id_0> effect <extra_id_5> dystonia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> ciprofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> ciprofloxacin <extra_id_1> <extra_id_0> effect <extra_id_5> prolonged ECT seizure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> resolved <extra_id_0> subject <extra_id_5> his delirium <extra_id_1> <extra_id_0> gender <extra_id_5> his <extra_id_1> <extra_id_0> subject disorder <extra_id_5> delirium <extra_id_1> <extra_id_0> treatment <extra_id_5> abstinence from oolong tea <extra_id_1> <extra_id_0> drug <extra_id_5> oolong tea <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> delirium <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> to <extra_id_0> treatment <extra_id_5> intrathecal diamorphine <extra_id_1> <extra_id_0> drug <extra_id_5> diamorphine <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal <extra_id_1> <extra_id_0> effect <extra_id_5> Anaphylaxis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> result <extra_id_0> treatment <extra_id_5> acyclovir when given intravenously in doses of 10 mg / kg <extra_id_1> <extra_id_0> drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> dosage <extra_id_5> 10 mg / kg <extra_id_1> <extra_id_0> route <extra_id_5> intravenously <extra_id_1> <extra_id_0> effect <extra_id_5> increased serum lithium concentrations <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> After <extra_id_0> subject <extra_id_5> he <extra_id_1> <extra_id_0> gender <extra_id_5> he <extra_id_1> <extra_id_0> treatment <extra_id_5> After approximately two weeks of sertraline treatment <extra_id_1> <extra_id_0> drug <extra_id_5> sertraline <extra_id_1> <extra_id_0> duration <extra_id_5> two weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> two weeks <extra_id_1> <extra_id_0> effect <extra_id_5> intense itching sensation in his scalp <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side effects <extra_id_0> treatment <extra_id_5> cytostatic chemotherapeutic agents <extra_id_1> <extra_id_0> drug <extra_id_5> cytostatic chemotherapeutic agents <extra_id_1> <extra_id_0> effect <extra_id_5> Pigmentary aberrations <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> causing <extra_id_0> treatment <extra_id_5> Atovaquone <extra_id_1> <extra_id_0> drug <extra_id_5> Atovaquone <extra_id_1> <extra_id_0> effect <extra_id_5> vortex keratopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> treatment <extra_id_5> injection of the morphine antagonist naloxone <extra_id_1> <extra_id_0> drug <extra_id_5> naloxone <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> time elapsed <extra_id_5> a few minutes <extra_id_1> <extra_id_0> effect <extra_id_5> generalized tonic - clonic seizure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> consequence <extra_id_0> treatment <extra_id_5> progestin <extra_id_1> <extra_id_0> drug <extra_id_5> progestin <extra_id_1> <extra_id_0> effect <extra_id_5> Squamous metaplasia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> treatment <extra_id_5> vasopressin <extra_id_1> <extra_id_0> drug <extra_id_5> vasopressin <extra_id_1> <extra_id_0> effect <extra_id_5> gastrointestinal hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> regressed <extra_id_0> treatment <extra_id_5> theophylline <extra_id_1> <extra_id_0> drug <extra_id_5> theophylline <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> gynecomastia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> subject <extra_id_5> this patient <extra_id_1> <extra_id_0> treatment <extra_id_5> erroneous intake of 1 g doxycycline <extra_id_1> <extra_id_0> drug <extra_id_5> doxycycline <extra_id_1> <extra_id_0> dosage <extra_id_5> 1 g <extra_id_1> <extra_id_0> effect <extra_id_5> Renal hypophosphatemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> in the third week of MTX treatment <extra_id_1> <extra_id_0> drug <extra_id_5> MTX <extra_id_1> <extra_id_0> duration <extra_id_5> the third week <extra_id_1> <extra_id_0> time elapsed <extra_id_5> the third week <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> meningeal tumor <extra_id_1> <extra_id_0> effect <extra_id_5> progressive visual loss and loss of consciousness which worsened during subsequent Ara - C treatment and led to death within 3 weeks <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a nine - year - old boy <extra_id_1> <extra_id_0> age <extra_id_5> nine - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> boy <extra_id_1> <extra_id_0> subject disorder <extra_id_5> tuberculosis <extra_id_1> <extra_id_0> treatment <extra_id_5> seven months ' continuous treatment for suspected tuberculosis with rifampicin and ethambutol <extra_id_1> <extra_id_0> drug <extra_id_5> rifampicin <extra_id_1> <extra_id_0> drug <extra_id_5> ethambutol <extra_id_1> <extra_id_0> duration <extra_id_5> seven months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> seven months <extra_id_1> <extra_id_0> combination drug <extra_id_5> rifampicin <extra_id_1> <extra_id_0> combination drug <extra_id_5> ethambutol <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> tuberculosis <extra_id_1> <extra_id_0> effect <extra_id_5> polyarthritis , rash and hepatitis <extra_id_1> <extra_id_0> effect <extra_id_5> anti - native DNA antibodies and positive antinuclear factor <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> statin treatment <extra_id_1> <extra_id_0> drug <extra_id_5> statin <extra_id_1> <extra_id_0> effect <extra_id_5> myasthenic syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatments <extra_id_0> treatment <extra_id_5> Topical imiquimod and tumor necrosis factor ( TNF) - alpha inhibitors <extra_id_1> <extra_id_0> drug <extra_id_5> imiquimod <extra_id_1> <extra_id_0> drug <extra_id_5> tumor necrosis factor ( TNF) - alpha inhibitors <extra_id_1> <extra_id_0> route <extra_id_5> Topical <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> non - melanoma skin cancer ( NMSC ) and moderate to severe psoriasis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> zomepirac <extra_id_1> <extra_id_0> drug <extra_id_5> zomepirac <extra_id_1> <extra_id_0> effect <extra_id_5> Focal renal cortical necrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> 2 cases <extra_id_1> <extra_id_0> population <extra_id_5> 2 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> dermatologic problems <extra_id_1> <extra_id_0> treatment <extra_id_5> mequitazine <extra_id_1> <extra_id_0> drug <extra_id_5> mequitazine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> dermatologic problems <extra_id_1> <extra_id_0> effect <extra_id_5> photosensitivity reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> no further episodes <extra_id_0> treatment <extra_id_5> Carboplatin was substituted for cisplatin <extra_id_1> <extra_id_0> drug <extra_id_5> Carboplatin <extra_id_1> <extra_id_0> drug <extra_id_5> cisplatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> Carboplatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> cisplatin <extra_id_1> <extra_id_0> effect <extra_id_5> no further episodes of SIADH <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> intravitreal injection of triamcinolone acetonide <extra_id_1> <extra_id_0> drug <extra_id_5> triamcinolone acetonide <extra_id_1> <extra_id_0> route <extra_id_5> intravitreal injection <extra_id_1> <extra_id_0> effect <extra_id_5> Severe steroid - induced glaucoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> progression <extra_id_0> treatment <extra_id_5> rituximab <extra_id_1> <extra_id_0> drug <extra_id_5> rituximab <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> nodular lymphocyte - predominant Hodgkin 's lymphoma <extra_id_1> <extra_id_0> effect <extra_id_5> CD20 - negative T - cell - rich B - cell lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> an adult patient with acute lymphoblastic leukemia <extra_id_1> <extra_id_0> age <extra_id_5> adult <extra_id_1> <extra_id_0> subject disorder <extra_id_5> acute lymphoblastic leukemia <extra_id_1> <extra_id_0> treatment <extra_id_5> consolidation treatment with L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute lymphoblastic leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> repeated transient ischemic attacks followed by a seizure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> subject <extra_id_5> a patient with pancreatic cancer <extra_id_1> <extra_id_0> subject disorder <extra_id_5> pancreatic cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> Gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> Gemcitabine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> pancreatic cancer <extra_id_1> <extra_id_0> effect <extra_id_5> radiation recall <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> continued <extra_id_0> treatment <extra_id_5> CBZ <extra_id_1> <extra_id_0> drug <extra_id_5> CBZ <extra_id_1> <extra_id_0> dosage <extra_id_5> the same or higher dose <extra_id_1> <extra_id_0> duration <extra_id_5> 6 months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 6 months <extra_id_1> <extra_id_0> effect <extra_id_5> the tics abated and then ceased spontaneously <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurring <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> effect <extra_id_5> neutropenia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> 3 AS patients <extra_id_1> <extra_id_0> population <extra_id_5> 3 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> active AS <extra_id_1> <extra_id_0> treatment <extra_id_5> etanercept <extra_id_1> <extra_id_0> drug <extra_id_5> etanercept <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> active AS <extra_id_1> <extra_id_0> effect <extra_id_5> new onset of CD <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> treatment <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary adverse reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> colchicine <extra_id_1> <extra_id_0> drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> responded <extra_id_0> treatment <extra_id_5> atropine <extra_id_1> <extra_id_0> drug <extra_id_5> atropine <extra_id_1> <extra_id_0> dosage <extra_id_5> 1.4 g / day <extra_id_1> <extra_id_0> duration <extra_id_5> 24 hours <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 24 hours <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> paroxysmal atrial fibrillation <extra_id_1> <extra_id_0> effect <extra_id_5> AVT with syncope <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> emerged <extra_id_0> subject <extra_id_5> Three male patients aged 78 - 83 years <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> population <extra_id_5> Three <extra_id_1> <extra_id_0> treatment <extra_id_5> CPA administration <extra_id_1> <extra_id_0> drug <extra_id_5> CPA <extra_id_1> <extra_id_0> effect <extra_id_5> severe hepatotoxic reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> antitumor antibiotics actinomycin - D ( NSC - 3053 ) and mithramycin ( NSC - 24559 ) <extra_id_1> <extra_id_0> drug <extra_id_5> actinomycin - D <extra_id_1> <extra_id_0> drug <extra_id_5> mithramycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> actinomycin - D <extra_id_1> <extra_id_0> combination drug <extra_id_5> mithramycin <extra_id_1> <extra_id_0> effect <extra_id_5> Exacerbations of the heart failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> a patient with rheumatoid arthritis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> leflunomide therapy <extra_id_1> <extra_id_0> drug <extra_id_5> leflunomide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> Diffuse alveolar hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> a 64 - year - old man with secondary adrenocortical insufficiency <extra_id_1> <extra_id_0> age <extra_id_5> 64 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> secondary adrenocortical insufficiency <extra_id_1> <extra_id_0> treatment <extra_id_5> a chronic transdermal fentanyl treatment <extra_id_1> <extra_id_0> drug <extra_id_5> fentanyl <extra_id_1> <extra_id_0> route <extra_id_5> transdermal <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> secondary adrenocortical insufficiency <extra_id_1> <extra_id_0> effect <extra_id_5> sciatic pain syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 52 - year - old , white female <extra_id_1> <extra_id_0> age <extra_id_5> 52 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> race <extra_id_5> white <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> 8 weeks treatment with sodium aurothiomalate <extra_id_1> <extra_id_0> drug <extra_id_5> sodium aurothiomalate <extra_id_1> <extra_id_0> duration <extra_id_5> 8 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 8 weeks <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> low - grade fever , cough , and dyspnea <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> treatment <extra_id_5> 3 weeks after initiating treatment with SASP <extra_id_1> <extra_id_0> drug <extra_id_5> SASP <extra_id_1> <extra_id_0> duration <extra_id_5> 3 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 3 weeks <extra_id_1> <extra_id_0> effect <extra_id_5> high fever , skin rash , liver dysfunction and atypical lymphocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> toxicity <extra_id_0> treatment <extra_id_5> chloroquine <extra_id_1> <extra_id_0> drug <extra_id_5> chloroquine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> high - grade chloroquine - resistant Plasmodium vivax <extra_id_1> <extra_id_0> effect <extra_id_5> severe chloroquine toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> All cases <extra_id_1> <extra_id_0> population <extra_id_5> All <extra_id_1> <extra_id_0> treatment <extra_id_5> rifabutin <extra_id_1> <extra_id_0> drug <extra_id_5> rifabutin <extra_id_1> <extra_id_0> effect <extra_id_5> corneal endothelial deposits <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> Two infants <extra_id_1> <extra_id_0> age <extra_id_5> infants <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> infantile spasms <extra_id_1> <extra_id_0> treatment <extra_id_5> cessation of prolonged ACTH therapy <extra_id_1> <extra_id_0> drug <extra_id_5> ACTH <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> infantile spasms <extra_id_1> <extra_id_0> effect <extra_id_5> hyperkalemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> effect <extra_id_5> CIPS <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> intravitreal triamcinolone acetonide injection <extra_id_1> <extra_id_0> drug <extra_id_5> triamcinolone acetonide <extra_id_1> <extra_id_0> route <extra_id_5> intravitreal <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> Acute syphilitic posterior placoid chorioretinitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> intramuscular L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> route <extra_id_5> intramuscular <extra_id_1> <extra_id_0> effect <extra_id_5> Delayed pseudocyst of the pancreas <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> a 35 - year - old woman with occult coronary artery disease <extra_id_1> <extra_id_0> age <extra_id_5> 35 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> occult coronary artery disease <extra_id_1> <extra_id_0> treatment <extra_id_5> a first - time dose of subcutaneous sumatriptan <extra_id_1> <extra_id_0> drug <extra_id_5> sumatriptan <extra_id_1> <extra_id_0> route <extra_id_5> subcutaneous <extra_id_1> <extra_id_0> time elapsed <extra_id_5> within minutes <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> occult coronary artery disease <extra_id_1> <extra_id_0> effect <extra_id_5> cardiac arrest <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> treatment <extra_id_5> Epoprostenol ( prostacyclin ) <extra_id_1> <extra_id_0> drug <extra_id_5> Epoprostenol <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> primary pulmonary hypertension <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> scleroderma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> a man <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> epididymitis <extra_id_1> <extra_id_0> treatment <extra_id_5> oral ofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> ofloxacin <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> epididymitis <extra_id_1> <extra_id_0> effect <extra_id_5> toxic epidermal necrolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> late - onset heparin <extra_id_1> <extra_id_0> drug <extra_id_5> heparin <extra_id_1> <extra_id_0> effect <extra_id_5> Massive pulmonary embolism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> during <extra_id_0> subject <extra_id_5> increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> subject disorder <extra_id_5> acute lymphoblastic leukemia <extra_id_1> <extra_id_0> subject disorder <extra_id_5> lymphoblastic lymphoma <extra_id_1> <extra_id_0> treatment <extra_id_5> high - dose cytarabine <extra_id_1> <extra_id_0> drug <extra_id_5> cytarabine <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute lymphoblastic leukemia <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> lymphoblastic lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> didanosine <extra_id_1> <extra_id_0> drug <extra_id_5> didanosine <extra_id_1> <extra_id_0> effect <extra_id_5> fulminant hepatic failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> amiodarone - simvastatin interaction <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> combination drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis , renal failure , and possibly hepatotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> from <extra_id_0> treatment <extra_id_5> hydroquinone cream <extra_id_1> <extra_id_0> drug <extra_id_5> hydroquinone <extra_id_1> <extra_id_0> route <extra_id_5> cream <extra_id_1> <extra_id_0> effect <extra_id_5> Nail staining <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> subject <extra_id_5> an epilepsy patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> epilepsy <extra_id_1> <extra_id_0> treatment <extra_id_5> diphenylhydantoin ( DILANTIN ) therapy for 20 years <extra_id_1> <extra_id_0> drug <extra_id_5> diphenylhydantoin <extra_id_1> <extra_id_0> duration <extra_id_5> 20 years <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 20 years <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> epilepsy <extra_id_1> <extra_id_0> effect <extra_id_5> an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> characterized <extra_id_0> treatment <extra_id_5> Ibuprofen overdose <extra_id_1> <extra_id_0> drug <extra_id_5> Ibuprofen <extra_id_1> <extra_id_0> dosage <extra_id_5> overdose <extra_id_1> <extra_id_0> effect <extra_id_5> GI upset , dizziness , and mild sedation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> administered <extra_id_0> treatment <extra_id_5> pramipexole , entacapone , and immediate - release levodopa / carbidopa 100 mg/25 mg , 1.5 tablets 4 times daily <extra_id_1> <extra_id_0> drug <extra_id_5> pramipexole <extra_id_1> <extra_id_0> drug <extra_id_5> entacapone <extra_id_1> <extra_id_0> drug <extra_id_5> levodopa <extra_id_1> <extra_id_0> drug <extra_id_5> carbidopa <extra_id_1> <extra_id_0> dosage <extra_id_5> 100 mg/25 mg <extra_id_1> <extra_id_0> dosage <extra_id_5> 1.5 tablets <extra_id_1> <extra_id_0> route <extra_id_5> nasogastric tube <extra_id_1> <extra_id_0> frequency <extra_id_5> 4 times daily <extra_id_1> <extra_id_0> combination drug <extra_id_5> pramipexole <extra_id_1> <extra_id_0> combination drug <extra_id_5> entacapone <extra_id_1> <extra_id_0> combination drug <extra_id_5> levodopa <extra_id_1> <extra_id_0> combination drug <extra_id_5> carbidopa <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> PD <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> propafenone and citalopram <extra_id_1> <extra_id_0> drug <extra_id_5> propafenone <extra_id_1> <extra_id_0> drug <extra_id_5> citalopram <extra_id_1> <extra_id_0> combination drug <extra_id_5> propafenone <extra_id_1> <extra_id_0> combination drug <extra_id_5> citalopram <extra_id_1> <extra_id_0> effect <extra_id_5> propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> a young healthy woman <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> thromboembolic episode <extra_id_1> <extra_id_0> treatment <extra_id_5> acenocoumarol <extra_id_1> <extra_id_0> drug <extra_id_5> acenocoumarol <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> thromboembolic episode <extra_id_1> <extra_id_0> effect <extra_id_5> early overanticoagulation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> A patient <extra_id_1> <extra_id_0> treatment <extra_id_5> parenteral amiodarone administration <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> route <extra_id_5> parenteral <extra_id_1> <extra_id_0> effect <extra_id_5> acute changes suggesting acute hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> resolved <extra_id_0> subject <extra_id_5> he <extra_id_1> <extra_id_0> gender <extra_id_5> he <extra_id_1> <extra_id_0> treatment <extra_id_5> olanzapine was stopped and recurred ( fasting blood glucose 150 mg / dL ) after 2 days of rechallenge with olanzapine 2.5 mg twice daily <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> dosage <extra_id_5> 2.5 mg <extra_id_1> <extra_id_0> frequency <extra_id_5> twice daily <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 2 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> fasting blood glucose 150 mg / dL <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> in <extra_id_0> subject <extra_id_5> HIV - infected patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> treatment <extra_id_5> didanosine therapy <extra_id_1> <extra_id_0> drug <extra_id_5> didanosine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> effect <extra_id_5> Fulminant hepatitis with severe lactate acidosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> intravitreal ranibizumab <extra_id_1> <extra_id_0> drug <extra_id_5> ranibizumab <extra_id_1> <extra_id_0> route <extra_id_5> intravitreal <extra_id_1> <extra_id_0> effect <extra_id_5> Persisent ocular hypertension <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> a 31 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 31 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> intrathecal administration of doxorubicin <extra_id_1> <extra_id_0> drug <extra_id_5> doxorubicin <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal <extra_id_1> <extra_id_0> effect <extra_id_5> toxic myelopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> The patient had a background of obsessive compulsive disorder <extra_id_1> <extra_id_0> subject disorder <extra_id_5> obsessive compulsive disorder <extra_id_1> <extra_id_0> treatment <extra_id_5> paroxetine <extra_id_1> <extra_id_0> drug <extra_id_5> paroxetine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> obsessive compulsive disorder <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> subject <extra_id_5> patients with defective calcium - activated K+ channels <extra_id_1> <extra_id_0> subject disorder <extra_id_5> defective calcium - activated K+ channels <extra_id_1> <extra_id_0> treatment <extra_id_5> Clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> Clozapine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> defective calcium - activated K+ channels <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> effect <extra_id_5> LABD <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> Nitrofurantoin <extra_id_1> <extra_id_0> drug <extra_id_5> Nitrofurantoin <extra_id_1> <extra_id_0> effect <extra_id_5> lung disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Trazodone <extra_id_1> <extra_id_0> drug <extra_id_5> Trazodone <extra_id_1> <extra_id_0> effect <extra_id_5> transient hypomanic symptoms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> continuous intravesical alum irrigation <extra_id_1> <extra_id_0> drug <extra_id_5> alum <extra_id_1> <extra_id_0> route <extra_id_5> irrigation <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hemorrhagic cystitis <extra_id_1> <extra_id_0> effect <extra_id_5> Acute aluminum toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Amphotericin B <extra_id_1> <extra_id_0> drug <extra_id_5> Amphotericin B <extra_id_1> <extra_id_0> effect <extra_id_5> cutaneous leucocytoclastic vasculitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> acyclovir therapy <extra_id_1> <extra_id_0> drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> effect <extra_id_5> serum lithium level had increased 4 - fold <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> interaction <extra_id_0> subject <extra_id_5> a kidney transplanted woman <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> kidney transplanted <extra_id_1> <extra_id_0> subject disorder <extra_id_5> pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae <extra_id_1> <extra_id_0> treatment <extra_id_5> clarithromycin and sirolimus <extra_id_1> <extra_id_0> drug <extra_id_5> clarithromycin <extra_id_1> <extra_id_0> drug <extra_id_5> sirolimus <extra_id_1> <extra_id_0> combination drug <extra_id_5> clarithromycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> sirolimus <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae <extra_id_1> <extra_id_0> effect <extra_id_5> pharmacokinetic interaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> A 25 - year - old man with a history of mid - borderline ( BB ) Hansen 's disease <extra_id_1> <extra_id_0> age <extra_id_5> 25 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> mid - borderline ( BB ) Hansen 's disease <extra_id_1> <extra_id_0> treatment <extra_id_5> dapsone and rifampin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> dapsone <extra_id_1> <extra_id_0> drug <extra_id_5> rifampin <extra_id_1> <extra_id_0> combination drug <extra_id_5> dapsone <extra_id_1> <extra_id_0> combination drug <extra_id_5> rifampin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> mid - borderline ( BB ) Hansen 's disease <extra_id_1> <extra_id_0> effect <extra_id_5> reversal reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> overdose <extra_id_0> treatment <extra_id_5> quetiapine <extra_id_1> <extra_id_0> drug <extra_id_5> quetiapine <extra_id_1> <extra_id_0> effect <extra_id_5> death <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induce <extra_id_0> treatment <extra_id_5> antiepileptic drugs <extra_id_1> <extra_id_0> drug <extra_id_5> antiepileptic <extra_id_1> <extra_id_0> effect <extra_id_5> new seizure types or exacerbate existing ones <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a pregnant patient with myotonic dystrophy <extra_id_1> <extra_id_0> subject disorder <extra_id_5> myotonic dystrophy <extra_id_1> <extra_id_0> treatment <extra_id_5> ritodrine - hydrochloride <extra_id_1> <extra_id_0> drug <extra_id_5> ritodrine <extra_id_1> <extra_id_0> drug <extra_id_5> hydrochloride <extra_id_1> <extra_id_0> combination drug <extra_id_5> ritodrine <extra_id_1> <extra_id_0> combination drug <extra_id_5> hydrochloride <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> myotonic dystrophy <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurring <extra_id_0> treatment <extra_id_5> progestin <extra_id_1> <extra_id_0> drug <extra_id_5> progestin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hyperplasia <extra_id_1> <extra_id_0> effect <extra_id_5> squamous metaplasia within endometrial glands <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> DPD - deficient patients with cancer <extra_id_1> <extra_id_0> subject disorder <extra_id_5> DPD - deficient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> 5 - FU therapy <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - FU <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cancer <extra_id_1> <extra_id_0> effect <extra_id_5> potentially lethal risks , and traumatic psychosocial stresses <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treatment <extra_id_0> treatment <extra_id_5> Methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> Methotrexate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> psoriasis <extra_id_1> <extra_id_0> effect <extra_id_5> toxic <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> treatment <extra_id_5> 11 , 12 , and 26 months after start of etanercept therapy <extra_id_1> <extra_id_0> drug <extra_id_5> etanercept <extra_id_1> <extra_id_0> duration <extra_id_5> 11 , 12 , and 26 months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 11 , 12 , and 26 months <extra_id_1> <extra_id_0> effect <extra_id_5> Typical symptoms of active CD <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> after <extra_id_0> subject <extra_id_5> he <extra_id_1> <extra_id_0> gender <extra_id_5> he <extra_id_1> <extra_id_0> subject disorder <extra_id_5> neck pain <extra_id_1> <extra_id_0> treatment <extra_id_5> aspirin <extra_id_1> <extra_id_0> drug <extra_id_5> aspirin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> neck pain <extra_id_1> <extra_id_0> effect <extra_id_5> tracheal compression with stridor <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> clindamycin phosphate vaginal cream <extra_id_1> <extra_id_0> drug <extra_id_5> clindamycin phosphate <extra_id_1> <extra_id_0> route <extra_id_5> vaginal cream <extra_id_1> <extra_id_0> effect <extra_id_5> toxin - positive Clostridium difficile - induced colitis ( CDIC ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> vancomycin <extra_id_1> <extra_id_0> drug <extra_id_5> vancomycin <extra_id_1> <extra_id_0> effect <extra_id_5> anaphylactic reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> because <extra_id_0> subject <extra_id_5> a 74 - year - old female patient <extra_id_1> <extra_id_0> age <extra_id_5> 74 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> subject disorder <extra_id_5> depression <extra_id_1> <extra_id_0> treatment <extra_id_5> amitriptyline <extra_id_1> <extra_id_0> drug <extra_id_5> amitriptyline <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> depression <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> ritodrine hydrochloride <extra_id_1> <extra_id_0> drug <extra_id_5> ritodrine hydrochloride <extra_id_1> <extra_id_0> effect <extra_id_5> Rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> Voriconazole ( VRC ) <extra_id_1> <extra_id_0> drug <extra_id_5> Voriconazole <extra_id_1> <extra_id_0> effect <extra_id_5> angio - oedema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> Tamoxifen <extra_id_1> <extra_id_0> drug <extra_id_5> Tamoxifen <extra_id_1> <extra_id_0> effect <extra_id_5> malignant transformation of endometriosis through atypical endometriosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> One patient <extra_id_1> <extra_id_0> population <extra_id_5> One <extra_id_1> <extra_id_0> subject disorder <extra_id_5> prostatitis <extra_id_1> <extra_id_0> treatment <extra_id_5> levofloxacin immediately prior to tolterodine initiation <extra_id_1> <extra_id_0> drug <extra_id_5> levofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> time elapsed <extra_id_5> immediately <extra_id_1> <extra_id_0> combination drug <extra_id_5> levofloxacin <extra_id_1> <extra_id_0> combination drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> prostatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> The first patient <extra_id_1> <extra_id_0> treatment <extra_id_5> 2 weeks after initiation of IFN - beta <extra_id_1> <extra_id_0> drug <extra_id_5> IFN - beta <extra_id_1> <extra_id_0> duration <extra_id_5> 2 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 2 weeks <extra_id_1> <extra_id_0> effect <extra_id_5> monoarthritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> interferon - alpha treatment <extra_id_1> <extra_id_0> drug <extra_id_5> interferon - alpha <extra_id_1> <extra_id_0> effect <extra_id_5> refractory akathisia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> erlotinib <extra_id_1> <extra_id_0> drug <extra_id_5> erlotinib <extra_id_1> <extra_id_0> effect <extra_id_5> Rosaceiform eruption <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> oral - verapamil <extra_id_1> <extra_id_0> treatment <extra_id_5> concomitant beta - adrenergic blockade <extra_id_1> <extra_id_0> drug <extra_id_5> verapamil <extra_id_1> <extra_id_0> drug <extra_id_5> beta - adrenergic blockade <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> combination drug <extra_id_5> verapamil <extra_id_1> <extra_id_0> combination drug <extra_id_5> beta - adrenergic blockade <extra_id_1> <extra_id_0> effect <extra_id_5> hypotension <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> toxicity <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> intravenous acyclovir is administered concurrently with lithium <extra_id_1> <extra_id_0> drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> combination drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> combination drug <extra_id_5> lithium <extra_id_1> <extra_id_0> effect <extra_id_5> lithium toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> decrease <extra_id_0> treatment <extra_id_5> HD Ara - C <extra_id_1> <extra_id_0> treatment <extra_id_5> HD MTX <extra_id_1> <extra_id_0> drug <extra_id_5> HD Ara - C <extra_id_1> <extra_id_0> drug <extra_id_5> HD MTX <extra_id_1> <extra_id_0> combination drug <extra_id_5> HD Ara - C <extra_id_1> <extra_id_0> combination drug <extra_id_5> HD MTX <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> CNS relapse <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> viloxazine <extra_id_1> <extra_id_0> drug <extra_id_5> viloxazine <extra_id_1> <extra_id_0> effect <extra_id_5> Theophylline intoxication <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> impaired <extra_id_0> treatment <extra_id_5> all test metals <extra_id_1> <extra_id_0> treatment <extra_id_5> zinc <extra_id_1> <extra_id_0> drug <extra_id_5> zinc <extra_id_1> <extra_id_0> dosage <extra_id_5> 25000 microg / l <extra_id_1> <extra_id_0> effect <extra_id_5> Cercarial encystment <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> effect <extra_id_0> treatment <extra_id_5> brimonidine <extra_id_1> <extra_id_0> drug <extra_id_5> brimonidine <extra_id_1> <extra_id_0> effect <extra_id_5> paradoxical effect <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> a child homozygous for MTHFR C677 T polymorphism <extra_id_1> <extra_id_0> age <extra_id_5> child <extra_id_1> <extra_id_0> subject disorder <extra_id_5> MTHFR C677 T polymorphism <extra_id_1> <extra_id_0> treatment <extra_id_5> high - dose methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> MTHFR C677 T polymorphism <extra_id_1> <extra_id_0> effect <extra_id_5> Renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> recovered <extra_id_0> treatment <extra_id_5> high - dose leucovorin , hemodialysis , charcoal hemoperfusion , and carboxypeptidase G2 <extra_id_1> <extra_id_0> drug <extra_id_5> leucovorin <extra_id_1> <extra_id_0> drug <extra_id_5> MTX <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> duration <extra_id_5> 4 - hour <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 4 - hour <extra_id_1> <extra_id_0> combination drug <extra_id_5> MTX <extra_id_1> <extra_id_0> combination drug <extra_id_5> leucovorin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> renal function <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> develop <extra_id_0> subject <extra_id_5> Ten to 15 % of patients <extra_id_1> <extra_id_0> population <extra_id_5> Ten to 15 % <extra_id_1> <extra_id_0> treatment <extra_id_5> ifosfamide <extra_id_1> <extra_id_0> drug <extra_id_5> ifosfamide <extra_id_1> <extra_id_0> effect <extra_id_5> encephalopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> 35 rheumatologists at the Robert Breck Brigham Arthritis Center <extra_id_1> <extra_id_0> population <extra_id_5> 35 <extra_id_1> <extra_id_0> treatment <extra_id_5> leflunomide <extra_id_1> <extra_id_0> drug <extra_id_5> leflunomide <extra_id_1> <extra_id_0> duration <extra_id_5> between November 1998 and January 2000 <extra_id_1> <extra_id_0> time elapsed <extra_id_5> between November 1998 and January 2000 <extra_id_1> <extra_id_0> effect <extra_id_5> weight loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurring <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> disulfiram treatment <extra_id_1> <extra_id_0> drug <extra_id_5> disulfiram <extra_id_1> <extra_id_0> effect <extra_id_5> catatonic syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> high - flux hemodiafiltration <extra_id_1> <extra_id_0> drug <extra_id_5> vancomycin <extra_id_1> <extra_id_0> route <extra_id_5> high - flux hemodiafiltration <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> vancomycin toxicity <extra_id_1> <extra_id_0> effect <extra_id_5> hypophosphatemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulted <extra_id_0> treatment <extra_id_5> Two weeks following rechallenge with alendronate sodium <extra_id_1> <extra_id_0> drug <extra_id_5> alendronate sodium <extra_id_1> <extra_id_0> duration <extra_id_5> Two weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> Two weeks <extra_id_1> <extra_id_0> effect <extra_id_5> recurrence of his scleritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> causing <extra_id_0> treatment <extra_id_5> intrathecal diamorphine <extra_id_1> <extra_id_0> drug <extra_id_5> diamorphine <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal <extra_id_1> <extra_id_0> effect <extra_id_5> anaphylaxis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> cerivastatin <extra_id_1> <extra_id_0> drug <extra_id_5> cerivastatin <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> inducer <extra_id_0> treatment <extra_id_5> azathioprine <extra_id_1> <extra_id_0> drug <extra_id_5> azathioprine <extra_id_1> <extra_id_0> effect <extra_id_5> warfarin resistance <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> alendronate sodium <extra_id_1> <extra_id_0> drug <extra_id_5> alendronate sodium <extra_id_1> <extra_id_0> effect <extra_id_5> nodular scleritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> Most cardiac surgical patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cardiac surgical <extra_id_1> <extra_id_0> treatment <extra_id_5> heparin <extra_id_1> <extra_id_0> drug <extra_id_5> heparin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cardiac surgical <extra_id_1> <extra_id_0> effect <extra_id_5> thrombocytopenia ( HIT ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> a case <extra_id_1> <extra_id_0> treatment <extra_id_5> atovaquone <extra_id_1> <extra_id_0> drug <extra_id_5> atovaquone <extra_id_1> <extra_id_0> effect <extra_id_5> vortex keratopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> she <extra_id_1> <extra_id_0> gender <extra_id_5> she <extra_id_1> <extra_id_0> treatment <extra_id_5> a maximal dose of phenylephrine <extra_id_1> <extra_id_0> drug <extra_id_5> phenylephrine <extra_id_1> <extra_id_0> dosage <extra_id_5> maximal dose <extra_id_1> <extra_id_0> effect <extra_id_5> prominent positive U waves <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> Two patients with ocular inflammation of unknown origin <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> ocular inflammation <extra_id_1> <extra_id_0> treatment <extra_id_5> IVTA injection <extra_id_1> <extra_id_0> drug <extra_id_5> IVTA <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> ocular inflammation <extra_id_1> <extra_id_0> effect <extra_id_5> severe chorioretinitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> started <extra_id_0> treatment <extra_id_5> Disopyramide <extra_id_1> <extra_id_0> drug <extra_id_5> Disopyramide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> supraventricular tachycardia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 50 - year - old woman with a history of migraine without aura , predominantly occurring around her menstrual periods <extra_id_1> <extra_id_0> age <extra_id_5> 50 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> migraine without aura <extra_id_1> <extra_id_0> treatment <extra_id_5> zolmitriptan <extra_id_1> <extra_id_0> drug <extra_id_5> zolmitriptan <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> migraine without aura <extra_id_1> <extra_id_0> effect <extra_id_5> spinal cord lesion <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> olanzapine <extra_id_1> <extra_id_0> treatment <extra_id_5> pravastatin <extra_id_1> <extra_id_0> drug <extra_id_5> pravastatin <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> combination drug <extra_id_5> pravastatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> lithium <extra_id_1> <extra_id_0> effect <extra_id_5> skin rash <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complicate <extra_id_0> treatment <extra_id_5> interferon alfa <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alfa <extra_id_1> <extra_id_0> effect <extra_id_5> Anterior ischemic optic neuropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> subject <extra_id_5> she <extra_id_1> <extra_id_0> gender <extra_id_5> she <extra_id_1> <extra_id_0> treatment <extra_id_5> After 5 weeks of therapy <extra_id_1> <extra_id_0> treatment <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> drug <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> duration <extra_id_5> 5 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 5 weeks <extra_id_1> <extra_id_0> effect <extra_id_5> general malaise <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> use <extra_id_0> treatment <extra_id_5> pamidronate <extra_id_1> <extra_id_0> drug <extra_id_5> pamidronate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute , severe hypercalcemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> relationship <extra_id_0> subject <extra_id_5> patient <extra_id_1> <extra_id_0> treatment <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> effect <extra_id_5> cutaneous eruption <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> administered <extra_id_0> subject <extra_id_5> a 58 - yr - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 58 - yr - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> parathyroidectomy <extra_id_1> <extra_id_0> treatment <extra_id_5> Methylene blue <extra_id_1> <extra_id_0> drug <extra_id_5> Methylene blue <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> parathyroidectomy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complained <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> PTSD <extra_id_1> <extra_id_0> treatment <extra_id_5> lithium <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> PTSD <extra_id_1> <extra_id_0> effect <extra_id_5> serious problems with irritability or angry outbursts <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> result <extra_id_0> treatment <extra_id_5> flucloxacillin <extra_id_1> <extra_id_0> drug <extra_id_5> flucloxacillin <extra_id_1> <extra_id_0> effect <extra_id_5> fatal hepatic injury <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> hepatic artery infusion HAI of FUdR. <extra_id_1> <extra_id_0> drug <extra_id_5> FUdR. <extra_id_1> <extra_id_0> route <extra_id_5> hepatic artery infusion <extra_id_1> <extra_id_0> effect <extra_id_5> Neurologic toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side effect <extra_id_0> subject <extra_id_5> infantile spasms <extra_id_1> <extra_id_0> age <extra_id_5> infantile <extra_id_1> <extra_id_0> subject disorder <extra_id_5> infantile spasms <extra_id_1> <extra_id_0> treatment <extra_id_5> prolonged adrenocorticotropic hormone therapy <extra_id_1> <extra_id_0> drug <extra_id_5> adrenocorticotropic hormone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> infantile spasms <extra_id_1> <extra_id_0> effect <extra_id_5> Hyperkalemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> naproxen and oxaprozin <extra_id_1> <extra_id_0> drug <extra_id_5> naproxen <extra_id_1> <extra_id_0> drug <extra_id_5> oxaprozin <extra_id_1> <extra_id_0> combination drug <extra_id_5> naproxen <extra_id_1> <extra_id_0> combination drug <extra_id_5> oxaprozin <extra_id_1> <extra_id_0> effect <extra_id_5> pseudoporphyria <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> She <extra_id_1> <extra_id_0> gender <extra_id_5> She <extra_id_1> <extra_id_0> treatment <extra_id_5> an average weekly warfarin dose of 39 mg ( 5.5 mg daily ) <extra_id_1> <extra_id_0> treatment <extra_id_5> azathioprine therapy <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> azathioprine <extra_id_1> <extra_id_0> dosage <extra_id_5> 39 mg ( 5.5 mg daily ) <extra_id_1> <extra_id_0> frequency <extra_id_5> weekly <extra_id_1> <extra_id_0> combination drug <extra_id_5> azathioprine <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> azathioprine <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> because <extra_id_0> treatment <extra_id_5> conventional amphotericin B <extra_id_1> <extra_id_0> drug <extra_id_5> amphotericin B <extra_id_1> <extra_id_0> effect <extra_id_5> severe side effects <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> diltiazem <extra_id_1> <extra_id_0> drug <extra_id_5> diltiazem <extra_id_1> <extra_id_0> effect <extra_id_5> Widespread cutaneous vasculitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> 4 weeks after starting gemfibrozil <extra_id_1> <extra_id_0> drug <extra_id_5> gemfibrozil <extra_id_1> <extra_id_0> duration <extra_id_5> 4 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 4 weeks <extra_id_1> <extra_id_0> combination drug <extra_id_5> gemfibrozil <extra_id_1> <extra_id_0> effect <extra_id_5> severe hypoprothrombinemia and bleeding <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a 40 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 40 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> oral flucloxacillin <extra_id_1> <extra_id_0> drug <extra_id_5> flucloxacillin <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> effect <extra_id_5> fulminant hepatic failure and aplastic anaemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> treatment <extra_id_5> Capecitabine <extra_id_1> <extra_id_0> drug <extra_id_5> Capecitabine <extra_id_1> <extra_id_0> effect <extra_id_5> acute coronary syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> lithium <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> effect <extra_id_5> biochemical hyperparathyroidism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> relationship <extra_id_0> treatment <extra_id_5> infliximab <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Crohn 's disease <extra_id_1> <extra_id_0> effect <extra_id_5> lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> treatment <extra_id_5> raloxifene <extra_id_1> <extra_id_0> drug <extra_id_5> raloxifene <extra_id_1> <extra_id_0> effect <extra_id_5> malignant mixed mesodermal tumor <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> recognition <extra_id_0> treatment <extra_id_5> high - dose methotrexate therapy <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose <extra_id_1> <extra_id_0> effect <extra_id_5> renal toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurs <extra_id_0> subject <extra_id_5> patients with rheumatoid arthritis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> methotrexate therapy <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> lymphoproliferative diseases <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> secondary <extra_id_0> treatment <extra_id_5> intrathecal methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal <extra_id_1> <extra_id_0> effect <extra_id_5> cytotoxic edema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> causes <extra_id_0> treatment <extra_id_5> Morphine <extra_id_1> <extra_id_0> drug <extra_id_5> Morphine <extra_id_1> <extra_id_0> effect <extra_id_5> hyperhidrosis and facial flushing <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> oral calcineurin and mTOR inhibitors <extra_id_1> <extra_id_0> drug <extra_id_5> calcineurin <extra_id_1> <extra_id_0> drug <extra_id_5> mTOR inhibitors <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> combination drug <extra_id_5> calcineurin <extra_id_1> <extra_id_0> combination drug <extra_id_5> mTOR inhibitors <extra_id_1> <extra_id_0> effect <extra_id_5> Severe aphthous stomatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> hospitalized <extra_id_0> subject <extra_id_5> A 79 - year - old man with ischemic heart disease , chronic atrial fibrillation , chronic renal failure , hypothyroidism , and gout arthritis <extra_id_1> <extra_id_0> age <extra_id_5> 79 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> ischemic heart disease , chronic atrial fibrillation , chronic renal failure , hypothyroidism , and gout arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> colchicine <extra_id_1> <extra_id_0> drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> ischemic heart disease , chronic atrial fibrillation , chronic renal failure , hypothyroidism , and gout arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> fatigue , myalgia , and leg weakness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a child with juvenile absence epilepsy <extra_id_1> <extra_id_0> age <extra_id_5> child <extra_id_1> <extra_id_0> subject disorder <extra_id_5> juvenile absence epilepsy <extra_id_1> <extra_id_0> treatment <extra_id_5> intravenous valproic acid <extra_id_1> <extra_id_0> drug <extra_id_5> valproic acid <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> juvenile absence epilepsy <extra_id_1> <extra_id_0> effect <extra_id_5> seizure exacerbation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> treatment <extra_id_5> acyclovir <extra_id_1> <extra_id_0> drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> effect <extra_id_5> VZV antigen - positive zoster <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> subject <extra_id_5> 3 cases <extra_id_1> <extra_id_0> population <extra_id_5> 3 <extra_id_1> <extra_id_0> treatment <extra_id_5> rifabutin <extra_id_1> <extra_id_0> drug <extra_id_5> rifabutin <extra_id_1> <extra_id_0> effect <extra_id_5> corneal endothelial deposits <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> promethazine <extra_id_1> <extra_id_0> drug <extra_id_5> promethazine <extra_id_1> <extra_id_0> effect <extra_id_5> coma <extra_id_1> <extra_id_1> <extra_id_0> potential therapeutic event <extra_id_5> to <extra_id_0> treatment <extra_id_5> flumazenil <extra_id_1> <extra_id_0> drug <extra_id_5> flumazenil <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> promethazine - induced coma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> subject <extra_id_5> 41 anecdotic cases <extra_id_1> <extra_id_0> population <extra_id_5> 41 <extra_id_1> <extra_id_0> treatment <extra_id_5> olanzapine ( Zyprexa ) <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> effect <extra_id_5> neutropenia or agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> patients with vitamin B12 deficiency <extra_id_1> <extra_id_0> subject disorder <extra_id_5> vitamin B12 deficiency <extra_id_1> <extra_id_0> treatment <extra_id_5> nitrous oxide anesthesia <extra_id_1> <extra_id_0> drug <extra_id_5> nitrous oxide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> vitamin B12 deficiency <extra_id_1> <extra_id_0> effect <extra_id_5> Neurologic degeneration <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulted <extra_id_0> treatment <extra_id_5> antiarrhythmics <extra_id_1> <extra_id_0> drug <extra_id_5> antiarrhythmics <extra_id_1> <extra_id_0> effect <extra_id_5> intolerable adverse effects or no effect on the arrhythmia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> to <extra_id_0> treatment <extra_id_5> compound tincture of benzoin <extra_id_1> <extra_id_0> drug <extra_id_5> benzoin <extra_id_1> <extra_id_0> route <extra_id_5> tincture <extra_id_1> <extra_id_0> effect <extra_id_5> Allergic contact dermatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> a 67 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 67 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> myocardial infarction <extra_id_1> <extra_id_0> treatment <extra_id_5> tissue plasminogen activator <extra_id_1> <extra_id_0> drug <extra_id_5> tissue plasminogen activator <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> myocardial infarction <extra_id_1> <extra_id_0> effect <extra_id_5> spontaneous choroidal hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> she <extra_id_1> <extra_id_0> gender <extra_id_5> she <extra_id_1> <extra_id_0> treatment <extra_id_5> Forty - one days later <extra_id_1> <extra_id_0> treatment <extra_id_5> triamcinolone and her boosted protease inhibitor therapy <extra_id_1> <extra_id_0> drug <extra_id_5> triamcinolone <extra_id_1> <extra_id_0> drug <extra_id_5> protease inhibitor <extra_id_1> <extra_id_0> duration <extra_id_5> Forty - one days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> Forty - one days <extra_id_1> <extra_id_0> combination drug <extra_id_5> triamcinolone <extra_id_1> <extra_id_0> combination drug <extra_id_5> protease inhibitor <extra_id_1> <extra_id_0> effect <extra_id_5> severe iatrogenic Cushing 's syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> five female patients <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> population <extra_id_5> five <extra_id_1> <extra_id_0> subject disorder <extra_id_5> peptic acid diseases <extra_id_1> <extra_id_0> treatment <extra_id_5> proton pump inhibitors omeprazole , lansoprazole , or pantoprazole for 7 - 15 days <extra_id_1> <extra_id_0> drug <extra_id_5> proton pump inhibitors omeprazole <extra_id_1> <extra_id_0> drug <extra_id_5> lansoprazole <extra_id_1> <extra_id_0> drug <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> duration <extra_id_5> 7 - 15 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 7 - 15 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> peptic acid diseases <extra_id_1> <extra_id_0> effect <extra_id_5> Pheripheral edema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> a child with metastatic osteosarcoma <extra_id_1> <extra_id_0> age <extra_id_5> child <extra_id_1> <extra_id_0> subject disorder <extra_id_5> metastatic osteosarcoma <extra_id_1> <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> metastatic osteosarcoma <extra_id_1> <extra_id_0> effect <extra_id_5> anaphylactic / anaphylactoid reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> involved <extra_id_0> treatment <extra_id_5> interferon alpha <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alpha <extra_id_1> <extra_id_0> effect <extra_id_5> lichen nitidus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> led <extra_id_0> treatment <extra_id_5> Alendronate <extra_id_1> <extra_id_0> drug <extra_id_5> Alendronate <extra_id_1> <extra_id_0> effect <extra_id_5> nodular scleritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> a 36 - year - old man ( 35 mg DGTX ) <extra_id_1> <extra_id_0> age <extra_id_5> 36 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> treatment <extra_id_5> prolonged and repeated i.v. - infusions of Fab fragments of anti - digitalis antibodies ( FAB ) <extra_id_1> <extra_id_0> drug <extra_id_5> Fab fragments of anti - digitalis antibodies ( FAB ) <extra_id_1> <extra_id_0> dosage <extra_id_5> 35 mg <extra_id_1> <extra_id_0> route <extra_id_5> i.v. - infusions <extra_id_1> <extra_id_0> frequency <extra_id_5> repeated <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> massive digitoxin ( DGTX ) intoxication <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> result <extra_id_0> treatment <extra_id_5> Gold - salt therapy <extra_id_1> <extra_id_0> drug <extra_id_5> Gold - salt <extra_id_1> <extra_id_0> effect <extra_id_5> damage to proximal tubules that leak renal tubular antigens , which in turn complex with autoantibody and produce an autoimmune membranous nephropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> to <extra_id_0> subject <extra_id_5> three more cases of children with recalcitrant atopic dermatitis <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> subject disorder <extra_id_5> recalcitrant atopic dermatitis <extra_id_1> <extra_id_0> treatment <extra_id_5> bisabolol <extra_id_1> <extra_id_0> drug <extra_id_5> bisabolol <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> recalcitrant atopic dermatitis <extra_id_1> <extra_id_0> effect <extra_id_5> allergic contact dermatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> Rituximab therapy <extra_id_1> <extra_id_0> drug <extra_id_5> Rituximab <extra_id_1> <extra_id_0> effect <extra_id_5> CD20 - negative tumors <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 48 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 48 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> thyrotoxicosis <extra_id_1> <extra_id_0> treatment <extra_id_5> methimazole <extra_id_1> <extra_id_0> drug <extra_id_5> methimazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> thyrotoxicosis <extra_id_1> <extra_id_0> effect <extra_id_5> agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> 12 cases <extra_id_1> <extra_id_0> population <extra_id_5> 12 <extra_id_1> <extra_id_0> treatment <extra_id_5> Methylene blue <extra_id_1> <extra_id_0> drug <extra_id_5> Methylene blue <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> ifosfamide - induced encephalopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> diagnosed <extra_id_0> subject <extra_id_5> a women <extra_id_1> <extra_id_0> gender <extra_id_5> women <extra_id_1> <extra_id_0> treatment <extra_id_5> raloxifene <extra_id_1> <extra_id_0> drug <extra_id_5> raloxifene <extra_id_1> <extra_id_0> effect <extra_id_5> malignant mixed mesodermal tumor <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> result <extra_id_0> treatment <extra_id_5> Interactions between warfarin and cloxacillin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> cloxacillin <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> combination drug <extra_id_5> cloxacillin <extra_id_1> <extra_id_0> effect <extra_id_5> serious adverse reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> three cases <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> treatment <extra_id_5> ofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> ofloxacin <extra_id_1> <extra_id_0> effect <extra_id_5> Stevens - Johnson syndrome or toxic epidermal necrolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> accelerated <extra_id_0> treatment <extra_id_5> Acetazolamide <extra_id_1> <extra_id_0> drug <extra_id_5> Acetazolamide <extra_id_1> <extra_id_0> effect <extra_id_5> osteomalacia <extra_id_1> <extra_id_0> effect <extra_id_5> increased renal calcium excretion <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> receiving <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> anticalcineurinic drug ( CyA or tacrolimus ) , even under monotherapy or with a low steroid dose <extra_id_1> <extra_id_0> drug <extra_id_5> anticalcineurinic drug <extra_id_1> <extra_id_0> drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> dosage <extra_id_5> low steroid dose <extra_id_1> <extra_id_0> combination drug <extra_id_5> anticalcineurinic drug <extra_id_1> <extra_id_0> combination drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> effect <extra_id_5> RSDS <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> several reported cases <extra_id_1> <extra_id_0> population <extra_id_5> several <extra_id_1> <extra_id_0> treatment <extra_id_5> omeprazole <extra_id_1> <extra_id_0> drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> effect <extra_id_5> AIN <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> result <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> serious bleeding risk <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Adriamycin <extra_id_1> <extra_id_0> treatment <extra_id_5> cis - platinum <extra_id_1> <extra_id_0> drug <extra_id_5> Adriamycin <extra_id_1> <extra_id_0> drug <extra_id_5> cis - platinum <extra_id_1> <extra_id_0> combination drug <extra_id_5> Adriamycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> cis - platinum <extra_id_1> <extra_id_0> effect <extra_id_5> cardiomyopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> admitted <extra_id_0> subject <extra_id_5> An 11 - year - old boy <extra_id_1> <extra_id_0> age <extra_id_5> 11 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> boy <extra_id_1> <extra_id_0> subject disorder <extra_id_5> respiratory distress syndrome <extra_id_1> <extra_id_0> treatment <extra_id_5> a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug <extra_id_1> <extra_id_0> drug <extra_id_5> methotrimeprazine meleate <extra_id_1> <extra_id_0> dosage <extra_id_5> relatively high dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> respiratory distress syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> respiratory distress syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> An adult male <extra_id_1> <extra_id_0> age <extra_id_5> adult <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> treatment <extra_id_5> ingesting methanol <extra_id_1> <extra_id_0> drug <extra_id_5> methanol <extra_id_1> <extra_id_0> route <extra_id_5> ingesting <extra_id_1> <extra_id_0> effect <extra_id_5> central blindness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> All <extra_id_1> <extra_id_0> population <extra_id_5> All <extra_id_1> <extra_id_0> subject disorder <extra_id_5> RA <extra_id_1> <extra_id_0> treatment <extra_id_5> within 20 weeks of beginning i m gold therapy <extra_id_1> <extra_id_0> drug <extra_id_5> i m gold <extra_id_1> <extra_id_0> duration <extra_id_5> 20 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 20 weeks <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> RA <extra_id_1> <extra_id_0> effect <extra_id_5> mucocutaneous side effects <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> Two children , 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> idiopathic nephrotic syndrome <extra_id_1> <extra_id_0> subject disorder <extra_id_5> endo - extracapillary glomerulonephritis <extra_id_1> <extra_id_0> treatment <extra_id_5> i.v . pulse methylprednisolone ( IVPMP ) treatment <extra_id_1> <extra_id_0> drug <extra_id_5> methylprednisolone <extra_id_1> <extra_id_0> route <extra_id_5> i.v . pulse <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> idiopathic nephrotic syndrome <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> endo - extracapillary glomerulonephritis <extra_id_1> <extra_id_0> effect <extra_id_5> seizures and transient blindness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> subject <extra_id_5> a boy with nephrotic syndrome <extra_id_1> <extra_id_0> gender <extra_id_5> boy <extra_id_1> <extra_id_0> subject disorder <extra_id_5> nephrotic syndrome <extra_id_1> <extra_id_0> treatment <extra_id_5> prednisolone therapy <extra_id_1> <extra_id_0> drug <extra_id_5> prednisolone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> nephrotic syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> Stevens - Johnson syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> VRC <extra_id_1> <extra_id_0> drug <extra_id_5> VRC <extra_id_1> <extra_id_0> effect <extra_id_5> angio - oedema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Insulin <extra_id_1> <extra_id_0> drug <extra_id_5> Insulin <extra_id_1> <extra_id_0> effect <extra_id_5> cardiac failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> disappeared <extra_id_0> treatment <extra_id_5> clemastine and betametasone treatment <extra_id_1> <extra_id_0> drug <extra_id_5> clemastine <extra_id_1> <extra_id_0> drug <extra_id_5> betametasone <extra_id_1> <extra_id_0> combination drug <extra_id_5> clemastine <extra_id_1> <extra_id_0> combination drug <extra_id_5> betametasone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> symptoms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> implicates <extra_id_0> treatment <extra_id_5> ofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> ofloxacin <extra_id_1> <extra_id_0> effect <extra_id_5> toxic epidermal necrolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> lithium therapy <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> effect <extra_id_5> nephrotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 56 - year - old male parkinsonian patient <extra_id_1> <extra_id_0> age <extra_id_5> 56 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> subject disorder <extra_id_5> parkinsonian <extra_id_1> <extra_id_0> treatment <extra_id_5> oral administration of cinepazide <extra_id_1> <extra_id_0> drug <extra_id_5> cinepazide <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> parkinsonian <extra_id_1> <extra_id_0> effect <extra_id_5> unique behavioral change <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> production <extra_id_0> treatment <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> drug <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> effect <extra_id_5> dystonia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> because <extra_id_0> treatment <extra_id_5> Metamizole <extra_id_1> <extra_id_0> drug <extra_id_5> Metamizole <extra_id_1> <extra_id_0> effect <extra_id_5> agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> correction <extra_id_0> treatment <extra_id_5> hemopoietic colony stimulating factors <extra_id_1> <extra_id_0> drug <extra_id_5> hemopoietic colony stimulating factors <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> thionamide - induced hematologic adverse reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> Two case reports <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> open angle glaucoma <extra_id_1> <extra_id_0> treatment <extra_id_5> metripranolol 0.6 % eye drops <extra_id_1> <extra_id_0> drug <extra_id_5> metripranolol <extra_id_1> <extra_id_0> route <extra_id_5> eye drops <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> open angle glaucoma <extra_id_1> <extra_id_0> effect <extra_id_5> bilateral granulomatous anterior uveitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> propranolol <extra_id_1> <extra_id_0> drug <extra_id_5> propranolol <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> asthma <extra_id_1> <extra_id_0> effect <extra_id_5> life - threatening bronchospasm <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> 2 female patients <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> population <extra_id_5> 2 <extra_id_1> <extra_id_0> treatment <extra_id_5> selective serotonin reuptake inhibitors paroxetine and sertraline <extra_id_1> <extra_id_0> treatment <extra_id_5> venlafaxine <extra_id_1> <extra_id_0> drug <extra_id_5> venlafaxine <extra_id_1> <extra_id_0> drug <extra_id_5> paroxetine <extra_id_1> <extra_id_0> drug <extra_id_5> sertraline <extra_id_1> <extra_id_0> drug <extra_id_5> venlafaxine <extra_id_1> <extra_id_0> combination drug <extra_id_5> venlafaxine <extra_id_1> <extra_id_0> combination drug <extra_id_5> paroxetine <extra_id_1> <extra_id_0> combination drug <extra_id_5> sertraline <extra_id_1> <extra_id_0> effect <extra_id_5> incontinence <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a woman with classical rheumatoid arthritis <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> classical rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> introduction of sulphasalazine ( SASP ) therapy <extra_id_1> <extra_id_0> drug <extra_id_5> sulphasalazine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> classical rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> severe and lasting psoriasis - like skin reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> darifenacin <extra_id_1> <extra_id_0> drug <extra_id_5> darifenacin <extra_id_1> <extra_id_0> effect <extra_id_5> Interstitial granulomatous dermatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> methanol <extra_id_1> <extra_id_0> drug <extra_id_5> methanol <extra_id_1> <extra_id_0> effect <extra_id_5> visual impairment <extra_id_1> <extra_id_1> <extra_id_0> potential therapeutic event <extra_id_5> Reversal <extra_id_0> treatment <extra_id_5> fomepizole <extra_id_1> <extra_id_0> drug <extra_id_5> fomepizole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> methanol - induced visual impairment <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> decrease <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> Proton - pump inhibitors ( PPIs ) <extra_id_1> <extra_id_0> drug <extra_id_5> Proton - pump inhibitors <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> complications <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> responsible <extra_id_0> treatment <extra_id_5> caffeine <extra_id_1> <extra_id_0> treatment <extra_id_5> oolong tea <extra_id_1> <extra_id_0> drug <extra_id_5> caffeine <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis as well as the delirium <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> achieved <extra_id_0> subject <extra_id_5> children with increased - risk ALL or stage III and IV lymphoblastic lymphoma <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> subject disorder <extra_id_5> increased - risk ALL or stage III and IV lymphoblastic lymphoma <extra_id_1> <extra_id_0> treatment <extra_id_5> HD IV MTX and intrathecal injections of MTX <extra_id_1> <extra_id_0> drug <extra_id_5> HD IV MTX <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal injections <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> increased - risk ALL or stage III and IV lymphoblastic lymphoma <extra_id_1> <extra_id_0> effect <extra_id_5> Prevention of CNS relapse <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> interferon alpha treatment <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alpha <extra_id_1> <extra_id_0> effect <extra_id_5> Generalized lichen nitidus with involvement of the palms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> effect <extra_id_0> treatment <extra_id_5> cyclophosphamide therapy <extra_id_1> <extra_id_0> drug <extra_id_5> cyclophosphamide <extra_id_1> <extra_id_0> effect <extra_id_5> Hemorrhagic cystitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> in <extra_id_0> subject <extra_id_5> certain patients with lithium nephrotoxicity <extra_id_1> <extra_id_0> subject disorder <extra_id_5> lithium nephrotoxicity <extra_id_1> <extra_id_0> treatment <extra_id_5> lithium <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> lithium nephrotoxicity <extra_id_1> <extra_id_0> effect <extra_id_5> Secondary hyperparathyroidism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> a case <extra_id_1> <extra_id_0> treatment <extra_id_5> the internal use of low - dose aspirin for 16 months <extra_id_1> <extra_id_0> drug <extra_id_5> aspirin <extra_id_1> <extra_id_0> dosage <extra_id_5> low - dose <extra_id_1> <extra_id_0> duration <extra_id_5> 16 months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 16 months <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> asymptomatic falx meningioma <extra_id_1> <extra_id_0> effect <extra_id_5> hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> noted <extra_id_0> subject <extra_id_5> five out of six patients <extra_id_1> <extra_id_0> population <extra_id_5> five out of six <extra_id_1> <extra_id_0> treatment <extra_id_5> ouabain <extra_id_1> <extra_id_0> treatment <extra_id_5> digoxin <extra_id_1> <extra_id_0> drug <extra_id_5> ouabain <extra_id_1> <extra_id_0> drug <extra_id_5> digoxin <extra_id_1> <extra_id_0> effect <extra_id_5> Minor electrocardiographical changes <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> develop <extra_id_0> treatment <extra_id_5> co - administration of pravastatin <extra_id_1> <extra_id_0> drug <extra_id_5> pravastatin <extra_id_1> <extra_id_0> effect <extra_id_5> allergic reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> cyclophosphamide <extra_id_1> <extra_id_0> drug <extra_id_5> cyclophosphamide <extra_id_1> <extra_id_0> effect <extra_id_5> hepatic angiosarcoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> neurotoxicity <extra_id_0> treatment <extra_id_5> 5 - FU <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - FU <extra_id_1> <extra_id_0> effect <extra_id_5> ocular motor disturbances <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> included <extra_id_0> subject <extra_id_5> an eight - year old boy <extra_id_1> <extra_id_0> age <extra_id_5> eight - year old <extra_id_1> <extra_id_0> gender <extra_id_5> boy <extra_id_1> <extra_id_0> subject disorder <extra_id_5> synovial sarcoma <extra_id_1> <extra_id_0> treatment <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> cisplatinum <extra_id_1> <extra_id_0> drug <extra_id_5> adriamycin <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> synovial sarcoma <extra_id_1> <extra_id_0> effect <extra_id_5> cisplatinum nephrotoxicity and adriamycin cardiotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> requires <extra_id_0> subject <extra_id_5> renal transplant recipients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> renal transplant <extra_id_1> <extra_id_0> treatment <extra_id_5> antimicrobial agents <extra_id_1> <extra_id_0> drug <extra_id_5> antimicrobial agents <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> renal transplant <extra_id_1> <extra_id_0> effect <extra_id_5> Bacterial infection <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reduces <extra_id_0> subject <extra_id_5> patients with severe , persistent asthma <extra_id_1> <extra_id_0> subject disorder <extra_id_5> severe , persistent asthma <extra_id_1> <extra_id_0> treatment <extra_id_5> ciclesonide <extra_id_1> <extra_id_0> drug <extra_id_5> ciclesonide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> severe , persistent asthma <extra_id_1> <extra_id_0> effect <extra_id_5> reduces the need for OCS <extra_id_1> <extra_id_0> effect <extra_id_5> maintaining asthma control <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> intrathecal administration of doxorubicin <extra_id_1> <extra_id_0> drug <extra_id_5> doxorubicin <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal <extra_id_1> <extra_id_0> effect <extra_id_5> severe myelopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> secondary <extra_id_0> treatment <extra_id_5> alpha interferon <extra_id_1> <extra_id_0> drug <extra_id_5> alpha interferon <extra_id_1> <extra_id_0> effect <extra_id_5> Multiple sclerosis - like disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient with mild chronic renal insufficiency <extra_id_1> <extra_id_0> subject disorder <extra_id_5> mild chronic renal insufficiency <extra_id_1> <extra_id_0> treatment <extra_id_5> taking simvastatin for over a year <extra_id_1> <extra_id_0> treatment <extra_id_5> colchicine for acute gouty bursitis <extra_id_1> <extra_id_0> drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> duration <extra_id_5> over a year <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 3 weeks <extra_id_1> <extra_id_0> combination drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> combination drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute gouty bursitis <extra_id_1> <extra_id_0> effect <extra_id_5> acute weakness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> Shortly after chemotherapy and an injection of pegfilgrastim <extra_id_1> <extra_id_0> drug <extra_id_5> pegfilgrastim <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> poorly defined , rapidly progressive erythema , edema , and pain in his right forearm <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> leading <extra_id_0> subject <extra_id_5> polytrauma patient with Parkinson 's disease ( PD ) <extra_id_1> <extra_id_0> subject disorder <extra_id_5> polytrauma <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Parkinson 's disease ( PD ) <extra_id_1> <extra_id_0> treatment <extra_id_5> interaction between enteral feeds and levodopa <extra_id_1> <extra_id_0> drug <extra_id_5> levodopa <extra_id_1> <extra_id_0> route <extra_id_5> enteral feeds <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Parkinson 's disease ( PD ) <extra_id_1> <extra_id_0> effect <extra_id_5> neuroleptic malignant - like syndrome ( NMLS ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> receiving <extra_id_0> subject <extra_id_5> a schizophrenia patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> treatment <extra_id_5> olanzapine and thiazide <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> thiazide <extra_id_1> <extra_id_0> combination drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> combination drug <extra_id_5> thiazide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> effect <extra_id_5> neutropenia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> imiquimod <extra_id_1> <extra_id_0> drug <extra_id_5> imiquimod <extra_id_1> <extra_id_0> effect <extra_id_5> mild to moderate application site reactions ( ASRs ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> to <extra_id_0> subject <extra_id_5> Nineteen cases <extra_id_1> <extra_id_0> population <extra_id_5> Nineteen <extra_id_1> <extra_id_0> treatment <extra_id_5> compound tincture of benzoin <extra_id_1> <extra_id_0> drug <extra_id_5> benzoin <extra_id_1> <extra_id_0> route <extra_id_5> tincture <extra_id_1> <extra_id_0> effect <extra_id_5> allergic contact dermatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> 3 children with epilepsy <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> population <extra_id_5> 3 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> epilepsy <extra_id_1> <extra_id_0> treatment <extra_id_5> initiation of CBZ <extra_id_1> <extra_id_0> drug <extra_id_5> CBZ <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> epilepsy <extra_id_1> <extra_id_0> effect <extra_id_5> facial motor tics <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> toxicity <extra_id_0> treatment <extra_id_5> cadmium , zinc and cadmium / zinc mixtures at concentrations ranging from 1000 to 50000 microg / l <extra_id_1> <extra_id_0> drug <extra_id_5> cadmium <extra_id_1> <extra_id_0> drug <extra_id_5> zinc <extra_id_1> <extra_id_0> dosage <extra_id_5> 1000 to 50000 microg / l <extra_id_1> <extra_id_0> combination drug <extra_id_5> cadmium <extra_id_1> <extra_id_0> combination drug <extra_id_5> zinc <extra_id_1> <extra_id_0> effect <extra_id_5> cercariae and metacercariae of Parorchis acanthus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side - effect <extra_id_0> subject <extra_id_5> a 29 - year Nigerian female patient with generalized tonic - elonic seizures <extra_id_1> <extra_id_0> age <extra_id_5> 29 - year <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> race <extra_id_5> Nigerian <extra_id_1> <extra_id_0> subject disorder <extra_id_5> generalized tonic - elonic seizures <extra_id_1> <extra_id_0> treatment <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> drug <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> generalized tonic - elonic seizures <extra_id_1> <extra_id_0> effect <extra_id_5> syndrome of inappropriate antidiuresis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treated <extra_id_0> subject <extra_id_5> A patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> atrial fibrillation <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> atrial fibrillation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> risk <extra_id_0> treatment <extra_id_5> pravastatin <extra_id_1> <extra_id_0> drug <extra_id_5> pravastatin <extra_id_1> <extra_id_0> effect <extra_id_5> adverse skin reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> secondary <extra_id_0> treatment <extra_id_5> all - trans retinoic acid <extra_id_1> <extra_id_0> drug <extra_id_5> all - trans retinoic acid <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute promyelocytic leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> Pulmonary leukostasis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complained <extra_id_0> subject <extra_id_5> A 74 - year - old hypercholestrerolaemic woman <extra_id_1> <extra_id_0> age <extra_id_5> 74 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> hypercholestrerolaemic <extra_id_1> <extra_id_0> treatment <extra_id_5> cerivastatin ( 0.15 mg / day ) for 22 days <extra_id_1> <extra_id_0> drug <extra_id_5> cerivastatin <extra_id_1> <extra_id_0> dosage <extra_id_5> 0.15 mg / day <extra_id_1> <extra_id_0> duration <extra_id_5> 22 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 22 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hypercholestrerolaemic <extra_id_1> <extra_id_0> effect <extra_id_5> general muscle weakness and muscle pain <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> two <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> cimetidine <extra_id_1> <extra_id_0> drug <extra_id_5> cimetidine <extra_id_1> <extra_id_0> effect <extra_id_5> hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> concomitant administration of viloxazine <extra_id_1> <extra_id_0> drug <extra_id_5> viloxazine <extra_id_1> <extra_id_0> effect <extra_id_5> theophylline intoxication <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> secondary <extra_id_0> treatment <extra_id_5> interferon alfa <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alfa <extra_id_1> <extra_id_0> effect <extra_id_5> Anterior ischemic optic neuropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> treatment <extra_id_5> recombinant and natural interferon alpha administration <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alpha <extra_id_1> <extra_id_0> effect <extra_id_5> bilateral optic neuritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> Rofecoxib <extra_id_1> <extra_id_0> drug <extra_id_5> Rofecoxib <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> dysmenorrhea <extra_id_1> <extra_id_0> effect <extra_id_5> herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red - brown lesion on the dorsal hand <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> 4 cases <extra_id_1> <extra_id_0> population <extra_id_5> 4 <extra_id_1> <extra_id_0> treatment <extra_id_5> Statin <extra_id_1> <extra_id_0> drug <extra_id_5> Statin <extra_id_1> <extra_id_0> effect <extra_id_5> myasthenia gravis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> noted <extra_id_0> subject <extra_id_5> Two <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> treatment <extra_id_5> alcohol and imipramine <extra_id_1> <extra_id_0> drug <extra_id_5> alcohol <extra_id_1> <extra_id_0> drug <extra_id_5> imipramine <extra_id_1> <extra_id_0> combination drug <extra_id_5> alcohol <extra_id_1> <extra_id_0> combination drug <extra_id_5> imipramine <extra_id_1> <extra_id_0> effect <extra_id_5> spindle coma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> intermittent Decadron <extra_id_1> <extra_id_0> drug <extra_id_5> Decadron <extra_id_1> <extra_id_0> effect <extra_id_5> Cataracts <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> present <extra_id_0> subject <extra_id_5> two epileptic patients <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> epileptic <extra_id_1> <extra_id_0> treatment <extra_id_5> long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide <extra_id_1> <extra_id_0> drug <extra_id_5> phenytoin <extra_id_1> <extra_id_0> drug <extra_id_5> phenobarbital <extra_id_1> <extra_id_0> drug <extra_id_5> acetazolamide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> epileptic <extra_id_1> <extra_id_0> effect <extra_id_5> Severe osteomalacia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> suggested <extra_id_0> treatment <extra_id_5> acetaminophen is prescribed with caffeine <extra_id_1> <extra_id_0> drug <extra_id_5> caffeine <extra_id_1> <extra_id_0> drug <extra_id_5> acetaminophen <extra_id_1> <extra_id_0> combination drug <extra_id_5> caffeine <extra_id_1> <extra_id_0> combination drug <extra_id_5> acetaminophen <extra_id_1> <extra_id_0> effect <extra_id_5> hepatotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> toxicity <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> effect <extra_id_5> Erosion of psoriatic plaques <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> transdermal scopolamine patch <extra_id_1> <extra_id_0> drug <extra_id_5> scopolamine <extra_id_1> <extra_id_0> route <extra_id_5> transdermal <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> opioid <extra_id_1> <extra_id_0> effect <extra_id_5> anisocoria <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> Efficacy and safety <extra_id_0> treatment <extra_id_5> tifacogin ( recombinant tissue factor pathway inhibitor ) <extra_id_1> <extra_id_0> drug <extra_id_5> tifacogin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> severe sepsis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> diagnosed <extra_id_0> subject <extra_id_5> a 64 - year - old woman with a bicornuate uterus <extra_id_1> <extra_id_0> age <extra_id_5> 64 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> bicornuate uterus <extra_id_1> <extra_id_0> treatment <extra_id_5> raloxifene <extra_id_1> <extra_id_0> drug <extra_id_5> raloxifene <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> bicornuate uterus <extra_id_1> <extra_id_0> effect <extra_id_5> malignant mixed mesodermal tumor <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> responsible <extra_id_0> treatment <extra_id_5> pegvisomant <extra_id_1> <extra_id_0> drug <extra_id_5> pegvisomant <extra_id_1> <extra_id_0> effect <extra_id_5> hepatic enzyme disturbances <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> taking <extra_id_0> subject <extra_id_5> patients with uncontrolled partial - onset seizures <extra_id_1> <extra_id_0> subject disorder <extra_id_5> uncontrolled partial - onset seizures <extra_id_1> <extra_id_0> treatment <extra_id_5> one to three concomitant antiepileptic drugs ( AEDs ) <extra_id_1> <extra_id_0> drug <extra_id_5> lacosamide <extra_id_1> <extra_id_0> drug <extra_id_5> antiepileptic drugs ( AEDs ) <extra_id_1> <extra_id_0> combination drug <extra_id_5> lacosamide <extra_id_1> <extra_id_0> combination drug <extra_id_5> antiepileptic drugs ( AEDs ) <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> uncontrolled partial - onset seizures <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> occurred <extra_id_0> treatment <extra_id_5> discontinuation of hydroxychloroquine therapy <extra_id_1> <extra_id_0> drug <extra_id_5> hydroxychloroquine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> nephrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developing <extra_id_0> subject <extra_id_5> elderly patients <extra_id_1> <extra_id_0> age <extra_id_5> elderly <extra_id_1> <extra_id_0> treatment <extra_id_5> olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> effect <extra_id_5> rapidly developing hyperglycemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> recovery <extra_id_0> subject <extra_id_5> a patient with collapsing focal glomeruloesclerosis ( collapsing FGS ) <extra_id_1> <extra_id_0> subject disorder <extra_id_5> collapsing focal glomeruloesclerosis ( collapsing FGS ) <extra_id_1> <extra_id_0> treatment <extra_id_5> withdrawal of cyclosporine ( CSA ) <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> collapsing focal glomeruloesclerosis ( collapsing FGS ) <extra_id_1> <extra_id_0> effect <extra_id_5> PRES <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> subject <extra_id_5> patient <extra_id_1> <extra_id_0> treatment <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> drug <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> effect <extra_id_5> priapism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurring <extra_id_0> treatment <extra_id_5> cyclophosphamide therapy <extra_id_1> <extra_id_0> drug <extra_id_5> cyclophosphamide <extra_id_1> <extra_id_0> effect <extra_id_5> Hepatic angiosarcoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> receive <extra_id_0> subject <extra_id_5> children with increased - risk ( risk factor > 0.8 or T - lineage ) ALL or stage III and IV lymphoblastic lymphoma <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> subject disorder <extra_id_5> increased - risk ( risk factor > 0.8 or T - lineage ) ALL or stage III and IV lymphoblastic lymphoma <extra_id_1> <extra_id_0> treatment <extra_id_5> four courses of HD MTX ( 5 g / m(2 ) over 24 hours every 2 weeks ) and four intrathecal administrations of MTX ( Arm A ) or the same treatment schedule with additional HD IV Ara - C ( 1 g / m(2 ) in bolus injection 12 and 24 hours after the start of each MTX infusion ) ( Arm B ) <extra_id_1> <extra_id_0> drug <extra_id_5> HD MTX <extra_id_1> <extra_id_0> drug <extra_id_5> HD IV Ara - C <extra_id_1> <extra_id_0> dosage <extra_id_5> 5 g / m(2 ) <extra_id_1> <extra_id_0> dosage <extra_id_5> 1 g / m(2 ) <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 12 and 24 hours <extra_id_1> <extra_id_0> combination drug <extra_id_5> HD MTX <extra_id_1> <extra_id_0> combination drug <extra_id_5> HD IV Ara - C <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> increased - risk ( risk factor > 0.8 or T - lineage ) ALL or stage III and IV lymphoblastic lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> toxicity <extra_id_0> treatment <extra_id_5> KW - 2149 <extra_id_1> <extra_id_0> drug <extra_id_5> KW - 2149 <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Flucloxacillin <extra_id_1> <extra_id_0> drug <extra_id_5> Flucloxacillin <extra_id_1> <extra_id_0> effect <extra_id_5> aplastic anaemia and liver failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> patients with cancer <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cancer <extra_id_1> <extra_id_0> effect <extra_id_5> anaphylaxis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> BCNU <extra_id_1> <extra_id_0> drug <extra_id_5> BCNU <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> sulfonamide <extra_id_1> <extra_id_0> drug <extra_id_5> sulfonamide <extra_id_1> <extra_id_0> effect <extra_id_5> injury to the urinary tract <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> Brimonidine <extra_id_1> <extra_id_0> drug <extra_id_5> Brimonidine <extra_id_1> <extra_id_0> effect <extra_id_5> IOP elevation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> an HIV carrier <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> treatment <extra_id_5> nevirapine <extra_id_1> <extra_id_0> drug <extra_id_5> nevirapine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> effect <extra_id_5> leukopenia <extra_id_1> <extra_id_0> effect <extra_id_5> mild hepatotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> evaluated <extra_id_0> subject <extra_id_5> 20 patients with hepatocellular carcinoma ( HCC ) associated with cirrhosis of the liver <extra_id_1> <extra_id_0> population <extra_id_5> 20 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cirrhosis of the liver <extra_id_1> <extra_id_0> treatment <extra_id_5> Lp - TAE alone and combined with radiofrequency ( RF ) capacitive hyperthermia ( HT ) <extra_id_1> <extra_id_0> drug <extra_id_5> Lp - TAE <extra_id_1> <extra_id_0> drug <extra_id_5> radiofrequency ( RF ) capacitive hyperthermia ( HT ) <extra_id_1> <extra_id_0> combination drug <extra_id_5> Lp - TAE <extra_id_1> <extra_id_0> combination drug <extra_id_5> radiofrequency ( RF ) capacitive hyperthermia ( HT ) <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cirrhosis of the liver <extra_id_1> <extra_id_0> effect <extra_id_5> clinical effect and safety <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> intracavernous injection of phentolamine / papaverine <extra_id_1> <extra_id_0> drug <extra_id_5> phentolamine <extra_id_1> <extra_id_0> drug <extra_id_5> papaverine <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> combination drug <extra_id_5> phentolamine <extra_id_1> <extra_id_0> combination drug <extra_id_5> papaverine <extra_id_1> <extra_id_0> effect <extra_id_5> Fibrosis of corpus cavernosum <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> three children <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> treatment <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> drug <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> effect <extra_id_5> four episodes of dystonia proceeding to opisthotonus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> exacerbated <extra_id_0> treatment <extra_id_5> valproic acid <extra_id_1> <extra_id_0> drug <extra_id_5> valproic acid <extra_id_1> <extra_id_0> effect <extra_id_5> Juvenile absence epilepsy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> result <extra_id_0> treatment <extra_id_5> suicidal ingestion of drugs <extra_id_1> <extra_id_0> drug <extra_id_5> quetiapine <extra_id_1> <extra_id_0> route <extra_id_5> ingestion <extra_id_1> <extra_id_0> effect <extra_id_5> deaths <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> zafirlukast therapy <extra_id_1> <extra_id_0> drug <extra_id_5> zafirlukast <extra_id_1> <extra_id_0> effect <extra_id_5> hypereosinophilia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> effect <extra_id_5> anaphylaxis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Pentazocine <extra_id_1> <extra_id_0> drug <extra_id_5> Pentazocine <extra_id_1> <extra_id_0> effect <extra_id_5> fibrous myopathy and localized neuropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> used <extra_id_0> treatment <extra_id_5> Intensive high - flux hemodiafiltration <extra_id_1> <extra_id_0> drug <extra_id_5> vancomycin <extra_id_1> <extra_id_0> route <extra_id_5> Intensive high - flux hemodiafiltration <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> vancomycin toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> a patient with hepatitis C <extra_id_1> <extra_id_0> subject disorder <extra_id_5> hepatitis C <extra_id_1> <extra_id_0> treatment <extra_id_5> systemic treatment with interferon alpha and ribavirin <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alpha <extra_id_1> <extra_id_0> drug <extra_id_5> ribavirin <extra_id_1> <extra_id_0> route <extra_id_5> systemic <extra_id_1> <extra_id_0> combination drug <extra_id_5> interferon alpha <extra_id_1> <extra_id_0> combination drug <extra_id_5> ribavirin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hepatitis C <extra_id_1> <extra_id_0> effect <extra_id_5> generalized lichen nitidus with involvement of the palms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> a woman with chronic schizophrenia <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic schizophrenia <extra_id_1> <extra_id_0> treatment <extra_id_5> propranolol <extra_id_1> <extra_id_0> drug <extra_id_5> propranolol <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic schizophrenia <extra_id_1> <extra_id_0> effect <extra_id_5> delirium , grand mal seizure , and photosensitivity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> an infant with complex congenital heart disease <extra_id_1> <extra_id_0> age <extra_id_5> infant <extra_id_1> <extra_id_0> subject disorder <extra_id_5> complex congenital heart disease <extra_id_1> <extra_id_0> treatment <extra_id_5> captopril <extra_id_1> <extra_id_0> drug <extra_id_5> captopril <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> complex congenital heart disease <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary infiltrates with eosinophilia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> valproic acid <extra_id_1> <extra_id_0> drug <extra_id_5> valproic acid <extra_id_1> <extra_id_0> effect <extra_id_5> hyperammonemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a case <extra_id_1> <extra_id_0> treatment <extra_id_5> pharmacokinetic and pharmacodynamic interactions between three different selective serotonin - reuptake inhibitors ( SSRI ) and possibly ciprofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> ciprofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> selective serotonin - reuptake inhibitors ( SSRI ) <extra_id_1> <extra_id_0> combination drug <extra_id_5> ciprofloxacin <extra_id_1> <extra_id_0> combination drug <extra_id_5> selective serotonin - reuptake inhibitors ( SSRI ) <extra_id_1> <extra_id_0> effect <extra_id_5> serotonin syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> cyclosporin a withdrawal <extra_id_1> <extra_id_0> treatment <extra_id_5> etanercept <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporin a <extra_id_1> <extra_id_0> drug <extra_id_5> etanercept <extra_id_1> <extra_id_0> combination drug <extra_id_5> etanercept <extra_id_1> <extra_id_0> combination drug <extra_id_5> cyclosporin a <extra_id_1> <extra_id_0> effect <extra_id_5> Generalised pustular psoriasis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> became <extra_id_0> subject <extra_id_5> A 36 - y - o patient with schizophrenia <extra_id_1> <extra_id_0> age <extra_id_5> 36 - y - o <extra_id_1> <extra_id_0> subject disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> treatment <extra_id_5> gradually increasing quantities of oolong tea that eventually reached 15 L each day <extra_id_1> <extra_id_0> drug <extra_id_5> oolong <extra_id_1> <extra_id_0> dosage <extra_id_5> 15 L <extra_id_1> <extra_id_0> frequency <extra_id_5> each day <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> effect <extra_id_5> delirious <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a neonate <extra_id_1> <extra_id_0> age <extra_id_5> neonate <extra_id_1> <extra_id_0> treatment <extra_id_5> Intraventricular nafcillin <extra_id_1> <extra_id_0> drug <extra_id_5> nafcillin <extra_id_1> <extra_id_0> route <extra_id_5> Intraventricular <extra_id_1> <extra_id_0> effect <extra_id_5> seizures <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> cephalosporin <extra_id_1> <extra_id_0> drug <extra_id_5> cephalosporin <extra_id_1> <extra_id_0> effect <extra_id_5> coagulopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> thiabendazole <extra_id_1> <extra_id_0> drug <extra_id_5> thiabendazole <extra_id_1> <extra_id_0> effect <extra_id_5> Intrahepatic cholestasis and sicca complex <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> diphenylhydantoin <extra_id_1> <extra_id_0> drug <extra_id_5> diphenylhydantoin <extra_id_1> <extra_id_0> effect <extra_id_5> monoclonal gammopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Moxalactam <extra_id_1> <extra_id_0> drug <extra_id_5> Moxalactam <extra_id_1> <extra_id_0> effect <extra_id_5> platelet dysfunction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> responsible <extra_id_0> subject <extra_id_5> all three AIDS patients <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> subject disorder <extra_id_5> AIDS <extra_id_1> <extra_id_0> treatment <extra_id_5> ddI <extra_id_1> <extra_id_0> drug <extra_id_5> ddI <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> AIDS <extra_id_1> <extra_id_0> effect <extra_id_5> fulminant hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> Two patients <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> stroke prophylaxis in association with chronic atrial fibrillation <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> treatment <extra_id_5> tolterodine <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> stroke prophylaxis in association with chronic atrial fibrillation <extra_id_1> <extra_id_0> effect <extra_id_5> adverse effects <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> A 45 - year - old HIV - positive man ( CD4 + count 450 cells / mm(3 ) and history of AIDS - defining illness ) <extra_id_1> <extra_id_0> age <extra_id_5> 45 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV - positive <extra_id_1> <extra_id_0> subject disorder <extra_id_5> neurosyphilis <extra_id_1> <extra_id_0> treatment <extra_id_5> an initial intravenous dose of penicillin G <extra_id_1> <extra_id_0> drug <extra_id_5> penicillin G <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> neurosyphilis <extra_id_1> <extra_id_0> effect <extra_id_5> JHR <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> The second patient <extra_id_1> <extra_id_0> treatment <extra_id_5> 50 months of IFN - beta therapy <extra_id_1> <extra_id_0> drug <extra_id_5> IFN - beta <extra_id_1> <extra_id_0> duration <extra_id_5> 50 months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 50 months <extra_id_1> <extra_id_0> effect <extra_id_5> autoimmune thyroid disease and a refractory pre - patellar bursitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> had <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> isotretinoin <extra_id_1> <extra_id_0> drug <extra_id_5> isotretinoin <extra_id_1> <extra_id_0> effect <extra_id_5> agenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias , hydrocephalus , and abnormalities of the corticospinal tracts <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> long - term oral isotretinoin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> isotretinoin <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> effect <extra_id_5> Reversible sclerotic changes of lumbar spine and femur <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> trazodone <extra_id_1> <extra_id_0> drug <extra_id_5> trazodone <extra_id_1> <extra_id_0> effect <extra_id_5> priapism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> infliximab infusion <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Crohn 's disease <extra_id_1> <extra_id_0> effect <extra_id_5> Severe adenovirus pneumonia ( AVP ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> theophylline <extra_id_1> <extra_id_0> drug <extra_id_5> theophylline <extra_id_1> <extra_id_0> effect <extra_id_5> gynecomastia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient with an underlying vascular malformation <extra_id_1> <extra_id_0> subject disorder <extra_id_5> underlying vascular malformation <extra_id_1> <extra_id_0> treatment <extra_id_5> pseudoephedrine <extra_id_1> <extra_id_0> drug <extra_id_5> pseudoephedrine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> underlying vascular malformation <extra_id_1> <extra_id_0> effect <extra_id_5> intracerebral hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 58 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 58 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> four days after the application of a patch of transdermal scopolamine delivery system ( TRANSDERM - V ) <extra_id_1> <extra_id_0> drug <extra_id_5> scopolamine <extra_id_1> <extra_id_0> route <extra_id_5> transdermal <extra_id_1> <extra_id_0> time elapsed <extra_id_5> four days <extra_id_1> <extra_id_0> effect <extra_id_5> unilateral acute angle - closure glaucoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a 50 - year - old male patient with a 15 - year history of psoriasis including mutilating psoriatic arthritis <extra_id_1> <extra_id_0> age <extra_id_5> 50 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> subject disorder <extra_id_5> psoriasis including mutilating psoriatic arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> withdrawal of cyclosporin A <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporin A <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> psoriasis including mutilating psoriatic arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> generalised pustular exacerbation and a aggravation of the joint condition <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> exhibited <extra_id_0> subject <extra_id_5> she <extra_id_1> <extra_id_0> gender <extra_id_5> she <extra_id_1> <extra_id_0> treatment <extra_id_5> Six days after starting acyclovir <extra_id_1> <extra_id_0> drug <extra_id_5> acyclovir <extra_id_1> <extra_id_0> duration <extra_id_5> Six days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> Six days <extra_id_1> <extra_id_0> effect <extra_id_5> lithium toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> to <extra_id_0> treatment <extra_id_5> encystment and in vitro excystment of Parorchis acanthus ( Digenea <extra_id_5> Philophthalmidae ) <extra_id_1> <extra_id_0> drug <extra_id_5> cadmium <extra_id_1> <extra_id_0> drug <extra_id_5> zinc <extra_id_1> <extra_id_0> route <extra_id_5> encystment and in vitro excystment <extra_id_1> <extra_id_0> combination drug <extra_id_5> cadmium <extra_id_1> <extra_id_0> combination drug <extra_id_5> zinc <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Parorchis acanthus <extra_id_1> <extra_id_0> effect <extra_id_5> Toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> effectuated <extra_id_0> treatment <extra_id_5> lithium <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> effect <extra_id_5> neurotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> One patient <extra_id_1> <extra_id_0> population <extra_id_5> One <extra_id_1> <extra_id_0> treatment <extra_id_5> ouabain <extra_id_1> <extra_id_0> drug <extra_id_5> ouabain <extra_id_1> <extra_id_0> effect <extra_id_5> cardiomyopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> involved <extra_id_0> treatment <extra_id_5> tamoxifen <extra_id_1> <extra_id_0> drug <extra_id_5> tamoxifen <extra_id_1> <extra_id_0> effect <extra_id_5> pathogenesis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> glibenclamide <extra_id_1> <extra_id_0> drug <extra_id_5> glibenclamide <extra_id_1> <extra_id_0> effect <extra_id_5> Intrahepatic cholestasis and cutaneous bullae <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> enhances <extra_id_0> subject <extra_id_5> painful diabetic neuropathy patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> painful diabetic neuropathy <extra_id_1> <extra_id_0> treatment <extra_id_5> Prolonged - release oxycodone <extra_id_1> <extra_id_0> drug <extra_id_5> Prolonged - release oxycodone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> painful diabetic neuropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> drug <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> effect <extra_id_5> acute interstitial nephritis ( AIN ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient of organic bipolar affective disorder <extra_id_1> <extra_id_0> subject disorder <extra_id_5> organic bipolar affective disorder <extra_id_1> <extra_id_0> treatment <extra_id_5> atypical antipsychotic aripiprazole <extra_id_1> <extra_id_0> drug <extra_id_5> aripiprazole <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> organic bipolar affective disorder <extra_id_1> <extra_id_0> effect <extra_id_5> hiccups <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> administered <extra_id_0> subject <extra_id_5> A 28 year - old man with chronic hepatitis B <extra_id_1> <extra_id_0> age <extra_id_5> 28 year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic hepatitis B <extra_id_1> <extra_id_0> treatment <extra_id_5> interferon - alpha ( 5 x 10(6 ) IU ) intramuscularly once a day for 28 days <extra_id_1> <extra_id_0> drug <extra_id_5> interferon - alpha <extra_id_1> <extra_id_0> dosage <extra_id_5> 5 x 10(6 ) IU <extra_id_1> <extra_id_0> route <extra_id_5> intramuscularly <extra_id_1> <extra_id_0> duration <extra_id_5> 28 days <extra_id_1> <extra_id_0> frequency <extra_id_5> once a day <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 28 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic hepatitis B <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> high - dosage olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dosage <extra_id_1> <extra_id_0> effect <extra_id_5> parkinsonism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 65 - year - old woman with bipolar disorder and complicated cardiovascular disease <extra_id_1> <extra_id_0> age <extra_id_5> 65 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> bipolar disorder <extra_id_1> <extra_id_0> subject disorder <extra_id_5> complicated cardiovascular disease <extra_id_1> <extra_id_0> treatment <extra_id_5> high doses of trazodone <extra_id_1> <extra_id_0> drug <extra_id_5> trazodone <extra_id_1> <extra_id_0> dosage <extra_id_5> high doses <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute depression <extra_id_1> <extra_id_0> effect <extra_id_5> movement disorder <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> adverse bleeding <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> subject <extra_id_5> a case <extra_id_1> <extra_id_0> treatment <extra_id_5> methylene blue infusion <extra_id_1> <extra_id_0> drug <extra_id_5> methylene blue <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> parathyroidectomy <extra_id_1> <extra_id_0> effect <extra_id_5> autonomic , neurological and neuromuscular instability <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> children <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> treatment <extra_id_5> intensive chemotherapy containing busulfan <extra_id_1> <extra_id_0> drug <extra_id_5> busulfan <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> effect <extra_id_5> PVT <extra_id_1> <extra_id_0> effect <extra_id_5> HVOD <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> ofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> ofloxacin <extra_id_1> <extra_id_0> effect <extra_id_5> toxic epidermal necrolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulting <extra_id_0> treatment <extra_id_5> Concomitant use of simvastatin and amiodarone <extra_id_1> <extra_id_0> drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> combination drug <extra_id_5> simvastatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> effect <extra_id_5> severe rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> clindamycin phosphate vaginal cream <extra_id_1> <extra_id_0> drug <extra_id_5> clindamycin phosphate <extra_id_1> <extra_id_0> route <extra_id_5> vaginal cream <extra_id_1> <extra_id_0> effect <extra_id_5> CDIC <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> intercerebral hematoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> a patient with spinal cord astrocytoma <extra_id_1> <extra_id_0> subject disorder <extra_id_5> spinal cord astrocytoma <extra_id_1> <extra_id_0> treatment <extra_id_5> a single dose of vincristine <extra_id_1> <extra_id_0> drug <extra_id_5> vincristine <extra_id_1> <extra_id_0> dosage <extra_id_5> single dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> spinal cord astrocytoma <extra_id_1> <extra_id_0> effect <extra_id_5> Severe visual loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> ameliorate <extra_id_0> treatment <extra_id_5> Clonazepam , thioridazine , beta - blockers , anticholinergics , and bromocriptine <extra_id_1> <extra_id_0> drug <extra_id_5> Clonazepam <extra_id_1> <extra_id_0> drug <extra_id_5> thioridazine <extra_id_1> <extra_id_0> drug <extra_id_5> beta - blockers <extra_id_1> <extra_id_0> drug <extra_id_5> anticholinergics <extra_id_1> <extra_id_0> drug <extra_id_5> bromocriptine <extra_id_1> <extra_id_0> combination drug <extra_id_5> Clonazepam <extra_id_1> <extra_id_0> combination drug <extra_id_5> thioridazine <extra_id_1> <extra_id_0> combination drug <extra_id_5> beta - blockers <extra_id_1> <extra_id_0> combination drug <extra_id_5> anticholinergics <extra_id_1> <extra_id_0> combination drug <extra_id_5> bromocriptine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> akathisia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> four of 44 children ( 9 % ) <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> population <extra_id_5> four of 44 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> relapsed Wilms ' tumors <extra_id_1> <extra_id_0> treatment <extra_id_5> ifosfamide <extra_id_1> <extra_id_0> drug <extra_id_5> ifosfamide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> relapsed Wilms ' tumors <extra_id_1> <extra_id_0> effect <extra_id_5> Musculoskeletal complaints <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> causing <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> intracerebral hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> Gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> Gemcitabine <extra_id_1> <extra_id_0> effect <extra_id_5> radiation recall <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> effect <extra_id_0> treatment <extra_id_5> brimonidine <extra_id_1> <extra_id_0> drug <extra_id_5> brimonidine <extra_id_1> <extra_id_0> effect <extra_id_5> paradoxical ocular effect <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> eruption <extra_id_0> treatment <extra_id_5> rofecoxib <extra_id_1> <extra_id_0> drug <extra_id_5> rofecoxib <extra_id_1> <extra_id_0> effect <extra_id_5> Fixed drug eruption <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> documented <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> subject disorder <extra_id_5> bacterial vaginosis <extra_id_1> <extra_id_0> treatment <extra_id_5> clindamycin vaginal cream <extra_id_1> <extra_id_0> drug <extra_id_5> clindamycin <extra_id_1> <extra_id_0> route <extra_id_5> vaginal cream <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> bacterial vaginosis <extra_id_1> <extra_id_0> effect <extra_id_5> C. difficile toxin <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> drug <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> effect <extra_id_5> Acute interstitial nephritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> taxanes such as paclitaxel <extra_id_1> <extra_id_0> drug <extra_id_5> taxanes <extra_id_1> <extra_id_0> effect <extra_id_5> pneumonitis and lung fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> sustained <extra_id_0> subject <extra_id_5> Infant twins <extra_id_1> <extra_id_0> age <extra_id_5> Infant <extra_id_1> <extra_id_0> subject disorder <extra_id_5> candidiasis <extra_id_1> <extra_id_0> treatment <extra_id_5> a concentrated solution of benzalkonium ( Zephiran ) chloride <extra_id_1> <extra_id_0> drug <extra_id_5> benzalkonium ( Zephiran ) chloride <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> candidiasis <extra_id_1> <extra_id_0> effect <extra_id_5> severe circumoral and pharyngeal burns <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> teratogenicity <extra_id_0> treatment <extra_id_5> Isotretinoin <extra_id_1> <extra_id_0> drug <extra_id_5> Isotretinoin <extra_id_1> <extra_id_0> effect <extra_id_5> teratogenicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> cimetidine <extra_id_1> <extra_id_0> drug <extra_id_5> cimetidine <extra_id_1> <extra_id_0> effect <extra_id_5> Hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> improved <extra_id_0> subject <extra_id_5> an 11 - month - old female infant with a depressed level of consciousness <extra_id_1> <extra_id_0> age <extra_id_5> 11 - month - old <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> subject disorder <extra_id_5> depressed level of consciousness <extra_id_1> <extra_id_0> treatment <extra_id_5> administration of naloxone <extra_id_1> <extra_id_0> drug <extra_id_5> naloxone <extra_id_1> <extra_id_0> route <extra_id_5> ingestion <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> depressed level of consciousness <extra_id_1> <extra_id_0> effect <extra_id_5> mental status markedly improved <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> resulted <extra_id_0> treatment <extra_id_5> discontinuation of colchicine <extra_id_1> <extra_id_0> drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia <extra_id_1> <extra_id_0> age <extra_id_5> 73 year - old <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia <extra_id_1> <extra_id_0> treatment <extra_id_5> within 15 days of initiation of flecainide <extra_id_1> <extra_id_0> drug <extra_id_5> flecainide <extra_id_1> <extra_id_0> duration <extra_id_5> 15 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> within 15 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia <extra_id_1> <extra_id_0> effect <extra_id_5> acute reversible encephalopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> medication <extra_id_0> treatment <extra_id_5> sertraline <extra_id_1> <extra_id_0> drug <extra_id_5> sertraline <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> depressive symptoms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> association <extra_id_0> treatment <extra_id_5> CHOP chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> CHOP <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> CD30 ( Ki - 1) - positive anaplastic large - cell lymphoma <extra_id_1> <extra_id_0> effect <extra_id_5> Supravenous hyperpigmentation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> A 33 - year - old male <extra_id_1> <extra_id_0> age <extra_id_5> 33 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> male <extra_id_1> <extra_id_0> treatment <extra_id_5> 4 % hydroquinone in sorbolene cream and 0.1 % tretinoin cream to the face intermittently for 9 months <extra_id_1> <extra_id_0> drug <extra_id_5> hydroquinone <extra_id_1> <extra_id_0> drug <extra_id_5> sorbolene <extra_id_1> <extra_id_0> drug <extra_id_5> tretinoin <extra_id_1> <extra_id_0> route <extra_id_5> cream <extra_id_1> <extra_id_0> duration <extra_id_5> 9 months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 9 months <extra_id_1> <extra_id_0> combination drug <extra_id_5> hydroquinone <extra_id_1> <extra_id_0> combination drug <extra_id_5> sorbolene <extra_id_1> <extra_id_0> effect <extra_id_5> brown discolouration of the fingernails <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> acquired immunodeficiency syndrome <extra_id_1> <extra_id_0> treatment <extra_id_5> sulfadiazine <extra_id_1> <extra_id_0> drug <extra_id_5> sulfadiazine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acquired immunodeficiency syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> crystalluria and renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> calcium stearate <extra_id_1> <extra_id_0> drug <extra_id_5> calcium stearate <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> effect <extra_id_5> Acute eosinophilic pneumonia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> determined <extra_id_0> treatment <extra_id_5> olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> effect <extra_id_5> acute intoxication <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> morphine - 6 - glucuronide <extra_id_1> <extra_id_0> drug <extra_id_5> morphine - 6 - glucuronide <extra_id_1> <extra_id_0> effect <extra_id_5> Long lasting respiratory depression <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> seven children , 5 years of age and younger <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> population <extra_id_5> seven <extra_id_1> <extra_id_0> treatment <extra_id_5> antiemetic combination of pentobarbital and pyrilamine maleate <extra_id_1> <extra_id_0> drug <extra_id_5> pentobarbital <extra_id_1> <extra_id_0> drug <extra_id_5> pyrilamine maleate <extra_id_1> <extra_id_0> combination drug <extra_id_5> pentobarbital <extra_id_1> <extra_id_0> combination drug <extra_id_5> pyrilamine maleate <extra_id_1> <extra_id_0> effect <extra_id_5> toxic encephalopathy characterized by depressed level of consciousness , marked irritability , and ataxia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> 5 - fluorouracil chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> effect <extra_id_5> Oculomotor disturbances <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> doxorubicin <extra_id_1> <extra_id_0> drug <extra_id_5> doxorubicin <extra_id_1> <extra_id_0> effect <extra_id_5> thoracic pain and breathing distress <extra_id_1> <extra_id_0> effect <extra_id_5> superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> post - transplantation prophylaxis <extra_id_0> subject <extra_id_5> An 18 - year - old Japanese man weighing 53 kg with an anaplastic large cell lymphoma <extra_id_1> <extra_id_0> age <extra_id_5> 18 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> race <extra_id_5> Japanese <extra_id_1> <extra_id_0> subject disorder <extra_id_5> anaplastic large cell lymphoma <extra_id_1> <extra_id_0> treatment <extra_id_5> continuous IV administration of TAC <extra_id_1> <extra_id_0> drug <extra_id_5> TAC <extra_id_1> <extra_id_0> route <extra_id_5> IV <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> anaplastic large cell lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> ameliorated <extra_id_0> treatment <extra_id_5> Intravenous administration of levodopa <extra_id_1> <extra_id_0> drug <extra_id_5> levodopa <extra_id_1> <extra_id_0> route <extra_id_5> Intravenous <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> refractory akathisia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> subject <extra_id_5> Patients with lymphoblastic lymphoma <extra_id_1> <extra_id_0> subject disorder <extra_id_5> lymphoblastic lymphoma <extra_id_1> <extra_id_0> treatment <extra_id_5> L - asparaginase and steroid <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> steroid <extra_id_1> <extra_id_0> combination drug <extra_id_5> steroid <extra_id_1> <extra_id_0> combination drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> lymphoblastic lymphoma <extra_id_1> <extra_id_0> effect <extra_id_5> cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> subject <extra_id_5> patients with significant risk factors for coronary artery disease <extra_id_1> <extra_id_0> subject disorder <extra_id_5> coronary artery disease <extra_id_1> <extra_id_0> treatment <extra_id_5> sumatriptan <extra_id_1> <extra_id_0> drug <extra_id_5> sumatriptan <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> coronary artery disease <extra_id_1> <extra_id_0> effect <extra_id_5> coronary artery vasospasm <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> prescribed <extra_id_0> subject <extra_id_5> a 25 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 25 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> treatment <extra_id_5> olanzapine <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> effect <extra_id_5> found dead at home <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 67 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 67 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> treatment <extra_id_5> 10 - day course of oral ampicillin <extra_id_1> <extra_id_0> drug <extra_id_5> ampicillin <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> duration <extra_id_5> 10 - day <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 10 - day <extra_id_1> <extra_id_0> effect <extra_id_5> diarrhea <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> appearing <extra_id_0> treatment <extra_id_5> high - dose intravenous phenylephrine <extra_id_1> <extra_id_0> drug <extra_id_5> phenylephrine <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> effect <extra_id_5> Prominent positive U waves <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> taking <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> metformin <extra_id_1> <extra_id_0> drug <extra_id_5> metformin <extra_id_1> <extra_id_0> effect <extra_id_5> Severe acidosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> subject <extra_id_5> children with primary glomerulonephritis <extra_id_1> <extra_id_0> age <extra_id_5> children <extra_id_1> <extra_id_0> subject disorder <extra_id_5> primary glomerulonephritis <extra_id_1> <extra_id_0> treatment <extra_id_5> intravenous pulse methylprednisolone <extra_id_1> <extra_id_0> drug <extra_id_5> methylprednisolone <extra_id_1> <extra_id_0> route <extra_id_5> intravenous pulse <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> primary glomerulonephritis <extra_id_1> <extra_id_0> effect <extra_id_5> Seizures and transient blindness <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient with acromegaly <extra_id_1> <extra_id_0> subject disorder <extra_id_5> acromegaly <extra_id_1> <extra_id_0> treatment <extra_id_5> combined treatment with the long - acting somatostatin - analog octreotide and the GH receptor antagonist pegvisomant <extra_id_1> <extra_id_0> drug <extra_id_5> octreotide <extra_id_1> <extra_id_0> drug <extra_id_5> pegvisomant <extra_id_1> <extra_id_0> combination drug <extra_id_5> octreotide <extra_id_1> <extra_id_0> combination drug <extra_id_5> pegvisomant <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acromegaly <extra_id_1> <extra_id_0> effect <extra_id_5> severe drug - induced hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> receive <extra_id_0> subject <extra_id_5> 1754 patients ( > or = 18 years ) with severe sepsis and a high INR ( > or = 1.2 ) <extra_id_1> <extra_id_0> population <extra_id_5> 1754 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> high INR <extra_id_1> <extra_id_0> treatment <extra_id_5> intravenous infusion of either tifacogin ( 0.025 mg / kg per hour for 96 hours , n = 880 ) or placebo ( arginine citrate buffer , n = 874 ) <extra_id_1> <extra_id_0> drug <extra_id_5> tifacogin <extra_id_1> <extra_id_0> drug <extra_id_5> placebo <extra_id_1> <extra_id_0> dosage <extra_id_5> 0.025 mg / kg <extra_id_1> <extra_id_0> route <extra_id_5> intravenous infusion <extra_id_1> <extra_id_0> duration <extra_id_5> 96 hours <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 96 hours <extra_id_1> <extra_id_0> combination drug <extra_id_5> tifacogin <extra_id_1> <extra_id_0> combination drug <extra_id_5> placebo <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> low INR <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a 23 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 23 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> methicillin - resistant Staphylococcus aureus infection <extra_id_1> <extra_id_0> treatment <extra_id_5> vancomycin <extra_id_1> <extra_id_0> drug <extra_id_5> vancomycin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> methicillin - resistant Staphylococcus aureus infection <extra_id_1> <extra_id_0> effect <extra_id_5> anaphylactic reaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> Recovery <extra_id_0> treatment <extra_id_5> 15 days following cessation of the offending drug , Amikacin <extra_id_1> <extra_id_0> drug <extra_id_5> Amikacin <extra_id_1> <extra_id_0> duration <extra_id_5> 15 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 15 days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> tubular dysfunction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> effect <extra_id_5> pancreatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> BCNU <extra_id_1> <extra_id_0> drug <extra_id_5> BCNU <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 58 - year - old man with advanced renal cell carcinoma <extra_id_1> <extra_id_0> age <extra_id_5> 58 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> advanced renal cell carcinoma <extra_id_1> <extra_id_0> treatment <extra_id_5> five days after temsirolimus infusion <extra_id_1> <extra_id_0> drug <extra_id_5> temsirolimus <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> time elapsed <extra_id_5> five days <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> advanced renal cell carcinoma <extra_id_1> <extra_id_0> effect <extra_id_5> grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> presented <extra_id_0> subject <extra_id_5> A 2 - year - old mentally retarded boy with frontal lobe epilepsy <extra_id_1> <extra_id_0> age <extra_id_5> 2 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> boy <extra_id_1> <extra_id_0> subject disorder <extra_id_5> frontal lobe epilepsy <extra_id_1> <extra_id_0> treatment <extra_id_5> zonisamide <extra_id_1> <extra_id_0> drug <extra_id_5> zonisamide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> frontal lobe epilepsy <extra_id_1> <extra_id_0> effect <extra_id_5> heat stroke <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> methylene blue infusion <extra_id_1> <extra_id_0> drug <extra_id_5> methylene blue <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> parathyroidectomy <extra_id_1> <extra_id_0> effect <extra_id_5> Serotonin syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> Two patients <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> disseminated adenocarcinoma of the colon <extra_id_1> <extra_id_0> treatment <extra_id_5> 5 - fluorouracil ( 5 - FU ) <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> disseminated adenocarcinoma of the colon <extra_id_1> <extra_id_0> effect <extra_id_5> cerebellar dysfunction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> achieved <extra_id_0> treatment <extra_id_5> corticosteroids <extra_id_1> <extra_id_0> drug <extra_id_5> corticosteroids <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> clinical and radiological abnormalities <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> praziquantel therapy <extra_id_1> <extra_id_0> drug <extra_id_5> praziquantel <extra_id_1> <extra_id_0> effect <extra_id_5> Disseminated muscular cysticercosis with myositis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> widely separated courses of adriamycin <extra_id_1> <extra_id_0> treatment <extra_id_5> exacerbated by actinomycin - D and mithramycin <extra_id_1> <extra_id_0> drug <extra_id_5> adriamycin <extra_id_1> <extra_id_0> drug <extra_id_5> actinomycin - D <extra_id_1> <extra_id_0> drug <extra_id_5> mithramycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> adriamycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> actinomycin - D <extra_id_1> <extra_id_0> combination drug <extra_id_5> mithramycin <extra_id_1> <extra_id_0> effect <extra_id_5> Cardiomyopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> effect <extra_id_5> Linear immunoglobulin A bullous dermatosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> association <extra_id_0> subject <extra_id_5> both patients <extra_id_1> <extra_id_0> treatment <extra_id_5> tolterodine <extra_id_1> <extra_id_0> treatment <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> elevated INR <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> association <extra_id_0> treatment <extra_id_5> prostaglandin E1 <extra_id_1> <extra_id_0> drug <extra_id_5> prostaglandin E1 <extra_id_1> <extra_id_0> effect <extra_id_5> harlequin color change <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> on <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> refractory palmopustular psoriasis and psoriatic arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> Efalizumab and Etanercept <extra_id_1> <extra_id_0> drug <extra_id_5> Efalizumab <extra_id_1> <extra_id_0> drug <extra_id_5> Etanercept <extra_id_1> <extra_id_0> combination drug <extra_id_5> Efalizumab <extra_id_1> <extra_id_0> combination drug <extra_id_5> Etanercept <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> refractory palmopustular psoriasis and psoriatic arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> tuberculosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> treatment <extra_id_5> two local anesthetics <extra_id_1> <extra_id_0> treatment <extra_id_5> bupivacaine <extra_id_1> <extra_id_0> drug <extra_id_5> bupivacaine <extra_id_1> <extra_id_0> drug <extra_id_5> lidocaine <extra_id_1> <extra_id_0> combination drug <extra_id_5> bupivacaine <extra_id_1> <extra_id_0> combination drug <extra_id_5> lidocaine <extra_id_1> <extra_id_0> effect <extra_id_5> methemoglobinemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> patient <extra_id_1> <extra_id_0> treatment <extra_id_5> tolmetin <extra_id_1> <extra_id_0> drug <extra_id_5> tolmetin <extra_id_1> <extra_id_0> effect <extra_id_5> Nephrotic range pseudoproteinuria <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complained <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> effect <extra_id_5> leg pain <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> cerivastatin <extra_id_1> <extra_id_0> drug <extra_id_5> cerivastatin <extra_id_1> <extra_id_0> effect <extra_id_5> acute rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side effects <extra_id_0> subject <extra_id_5> a patient suffering from rheumatoid arthritis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> low - dose methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> low - dose <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> an acute megaloblastic anaemia and a pneumonitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a 57 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 57 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> metastatic squamous cell carcinoma of the hypopharynx <extra_id_1> <extra_id_0> treatment <extra_id_5> combined chemotherapy ( bleomycin and methotrexate ) <extra_id_1> <extra_id_0> drug <extra_id_5> bleomycin <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> combination drug <extra_id_5> bleomycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> metastatic squamous cell carcinoma of the hypopharynx <extra_id_1> <extra_id_0> effect <extra_id_5> acral erythrocyanosis progressing to acute digital ischemia and gangrene <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> a 7 year old girl with haemolytic uraemic syndrome <extra_id_1> <extra_id_0> age <extra_id_5> 7 year old <extra_id_1> <extra_id_0> gender <extra_id_5> girl <extra_id_1> <extra_id_0> subject disorder <extra_id_5> haemolytic uraemic syndrome <extra_id_1> <extra_id_0> treatment <extra_id_5> intravenous administration of morphine <extra_id_1> <extra_id_0> drug <extra_id_5> morphine <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> haemolytic uraemic syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> long lasting respiratory depression <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> with <extra_id_0> treatment <extra_id_5> quetiapine <extra_id_1> <extra_id_0> drug <extra_id_5> quetiapine <extra_id_1> <extra_id_0> effect <extra_id_5> leucocytopenia and thrombocytopenia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> intrabiliary infusion of mono - octanoin <extra_id_1> <extra_id_0> drug <extra_id_5> mono - octanoin <extra_id_1> <extra_id_0> route <extra_id_5> intrabiliary infusion <extra_id_1> <extra_id_0> effect <extra_id_5> Noncardiogenic pulmonary edema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> prevent <extra_id_0> treatment <extra_id_5> Cardiac glycosides <extra_id_1> <extra_id_0> drug <extra_id_5> Cardiac glycosides <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> doxorubicin cardiomyopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> receiving <extra_id_0> subject <extra_id_5> Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy <extra_id_1> <extra_id_0> population <extra_id_5> Three hundred and thirty eight <extra_id_1> <extra_id_0> subject disorder <extra_id_5> moderate to severe painful diabetic neuropathy <extra_id_1> <extra_id_0> treatment <extra_id_5> oral prolonged - release oxycodone or placebo tablets <extra_id_1> <extra_id_0> drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> drug <extra_id_5> oxycodone <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> duration <extra_id_5> 12 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 12 weeks <extra_id_1> <extra_id_0> combination drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> combination drug <extra_id_5> oxycodone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> moderate to severe painful diabetic neuropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> patients <extra_id_1> <extra_id_0> treatment <extra_id_5> thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA <extra_id_1> <extra_id_0> drug <extra_id_5> dabigatran etexilate <extra_id_1> <extra_id_0> drug <extra_id_5> NSAID <extra_id_1> <extra_id_0> drug <extra_id_5> ASA <extra_id_1> <extra_id_0> combination drug <extra_id_5> NSAID <extra_id_1> <extra_id_0> combination drug <extra_id_5> ASA <extra_id_1> <extra_id_0> effect <extra_id_5> bleeding risk <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Dapsone <extra_id_1> <extra_id_0> drug <extra_id_5> Dapsone <extra_id_1> <extra_id_0> effect <extra_id_5> erythroderma with Beau 's lines <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient with rheumatoid arthritis <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> Methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> Methotrexate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> hepatic necrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> three cases <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> treatment <extra_id_5> quetiapine <extra_id_1> <extra_id_0> drug <extra_id_5> quetiapine <extra_id_1> <extra_id_0> effect <extra_id_5> suicidal overdose deaths <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> Both patients <extra_id_1> <extra_id_0> population <extra_id_5> Both <extra_id_1> <extra_id_0> treatment <extra_id_5> o , p' - DDD and apparently adequate dexamethasone replacement therapy <extra_id_1> <extra_id_0> drug <extra_id_5> dexamethasone <extra_id_1> <extra_id_0> effect <extra_id_5> hypoadrenalism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> a 78 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 78 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> single sodium hyaluronate injection <extra_id_1> <extra_id_0> drug <extra_id_5> sodium hyaluronate <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> Neisseria mucosa knee arthritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulting <extra_id_0> subject <extra_id_5> an HIV - positive woman <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> treatment <extra_id_5> antiretroviral therapy <extra_id_1> <extra_id_0> drug <extra_id_5> antiretroviral <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> effect <extra_id_5> two ectopic pregnancies <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> periurethral injection of calcium hydroxylapatite <extra_id_1> <extra_id_0> drug <extra_id_5> calcium hydroxylapatite <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> stress urinary incontinence <extra_id_1> <extra_id_0> effect <extra_id_5> Massive prolapse of the urethral mucosa <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> A 35 - year - old female with borderline lepromatous ( BL ) leprosy <extra_id_1> <extra_id_0> age <extra_id_5> 35 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> subject disorder <extra_id_5> borderline lepromatous ( BL ) leprosy <extra_id_1> <extra_id_0> treatment <extra_id_5> dapsone <extra_id_1> <extra_id_0> drug <extra_id_5> dapsone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> borderline lepromatous ( BL ) leprosy <extra_id_1> <extra_id_0> effect <extra_id_5> erythroderma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> include <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> effect <extra_id_5> bone marrow suppression and oral and gastrointestinal ulceration <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> low - dose aspirin <extra_id_1> <extra_id_0> drug <extra_id_5> aspirin <extra_id_1> <extra_id_0> dosage <extra_id_5> low - dose <extra_id_1> <extra_id_0> route <extra_id_5> internal <extra_id_1> <extra_id_0> effect <extra_id_5> Hemorrhage from a falx meningioma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic lymphocytic leukemia <extra_id_1> <extra_id_0> treatment <extra_id_5> fludarabine <extra_id_1> <extra_id_0> drug <extra_id_5> fludarabine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic lymphocytic leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> respiratory syncytial virus pulmonary infection <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> amiodarone therapy <extra_id_1> <extra_id_0> drug <extra_id_5> amiodarone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> atrial fibrillation <extra_id_1> <extra_id_0> effect <extra_id_5> Nonsustained polymorphous ventricular tachycardia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> in <extra_id_0> treatment <extra_id_5> low dosage clofazimine <extra_id_1> <extra_id_0> drug <extra_id_5> clofazimine <extra_id_1> <extra_id_0> dosage <extra_id_5> low dosage <extra_id_1> <extra_id_0> effect <extra_id_5> Severe abdominal pain <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> clonazepam <extra_id_1> <extra_id_0> drug <extra_id_5> clonazepam <extra_id_1> <extra_id_0> effect <extra_id_5> agitation , aggression , hyperactivity , irritability , property destruction , and temper tantrums <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> cephalosporin or moxalactam antibiotics <extra_id_1> <extra_id_0> drug <extra_id_5> cephalosporin <extra_id_1> <extra_id_0> drug <extra_id_5> moxalactam antibiotics <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acute and chronic renal failure <extra_id_1> <extra_id_0> effect <extra_id_5> Coagulopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> therapy <extra_id_0> subject <extra_id_5> patients with hypercalcemia secondary to acute vitamin D poisoning <extra_id_1> <extra_id_0> subject disorder <extra_id_5> hypercalcemia <extra_id_1> <extra_id_0> treatment <extra_id_5> Pamidronate therapy <extra_id_1> <extra_id_0> drug <extra_id_5> Pamidronate <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> hypercalcemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> relationship <extra_id_0> subject <extra_id_5> this patient <extra_id_1> <extra_id_0> treatment <extra_id_5> amphotericin B deoxycholate <extra_id_1> <extra_id_0> drug <extra_id_5> amphotericin B deoxycholate <extra_id_1> <extra_id_0> effect <extra_id_5> cardiac toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> an infant with congenital heart disease <extra_id_1> <extra_id_0> age <extra_id_5> infant <extra_id_1> <extra_id_0> subject disorder <extra_id_5> congenital heart disease <extra_id_1> <extra_id_0> treatment <extra_id_5> Captopril <extra_id_1> <extra_id_0> drug <extra_id_5> Captopril <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> congenital heart disease <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary infiltrates with eosinophilia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induces <extra_id_0> treatment <extra_id_5> Chronic fentanyl application <extra_id_1> <extra_id_0> drug <extra_id_5> fentanyl <extra_id_1> <extra_id_0> effect <extra_id_5> adrenocortical insufficiency <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> After <extra_id_0> treatment <extra_id_5> discontinuing captopril and starting systemic steroids <extra_id_1> <extra_id_0> drug <extra_id_5> steroids <extra_id_1> <extra_id_0> route <extra_id_5> systemic <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> symptomatology rapidly improved , and her eosinophilia and radiographic abnormalities both resolved <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> suffering <extra_id_0> subject <extra_id_5> a woman schizophrenic patient <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> schizophrenic <extra_id_1> <extra_id_0> treatment <extra_id_5> clozapine <extra_id_1> <extra_id_0> drug <extra_id_5> clozapine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> schizophrenic <extra_id_1> <extra_id_0> effect <extra_id_5> EPS <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> subject <extra_id_5> this patient <extra_id_1> <extra_id_0> treatment <extra_id_5> calcium stearate <extra_id_1> <extra_id_0> drug <extra_id_5> calcium stearate <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> man , dogs , and cats <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> gender <extra_id_5> dogs <extra_id_1> <extra_id_0> gender <extra_id_5> cats <extra_id_1> <extra_id_0> treatment <extra_id_5> Benzocaine <extra_id_1> <extra_id_0> drug <extra_id_5> Benzocaine <extra_id_1> <extra_id_0> effect <extra_id_5> methemoglobinemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV - 1 <extra_id_1> <extra_id_0> treatment <extra_id_5> didanosine ( ddI ) <extra_id_1> <extra_id_0> drug <extra_id_5> didanosine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> HIV - 1 <extra_id_1> <extra_id_0> effect <extra_id_5> fulminant hepatic failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Leflunomide <extra_id_1> <extra_id_0> drug <extra_id_5> Leflunomide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> weight loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Antiretroviral <extra_id_1> <extra_id_0> drug <extra_id_5> Antiretroviral <extra_id_1> <extra_id_0> effect <extra_id_5> hepatic steatosis and lactic acidosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A woman <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> phenelzine <extra_id_1> <extra_id_0> drug <extra_id_5> phenelzine <extra_id_1> <extra_id_0> effect <extra_id_5> delusional parasitosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> causing <extra_id_0> treatment <extra_id_5> Percutaneous absorption of warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> route <extra_id_5> Percutaneous absorption <extra_id_1> <extra_id_0> effect <extra_id_5> coagulopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> nitrofurantoin <extra_id_1> <extra_id_0> drug <extra_id_5> nitrofurantoin <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary toxicity <extra_id_1> <extra_id_0> effect <extra_id_5> widespread reticular pattern and associated distortion of the lung parenchyma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Colchicine <extra_id_1> <extra_id_0> drug <extra_id_5> Colchicine <extra_id_1> <extra_id_0> effect <extra_id_5> rhabdomyolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> subject <extra_id_5> a case <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Crohn 's disease ( CD ) <extra_id_1> <extra_id_0> treatment <extra_id_5> three weeks following the administration of infliximab <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> duration <extra_id_5> three weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> three weeks <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Crohn 's disease ( CD ) <extra_id_1> <extra_id_0> effect <extra_id_5> severe AVP <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> subject <extra_id_5> each patient <extra_id_1> <extra_id_0> treatment <extra_id_5> the initiation of tolterodine <extra_id_1> <extra_id_0> drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> duration <extra_id_5> 10 - 14 days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 10 - 14 days <extra_id_1> <extra_id_0> effect <extra_id_5> significant increase in the patient 's INR <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occur <extra_id_0> subject <extra_id_5> 3 % or more of patients with cancer <extra_id_1> <extra_id_0> population <extra_id_5> 3 % or more <extra_id_1> <extra_id_0> subject disorder <extra_id_5> cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> standard doses of 5 - FU <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - FU <extra_id_1> <extra_id_0> dosage <extra_id_5> standard doses <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> cancer <extra_id_1> <extra_id_0> effect <extra_id_5> unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , mucositis , myelosuppression , neurotoxicity ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> concomitant acetaminophen and moxifloxacin use <extra_id_1> <extra_id_0> drug <extra_id_5> acetaminophen <extra_id_1> <extra_id_0> drug <extra_id_5> moxifloxacin <extra_id_1> <extra_id_0> combination drug <extra_id_5> acetaminophen <extra_id_1> <extra_id_0> combination drug <extra_id_5> moxifloxacin <extra_id_1> <extra_id_0> effect <extra_id_5> supratherapeutic INRs <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> colchicine and statin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> drug <extra_id_5> statin <extra_id_1> <extra_id_0> duration <extra_id_5> several months <extra_id_1> <extra_id_0> time elapsed <extra_id_5> several months <extra_id_1> <extra_id_0> combination drug <extra_id_5> colchicine <extra_id_1> <extra_id_0> combination drug <extra_id_5> statin <extra_id_1> <extra_id_0> effect <extra_id_5> myopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Cephalosporins <extra_id_1> <extra_id_0> drug <extra_id_5> Cephalosporins <extra_id_1> <extra_id_0> effect <extra_id_5> Vitamin K deficiency <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> subcutaneous injection of glatiramer acetate <extra_id_1> <extra_id_0> drug <extra_id_5> glatiramer acetate <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> Embolia cutis medicamentosa <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a 21 - year - old man with epilepsy <extra_id_1> <extra_id_0> age <extra_id_5> 21 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> epilepsy <extra_id_1> <extra_id_0> treatment <extra_id_5> valproic acid <extra_id_1> <extra_id_0> drug <extra_id_5> valproic acid <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> epilepsy <extra_id_1> <extra_id_0> effect <extra_id_5> dementia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a 50 - year - old woman with advanced non - small cell lung cancer <extra_id_1> <extra_id_0> age <extra_id_5> 50 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> advanced non - small cell lung cancer <extra_id_1> <extra_id_0> treatment <extra_id_5> cisplatin and gemcitabine chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> cisplatin <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> combination drug <extra_id_5> cisplatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> advanced non - small cell lung cancer <extra_id_1> <extra_id_0> effect <extra_id_5> status epilepticus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> VRC therapy <extra_id_1> <extra_id_0> drug <extra_id_5> VRC <extra_id_1> <extra_id_0> effect <extra_id_5> angio - oedema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occur <extra_id_0> treatment <extra_id_5> thalidomide treatment <extra_id_1> <extra_id_0> drug <extra_id_5> thalidomide <extra_id_1> <extra_id_0> effect <extra_id_5> Multiple syncopal episodes <extra_id_1> <extra_id_0> effect <extra_id_5> sustained ventricular tachycardia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> taking <extra_id_0> subject <extra_id_5> A 25 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 25 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> methysergide <extra_id_1> <extra_id_0> drug <extra_id_5> methysergide <extra_id_1> <extra_id_0> effect <extra_id_5> iliocaval manifestations of retroperitoneal fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> alendronate therapy <extra_id_1> <extra_id_0> drug <extra_id_5> alendronate <extra_id_1> <extra_id_0> effect <extra_id_5> Nodular scleritis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> ineffective <extra_id_0> subject <extra_id_5> both patients <extra_id_1> <extra_id_0> population <extra_id_5> both <extra_id_1> <extra_id_0> treatment <extra_id_5> tolterodine <extra_id_1> <extra_id_0> drug <extra_id_5> tolterodine <extra_id_1> <extra_id_0> effect <extra_id_5> elevated INRs <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> exacerbate <extra_id_0> subject <extra_id_5> any patient <extra_id_1> <extra_id_0> treatment <extra_id_5> lithium <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> effect <extra_id_5> loss of intracellular potassium <extra_id_1> <extra_id_0> effect <extra_id_5> increasing the risk of cardiac toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> role <extra_id_0> treatment <extra_id_5> disulfiram <extra_id_1> <extra_id_0> drug <extra_id_5> disulfiram <extra_id_1> <extra_id_0> effect <extra_id_5> catatonia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> L - asparaginase treatment <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> effect <extra_id_5> Sagittal sinus thrombosis <extra_id_1> <extra_id_0> effect <extra_id_5> transient free protein S deficiency <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> fenclofenac as well as aurothiomalate and sulphasalazine <extra_id_1> <extra_id_0> drug <extra_id_5> fenclofenac <extra_id_1> <extra_id_0> drug <extra_id_5> aurothiomalate <extra_id_1> <extra_id_0> drug <extra_id_5> sulphasalazine <extra_id_1> <extra_id_0> combination drug <extra_id_5> fenclofenac <extra_id_1> <extra_id_0> combination drug <extra_id_5> aurothiomalate <extra_id_1> <extra_id_0> combination drug <extra_id_5> sulphasalazine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> selective IgA deficiency with remission <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> effect <extra_id_0> treatment <extra_id_5> co - administration of prolonged - release oxycodone and existing gabapentin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> oxycodone <extra_id_1> <extra_id_0> drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> combination drug <extra_id_5> oxycodone <extra_id_1> <extra_id_0> combination drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> painful diabetic neuropathy <extra_id_1> <extra_id_0> effect <extra_id_5> clinically meaningful effect <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> determined <extra_id_0> treatment <extra_id_5> concomitant administration of clarithromycin and sirolimus <extra_id_1> <extra_id_0> drug <extra_id_5> clarithromycin <extra_id_1> <extra_id_0> drug <extra_id_5> sirolimus <extra_id_1> <extra_id_0> dosage <extra_id_5> 6.2 up to 54 ng / mL <extra_id_1> <extra_id_0> combination drug <extra_id_5> clarithromycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> sirolimus <extra_id_1> <extra_id_0> effect <extra_id_5> impressive increase of sirolimus trough blood concentrations <extra_id_1> <extra_id_0> effect <extra_id_5> acute impairment of renal function <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> followed <extra_id_0> subject <extra_id_5> one case <extra_id_1> <extra_id_0> population <extra_id_5> one <extra_id_1> <extra_id_0> treatment <extra_id_5> readministration of riluzole <extra_id_1> <extra_id_0> drug <extra_id_5> riluzole <extra_id_1> <extra_id_0> effect <extra_id_5> relapse of hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Pseudoephedrine <extra_id_1> <extra_id_0> drug <extra_id_5> Pseudoephedrine <extra_id_1> <extra_id_0> effect <extra_id_5> hemorrhage <extra_id_1> <extra_id_0> effect <extra_id_5> cerebral vascular malformation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a 34 - year - old man without a history of glaucoma <extra_id_1> <extra_id_0> age <extra_id_5> 34 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> treatment <extra_id_5> intravitreal injection of triamcinolone acetate <extra_id_1> <extra_id_0> drug <extra_id_5> triamcinolone acetate <extra_id_1> <extra_id_0> route <extra_id_5> intravitreal injection <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> glaucoma <extra_id_1> <extra_id_0> effect <extra_id_5> severe corticosteroid - induced glaucoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> in <extra_id_0> treatment <extra_id_5> quinine <extra_id_1> <extra_id_0> drug <extra_id_5> quinine <extra_id_1> <extra_id_0> effect <extra_id_5> transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> led <extra_id_0> subject <extra_id_5> him <extra_id_1> <extra_id_0> gender <extra_id_5> he <extra_id_1> <extra_id_0> treatment <extra_id_5> Two days ' administration of levomepromazine 100 mg <extra_id_1> <extra_id_0> drug <extra_id_5> levomepromazine <extra_id_1> <extra_id_0> dosage <extra_id_5> 100 mg <extra_id_1> <extra_id_0> duration <extra_id_5> Two days <extra_id_1> <extra_id_0> time elapsed <extra_id_5> Two days <extra_id_1> <extra_id_0> effect <extra_id_5> coma for 2 days <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Methimazole <extra_id_1> <extra_id_0> drug <extra_id_5> Methimazole <extra_id_1> <extra_id_0> effect <extra_id_5> aplastic anemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> two cases <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> intravitreal triamcinolone acetonide ( IVTA ) injection <extra_id_1> <extra_id_0> drug <extra_id_5> triamcinolone acetonide <extra_id_1> <extra_id_0> route <extra_id_5> intravitreal <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> acute syphilitic posterior placoid chorioretinitis ( ASPPC ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> from <extra_id_0> treatment <extra_id_5> ganciclovir <extra_id_1> <extra_id_0> drug <extra_id_5> ganciclovir <extra_id_1> <extra_id_0> effect <extra_id_5> Skin rash and splinter hemorrhages <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> pediatric patient with leukemia <extra_id_1> <extra_id_0> age <extra_id_5> pediatric <extra_id_1> <extra_id_0> subject disorder <extra_id_5> leukemia <extra_id_1> <extra_id_0> treatment <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> necrotizing pancreatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> INH therapy <extra_id_1> <extra_id_0> drug <extra_id_5> INH <extra_id_1> <extra_id_0> effect <extra_id_5> anagen effluvium with lichenoid eruption <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> treatment <extra_id_5> MB <extra_id_1> <extra_id_0> drug <extra_id_5> MB <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> ifosfamide - induced encephalopathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> low - dose carbamazepine therapy <extra_id_1> <extra_id_0> drug <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> dosage <extra_id_5> low - dose <extra_id_1> <extra_id_0> effect <extra_id_5> Hyponatraemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> capecitabine therapy <extra_id_1> <extra_id_0> drug <extra_id_5> capecitabine <extra_id_1> <extra_id_0> effect <extra_id_5> Acute coronary syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> treatment <extra_id_5> a single dose of vincristine <extra_id_1> <extra_id_0> drug <extra_id_5> vincristine <extra_id_1> <extra_id_0> dosage <extra_id_5> single dose <extra_id_1> <extra_id_0> effect <extra_id_5> severe visual loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a young woman with SLE and thrombocytopenia <extra_id_1> <extra_id_0> age <extra_id_5> young <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> SLE and thrombocytopenia <extra_id_1> <extra_id_0> treatment <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> SLE and thrombocytopenia <extra_id_1> <extra_id_0> effect <extra_id_5> perspiration , headache , and seizure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> secondary <extra_id_0> treatment <extra_id_5> gabapentin withdrawal <extra_id_1> <extra_id_0> drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> effect <extra_id_5> generalized seizures and status epilepticus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> insulin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> insulin <extra_id_1> <extra_id_0> effect <extra_id_5> Self - limited edema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> contributed <extra_id_0> subject <extra_id_5> these patients <extra_id_1> <extra_id_0> treatment <extra_id_5> dexamethasone <extra_id_1> <extra_id_0> drug <extra_id_5> dexamethasone <extra_id_1> <extra_id_0> effect <extra_id_5> osteonecrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> discontinuation of nefazodone <extra_id_1> <extra_id_0> drug <extra_id_5> nefazodone <extra_id_1> <extra_id_0> effect <extra_id_5> benzodiazepine withdrawal symptoms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> have <extra_id_0> treatment <extra_id_5> Isotretinoin <extra_id_1> <extra_id_0> drug <extra_id_5> Isotretinoin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> acne <extra_id_1> <extra_id_0> effect <extra_id_5> teratogenic effects <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induce <extra_id_0> treatment <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> drug <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> effect <extra_id_5> priapism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> Two patients <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic myeloid leukemia <extra_id_1> <extra_id_0> treatment <extra_id_5> high doses of CCNU ( 1100 mg / m2 and 1240 mg / m2 , respectively ) <extra_id_1> <extra_id_0> drug <extra_id_5> CCNU <extra_id_1> <extra_id_0> dosage <extra_id_5> 1100 mg / m2 <extra_id_1> <extra_id_0> dosage <extra_id_5> 1240 mg / m2 <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic myeloid leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> fatal pulmonary fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> ofloxacin <extra_id_1> <extra_id_0> drug <extra_id_5> ofloxacin <extra_id_1> <extra_id_0> effect <extra_id_5> toxic epidermal necrolysis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> aspirin <extra_id_1> <extra_id_0> drug <extra_id_5> aspirin <extra_id_1> <extra_id_0> effect <extra_id_5> hemorrhage from a meningioma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> axillary block with bupivacaine and additional injection of lidocaine in the operative field <extra_id_1> <extra_id_0> drug <extra_id_5> bupivacaine <extra_id_1> <extra_id_0> drug <extra_id_5> lidocaine <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> combination drug <extra_id_5> bupivacaine <extra_id_1> <extra_id_0> combination drug <extra_id_5> lidocaine <extra_id_1> <extra_id_0> effect <extra_id_5> Methemoglobinemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> role <extra_id_0> treatment <extra_id_5> morphine and its antagonist <extra_id_1> <extra_id_0> drug <extra_id_5> morphine <extra_id_1> <extra_id_0> effect <extra_id_5> Nonconvulsive status epilepticus <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> evolving <extra_id_0> subject <extra_id_5> two patients <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> hydroxyurea <extra_id_1> <extra_id_0> drug <extra_id_5> hydroxyurea <extra_id_1> <extra_id_0> effect <extra_id_5> Acute myeloid leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> essential thrombocythemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reversed <extra_id_0> treatment <extra_id_5> naloxone <extra_id_1> <extra_id_0> drug <extra_id_5> naloxone <extra_id_1> <extra_id_0> drug <extra_id_5> ibuprofen <extra_id_1> <extra_id_0> dosage <extra_id_5> overdose <extra_id_1> <extra_id_0> effect <extra_id_5> Central nervous system manifestations <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> sirolimus <extra_id_1> <extra_id_0> drug <extra_id_5> sirolimus <extra_id_1> <extra_id_0> effect <extra_id_5> Aphthous stomatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> propafenone and citalopram <extra_id_1> <extra_id_0> drug <extra_id_5> propafenone <extra_id_1> <extra_id_0> drug <extra_id_5> citalopram <extra_id_1> <extra_id_0> combination drug <extra_id_5> propafenone <extra_id_1> <extra_id_0> combination drug <extra_id_5> citalopram <extra_id_1> <extra_id_0> effect <extra_id_5> propafenone adverse effects <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> observed <extra_id_0> subject <extra_id_5> one out of 23 patients <extra_id_1> <extra_id_0> population <extra_id_5> one out of 23 <extra_id_1> <extra_id_0> subject disorder <extra_id_5> osteogenic sarcoma <extra_id_1> <extra_id_0> treatment <extra_id_5> high - dose methotrexate ( HD - MTX ) <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> dosage <extra_id_5> high - dose <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> osteogenic sarcoma <extra_id_1> <extra_id_0> effect <extra_id_5> Temporary neurologic abnormalities <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> propafenone and citalopram <extra_id_1> <extra_id_0> drug <extra_id_5> propafenone <extra_id_1> <extra_id_0> drug <extra_id_5> citalopram <extra_id_1> <extra_id_0> combination drug <extra_id_5> propafenone <extra_id_1> <extra_id_0> combination drug <extra_id_5> citalopram <extra_id_1> <extra_id_0> effect <extra_id_5> propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> intraarterial vasopressin therapy <extra_id_1> <extra_id_0> drug <extra_id_5> vasopressin <extra_id_1> <extra_id_0> route <extra_id_5> intraarterial <extra_id_1> <extra_id_0> effect <extra_id_5> Spontaneous bacterial peritonitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> reduces <extra_id_0> subject <extra_id_5> adult patients with severe , persistent asthma <extra_id_1> <extra_id_0> age <extra_id_5> adult <extra_id_1> <extra_id_0> subject disorder <extra_id_5> severe , persistent asthma <extra_id_1> <extra_id_0> treatment <extra_id_5> Ciclesonide <extra_id_1> <extra_id_0> drug <extra_id_5> Ciclesonide <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> severe , persistent asthma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> patients unsuspected of having vitamin B12 deficiency <extra_id_1> <extra_id_0> population <extra_id_5> Four <extra_id_1> <extra_id_0> population <extra_id_5> one <extra_id_1> <extra_id_0> subject disorder <extra_id_5> vitamin B12 deficiency <extra_id_1> <extra_id_0> treatment <extra_id_5> nitrous oxide anesthesia <extra_id_1> <extra_id_0> drug <extra_id_5> nitrous oxide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> vitamin B12 deficiency <extra_id_1> <extra_id_0> effect <extra_id_5> subacute combined degeneration of the spinal cord <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> a 31 - year - old patient hospitalized due to behavioral alterations <extra_id_1> <extra_id_0> age <extra_id_5> 31 - year - old <extra_id_1> <extra_id_0> subject disorder <extra_id_5> behavioral alterations <extra_id_1> <extra_id_0> treatment <extra_id_5> oral zuclopenthixol <extra_id_1> <extra_id_0> drug <extra_id_5> zuclopenthixol <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> behavioral alterations <extra_id_1> <extra_id_0> effect <extra_id_5> acute , painful erection <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> receiving <extra_id_0> subject <extra_id_5> Three cases <extra_id_1> <extra_id_0> population <extra_id_5> Three <extra_id_1> <extra_id_0> treatment <extra_id_5> long - term therapy with mitomycin C and 5 - fluorouracil <extra_id_1> <extra_id_0> drug <extra_id_5> mitomycin C <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> combination drug <extra_id_5> mitomycin C <extra_id_1> <extra_id_0> combination drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> effect <extra_id_5> acute renal toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A 40 - year - old man with a long standing history of rheumatoid arthritis <extra_id_1> <extra_id_0> age <extra_id_5> 40 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> treatment <extra_id_5> MTX over a 6 month period <extra_id_1> <extra_id_0> drug <extra_id_5> MTX <extra_id_1> <extra_id_0> duration <extra_id_5> 6 month <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 6 month <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> rheumatoid arthritis <extra_id_1> <extra_id_0> effect <extra_id_5> overwhelming hepatic necrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulted <extra_id_0> treatment <extra_id_5> a total daily dose of 25 mg sertraline <extra_id_1> <extra_id_0> drug <extra_id_5> sertraline <extra_id_1> <extra_id_0> dosage <extra_id_5> 25 mg <extra_id_1> <extra_id_0> frequency <extra_id_5> daily <extra_id_1> <extra_id_0> effect <extra_id_5> doubling of the lamotrigine blood level with symptoms of toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> treatment <extra_id_5> propranolol <extra_id_1> <extra_id_0> drug <extra_id_5> propranolol <extra_id_1> <extra_id_0> effect <extra_id_5> bronchospasm <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> A depressed woman with no history of bipolar illness <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> depressed <extra_id_1> <extra_id_0> treatment <extra_id_5> fluoxetine <extra_id_1> <extra_id_0> drug <extra_id_5> fluoxetine <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> depressed <extra_id_1> <extra_id_0> effect <extra_id_5> manic episode <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> trazodone <extra_id_1> <extra_id_0> drug <extra_id_5> trazodone <extra_id_1> <extra_id_0> effect <extra_id_5> Priapism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> complication <extra_id_0> treatment <extra_id_5> interferon alfa <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alfa <extra_id_1> <extra_id_0> effect <extra_id_5> anterior ischemic optic neuropathy <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> mequitazine <extra_id_1> <extra_id_0> drug <extra_id_5> mequitazine <extra_id_1> <extra_id_0> effect <extra_id_5> photosensitivity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> pentamidine <extra_id_1> <extra_id_0> drug <extra_id_5> pentamidine <extra_id_1> <extra_id_0> effect <extra_id_5> cardiotoxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> receiving <extra_id_0> subject <extra_id_5> patient <extra_id_1> <extra_id_0> treatment <extra_id_5> weekly warfarin <extra_id_1> <extra_id_0> treatment <extra_id_5> emtricitabine monotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> drug <extra_id_5> emtricitabine <extra_id_1> <extra_id_0> dosage <extra_id_5> 13.3 mg <extra_id_1> <extra_id_0> dosage <extra_id_5> 13.3 mg <extra_id_1> <extra_id_0> frequency <extra_id_5> weekly <extra_id_1> <extra_id_0> combination drug <extra_id_5> emtricitabine <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> international normalized ratio ( INR ) of 2.8 ( 95 % CI 2.5 to 3.1 ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> intracavernous self - injection of a combination of phentolamine and papaverine <extra_id_1> <extra_id_0> drug <extra_id_5> phentolamine <extra_id_1> <extra_id_0> drug <extra_id_5> papaverine <extra_id_1> <extra_id_0> route <extra_id_5> intracavernous self - injection <extra_id_1> <extra_id_0> combination drug <extra_id_5> phentolamine <extra_id_1> <extra_id_0> combination drug <extra_id_5> papaverine <extra_id_1> <extra_id_0> effect <extra_id_5> penile fibrosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> followed <extra_id_0> subject <extra_id_5> the same patient <extra_id_1> <extra_id_0> treatment <extra_id_5> propylthiouracil and methimazole <extra_id_1> <extra_id_0> drug <extra_id_5> propylthiouracil <extra_id_1> <extra_id_0> drug <extra_id_5> methimazole <extra_id_1> <extra_id_0> combination drug <extra_id_5> propylthiouracil <extra_id_1> <extra_id_0> combination drug <extra_id_5> methimazole <extra_id_1> <extra_id_0> effect <extra_id_5> agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> during <extra_id_0> treatment <extra_id_5> fluoxetine and sertraline treatment <extra_id_1> <extra_id_0> drug <extra_id_5> sertraline <extra_id_1> <extra_id_0> drug <extra_id_5> fluoxetine <extra_id_1> <extra_id_0> combination drug <extra_id_5> fluoxetine <extra_id_1> <extra_id_0> combination drug <extra_id_5> sertraline <extra_id_1> <extra_id_0> effect <extra_id_5> Itch and skin rash <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Oxycodone - gabapentin co - administration <extra_id_1> <extra_id_0> drug <extra_id_5> Oxycodone <extra_id_1> <extra_id_0> drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> combination drug <extra_id_5> Oxycodone <extra_id_1> <extra_id_0> combination drug <extra_id_5> gabapentin <extra_id_1> <extra_id_0> effect <extra_id_5> less escape medication use ( P = 0.03 ) and fewer nights of disturbed sleep ( P <unk> 0.05 ) <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> two case reports <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> epileptics <extra_id_1> <extra_id_0> treatment <extra_id_5> phenobarbital , phenytoin and fluoresone <extra_id_1> <extra_id_0> drug <extra_id_5> phenobarbital <extra_id_1> <extra_id_0> drug <extra_id_5> phenytoin <extra_id_1> <extra_id_0> drug <extra_id_5> fluoresone <extra_id_1> <extra_id_0> combination drug <extra_id_5> phenobarbital <extra_id_1> <extra_id_0> combination drug <extra_id_5> phenytoin <extra_id_1> <extra_id_0> combination drug <extra_id_5> fluoresone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> epileptics <extra_id_1> <extra_id_0> effect <extra_id_5> Gynecomastia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Captopril <extra_id_1> <extra_id_0> drug <extra_id_5> Captopril <extra_id_1> <extra_id_0> effect <extra_id_5> lichen planus pemphigoides with pemphigus - like features <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> thiabendazole <extra_id_1> <extra_id_0> drug <extra_id_5> thiabendazole <extra_id_1> <extra_id_0> effect <extra_id_5> cholestasis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> Use <extra_id_0> subject <extra_id_5> patients with mucocutaneous reactions <extra_id_1> <extra_id_0> subject disorder <extra_id_5> mucocutaneous reactions <extra_id_1> <extra_id_0> treatment <extra_id_5> very low dosage of gold <extra_id_1> <extra_id_0> drug <extra_id_5> gold <extra_id_1> <extra_id_0> dosage <extra_id_5> very low dosage <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> mucocutaneous reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> received <extra_id_0> subject <extra_id_5> A 55 - year - old HIV - positive African woman <extra_id_1> <extra_id_0> age <extra_id_5> 55 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> race <extra_id_5> African <extra_id_1> <extra_id_0> subject disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> treatment <extra_id_5> single epidural triamcinolone injection <extra_id_1> <extra_id_0> drug <extra_id_5> triamcinolone <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> HIV <extra_id_1> <extra_id_0> effect <extra_id_5> pain relief of postherpetic neuralgia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurred <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> subject disorder <extra_id_5> toothache <extra_id_1> <extra_id_0> treatment <extra_id_5> zomepirac sodium <extra_id_1> <extra_id_0> drug <extra_id_5> zomepirac sodium <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> toothache <extra_id_1> <extra_id_0> effect <extra_id_5> Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> three of six young female volunteers <extra_id_1> <extra_id_0> gender <extra_id_5> female <extra_id_1> <extra_id_0> population <extra_id_5> three of six <extra_id_1> <extra_id_0> population <extra_id_5> two <extra_id_1> <extra_id_0> treatment <extra_id_5> intravenous proton pump inhibitors omeprazole and pantoprazole <extra_id_1> <extra_id_0> treatment <extra_id_5> high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid <extra_id_1> <extra_id_0> drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> drug <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> dosage <extra_id_5> high doses <extra_id_1> <extra_id_0> route <extra_id_5> intravenous <extra_id_1> <extra_id_0> time elapsed <extra_id_5> within 8 hr <extra_id_1> <extra_id_0> combination drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> combination drug <extra_id_5> pantoprazole <extra_id_1> <extra_id_0> effect <extra_id_5> peripheral edema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> ameliorated <extra_id_0> subject <extra_id_5> his akathisia symptoms <extra_id_1> <extra_id_0> gender <extra_id_5> his <extra_id_1> <extra_id_0> subject disorder <extra_id_5> akathisia <extra_id_1> <extra_id_0> treatment <extra_id_5> Intravenous levodopa 25 mg <extra_id_1> <extra_id_0> drug <extra_id_5> levodopa <extra_id_1> <extra_id_0> dosage <extra_id_5> 25 mg <extra_id_1> <extra_id_0> route <extra_id_5> Intravenous <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> akathisia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a child <extra_id_1> <extra_id_0> age <extra_id_5> child <extra_id_1> <extra_id_0> treatment <extra_id_5> Cyclosporine <extra_id_1> <extra_id_0> drug <extra_id_5> Cyclosporine <extra_id_1> <extra_id_0> effect <extra_id_5> pain syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> treatment <extra_id_5> a single small dose of vincristine <extra_id_1> <extra_id_0> drug <extra_id_5> vincristine <extra_id_1> <extra_id_0> dosage <extra_id_5> single small dose <extra_id_1> <extra_id_0> effect <extra_id_5> Visual loss <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> salazosulfapyridine <extra_id_1> <extra_id_0> drug <extra_id_5> salazosulfapyridine <extra_id_1> <extra_id_0> effect <extra_id_5> infectious mononucleosis - like syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> raltegravir <extra_id_1> <extra_id_0> drug <extra_id_5> raltegravir <extra_id_1> <extra_id_0> effect <extra_id_5> DRESS syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> cause <extra_id_0> subject <extra_id_5> certain circumstances <extra_id_1> <extra_id_0> treatment <extra_id_5> topical brimonidine <extra_id_1> <extra_id_0> drug <extra_id_5> brimonidine <extra_id_1> <extra_id_0> route <extra_id_5> topical <extra_id_1> <extra_id_0> effect <extra_id_5> paradoxical raised IOP <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> over - treatment <extra_id_0> treatment <extra_id_5> chloroquine <extra_id_1> <extra_id_0> drug <extra_id_5> chloroquine <extra_id_1> <extra_id_0> dosage <extra_id_5> 902 micro g / L <extra_id_1> <extra_id_0> effect <extra_id_5> maximum serum concentration of chloroquine <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> clopidogrel and omeprazole <extra_id_1> <extra_id_0> drug <extra_id_5> clopidogrel <extra_id_1> <extra_id_0> drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> combination drug <extra_id_5> clopidogrel <extra_id_1> <extra_id_0> combination drug <extra_id_5> omeprazole <extra_id_1> <extra_id_0> effect <extra_id_5> cardiovascular interaction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> reactions <extra_id_0> treatment <extra_id_5> methotrexate <extra_id_1> <extra_id_0> drug <extra_id_5> methotrexate <extra_id_1> <extra_id_0> effect <extra_id_5> Anaphylactic / anaphylactoid reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treat <extra_id_0> treatment <extra_id_5> Continuous bladder irrigation of a 1 % alum solution <extra_id_1> <extra_id_0> drug <extra_id_5> alum <extra_id_1> <extra_id_0> route <extra_id_5> Continuous bladder irrigation <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> bleeding urothelium <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> treatment <extra_id_5> zolmitriptan <extra_id_1> <extra_id_0> drug <extra_id_5> zolmitriptan <extra_id_1> <extra_id_0> effect <extra_id_5> spinal cord infarction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> phenelzine <extra_id_1> <extra_id_0> drug <extra_id_5> phenelzine <extra_id_1> <extra_id_0> effect <extra_id_5> Delusional parasitosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> responsible <extra_id_0> treatment <extra_id_5> tissue plasminogen activator <extra_id_1> <extra_id_0> drug <extra_id_5> tissue plasminogen activator <extra_id_1> <extra_id_0> effect <extra_id_5> large extent of hemorrhage <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> causing <extra_id_0> treatment <extra_id_5> 5 - fluorouracil - based chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> 5 - fluorouracil <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> effect <extra_id_5> adverse reactions <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> used <extra_id_0> treatment <extra_id_5> Interferon - beta ( IFN - beta ) <extra_id_1> <extra_id_0> drug <extra_id_5> Interferon - beta <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> multiple sclerosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Quetiapine <extra_id_1> <extra_id_0> drug <extra_id_5> Quetiapine <extra_id_1> <extra_id_0> effect <extra_id_5> leucopenia and thrombocytopenia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occur <extra_id_0> treatment <extra_id_5> intravitreal ranibizumab <extra_id_1> <extra_id_0> drug <extra_id_5> ranibizumab <extra_id_1> <extra_id_0> route <extra_id_5> intravitreal <extra_id_1> <extra_id_0> effect <extra_id_5> Severe and sustained ocular hypertension <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> following <extra_id_0> subject <extra_id_5> four patients <extra_id_1> <extra_id_0> population <extra_id_5> four <extra_id_1> <extra_id_0> treatment <extra_id_5> injection of ranibizumab intravitreally <extra_id_1> <extra_id_0> drug <extra_id_5> ranibizumab <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> ocular hypertension <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> Vancomycin <extra_id_1> <extra_id_0> drug <extra_id_5> Vancomycin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> methicillin - resistant Staphylococcus aureus infections <extra_id_1> <extra_id_0> effect <extra_id_5> nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> resulted <extra_id_0> subject <extra_id_5> a patient with Sjogren 's syndrome <extra_id_1> <extra_id_0> subject disorder <extra_id_5> Sjogren 's syndrome <extra_id_1> <extra_id_0> treatment <extra_id_5> unintentional overdose of oral pilocarpine tablets <extra_id_1> <extra_id_0> drug <extra_id_5> pilocarpine <extra_id_1> <extra_id_0> dosage <extra_id_5> overdose <extra_id_1> <extra_id_0> route <extra_id_5> oral <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Sjogren 's syndrome <extra_id_1> <extra_id_0> effect <extra_id_5> bradycardia , mild hypotension , and muscarinic symptoms <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induce <extra_id_0> treatment <extra_id_5> treatment with immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha <extra_id_1> <extra_id_0> drug <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> drug <extra_id_5> cisplatin <extra_id_1> <extra_id_0> drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> drug <extra_id_5> interferon - alpha <extra_id_1> <extra_id_0> combination drug <extra_id_5> cyclosporine <extra_id_1> <extra_id_0> combination drug <extra_id_5> cisplatin <extra_id_1> <extra_id_0> combination drug <extra_id_5> tacrolimus <extra_id_1> <extra_id_0> combination drug <extra_id_5> interferon - alpha <extra_id_1> <extra_id_0> effect <extra_id_5> RPLS <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> Case 1 , a 62 - year - old woman <extra_id_1> <extra_id_0> age <extra_id_5> 62 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> subject disorder <extra_id_5> chronic active hepatitis C. <extra_id_1> <extra_id_0> treatment <extra_id_5> seven - month use of recombinant interferon alpha - 2a <extra_id_1> <extra_id_0> drug <extra_id_5> recombinant interferon alpha - 2a <extra_id_1> <extra_id_0> duration <extra_id_5> seven - month <extra_id_1> <extra_id_0> time elapsed <extra_id_5> seven - month <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> chronic active hepatitis C. <extra_id_1> <extra_id_0> effect <extra_id_5> bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> response <extra_id_0> subject <extra_id_5> patients with schizophrenia <extra_id_1> <extra_id_0> subject disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> treatment <extra_id_5> risperidone <extra_id_1> <extra_id_0> drug <extra_id_5> risperidone <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> schizophrenia <extra_id_1> <extra_id_0> effect <extra_id_5> increased affect <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> development <extra_id_0> treatment <extra_id_5> Therapy with IFN - beta <extra_id_1> <extra_id_0> drug <extra_id_5> IFN - beta <extra_id_1> <extra_id_0> effect <extra_id_5> autoimmune disorders <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> subject <extra_id_5> the patient <extra_id_1> <extra_id_0> treatment <extra_id_5> low - molecular - weight heparin <extra_id_1> <extra_id_0> drug <extra_id_5> low - molecular - weight heparin <extra_id_1> <extra_id_0> effect <extra_id_5> repeated venous thromboembolism <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> developed <extra_id_0> treatment <extra_id_5> rechallenge with controlled release carbamazepine <extra_id_1> <extra_id_0> drug <extra_id_5> carbamazepine <extra_id_1> <extra_id_0> effect <extra_id_5> Hyponatraemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> Azathioprine <extra_id_1> <extra_id_0> drug <extra_id_5> Azathioprine <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> combination drug <extra_id_5> Azathioprine <extra_id_1> <extra_id_0> combination drug <extra_id_5> warfarin <extra_id_1> <extra_id_0> effect <extra_id_5> resistance <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> valproic acid <extra_id_1> <extra_id_0> drug <extra_id_5> valproic acid <extra_id_1> <extra_id_0> effect <extra_id_5> dementia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> verapamil <extra_id_1> <extra_id_0> drug <extra_id_5> verapamil <extra_id_1> <extra_id_0> route <extra_id_5> Parenteral <extra_id_1> <extra_id_0> effect <extra_id_5> sustained hypotension <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> side - effects <extra_id_0> treatment <extra_id_5> Lp - TAE combined with HT <extra_id_1> <extra_id_0> drug <extra_id_5> HT <extra_id_1> <extra_id_0> drug <extra_id_5> Lp - TAE <extra_id_1> <extra_id_0> combination drug <extra_id_5> HT <extra_id_1> <extra_id_0> combination drug <extra_id_5> Lp - TAE <extra_id_1> <extra_id_0> effect <extra_id_5> low - grade fever , localized pain , myelo - suppression and liver dysfunction <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> with <extra_id_0> treatment <extra_id_5> cinepazide <extra_id_1> <extra_id_0> drug <extra_id_5> cinepazide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> parkinsonism <extra_id_1> <extra_id_0> effect <extra_id_5> Unique behavioral change <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> toxicity <extra_id_0> treatment <extra_id_5> vincristine <extra_id_1> <extra_id_0> drug <extra_id_5> vincristine <extra_id_1> <extra_id_0> effect <extra_id_5> optic nerve toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> experienced <extra_id_0> subject <extra_id_5> Two patients <extra_id_1> <extra_id_0> age <extra_id_5> 40 and 51 years <extra_id_1> <extra_id_0> population <extra_id_5> Two <extra_id_1> <extra_id_0> subject disorder <extra_id_5> malignant neoplasms <extra_id_1> <extra_id_0> treatment <extra_id_5> interferon alfa <extra_id_1> <extra_id_0> drug <extra_id_5> interferon alfa <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> malignant neoplasms <extra_id_1> <extra_id_0> effect <extra_id_5> sudden bilateral , sequential visual loss with disc - related field defects and segmental optic disc edema <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> intrathecal injection of doxorubicin <extra_id_1> <extra_id_0> drug <extra_id_5> doxorubicin <extra_id_1> <extra_id_0> route <extra_id_5> intrathecal injection <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> toxic myelopathy <extra_id_1> <extra_id_0> effect <extra_id_5> Neurological improvement and rehabilitation potential <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> associated <extra_id_0> treatment <extra_id_5> ganciclovir therapy <extra_id_1> <extra_id_0> drug <extra_id_5> ganciclovir <extra_id_1> <extra_id_0> effect <extra_id_5> Generalised cutaneous rash <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> occurs <extra_id_0> subject <extra_id_5> 1 % of such cases <extra_id_1> <extra_id_0> population <extra_id_5> 1 % <extra_id_1> <extra_id_0> treatment <extra_id_5> injection of chymopapain <extra_id_1> <extra_id_0> drug <extra_id_5> chymopapain <extra_id_1> <extra_id_0> route <extra_id_5> injection <extra_id_1> <extra_id_0> effect <extra_id_5> Anaphylaxis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> caused <extra_id_0> subject <extra_id_5> a child <extra_id_1> <extra_id_0> age <extra_id_5> child <extra_id_1> <extra_id_0> treatment <extra_id_5> zonisamide <extra_id_1> <extra_id_0> drug <extra_id_5> zonisamide <extra_id_1> <extra_id_0> effect <extra_id_5> Heat stroke - like episode <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> give rise <extra_id_0> treatment <extra_id_5> interaction between methylene blue and serotonergic agents <extra_id_1> <extra_id_0> drug <extra_id_5> methylene blue <extra_id_1> <extra_id_0> drug <extra_id_5> serotonergic agents <extra_id_1> <extra_id_0> combination drug <extra_id_5> methylene blue <extra_id_1> <extra_id_0> combination drug <extra_id_5> serotonergic agents <extra_id_1> <extra_id_0> effect <extra_id_5> serotonin syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> subject <extra_id_5> some patients <extra_id_1> <extra_id_0> treatment <extra_id_5> olanzapine treatment <extra_id_1> <extra_id_0> drug <extra_id_5> olanzapine <extra_id_1> <extra_id_0> effect <extra_id_5> leukopenia or agranulocytosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> after <extra_id_0> subject <extra_id_5> Adult <extra_id_1> <extra_id_0> age <extra_id_5> Adult <extra_id_1> <extra_id_0> treatment <extra_id_5> pegylated interferon alpha - 2a and ribavirin <extra_id_1> <extra_id_0> drug <extra_id_5> pegylated interferon alpha - 2a <extra_id_1> <extra_id_0> drug <extra_id_5> ribavirin <extra_id_1> <extra_id_0> combination drug <extra_id_5> pegylated interferon alpha - 2a <extra_id_1> <extra_id_0> combination drug <extra_id_5> ribavirin <extra_id_1> <extra_id_0> effect <extra_id_5> respiratory distress syndrome <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> result <extra_id_0> treatment <extra_id_5> metformin <extra_id_1> <extra_id_0> drug <extra_id_5> metformin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> Type 2 diabetes <extra_id_1> <extra_id_0> effect <extra_id_5> lactic acidosis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> treated <extra_id_0> subject <extra_id_5> patient with primary plasma - cell leukemia <extra_id_1> <extra_id_0> subject disorder <extra_id_5> primary plasma - cell leukemia <extra_id_1> <extra_id_0> treatment <extra_id_5> thalidomide <extra_id_1> <extra_id_0> drug <extra_id_5> thalidomide <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> primary plasma - cell leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> Sustained ventricular tachycardia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> diagnosed <extra_id_0> subject <extra_id_5> a 29 - year - old man with CD <extra_id_1> <extra_id_0> age <extra_id_5> 29 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> subject disorder <extra_id_5> CD <extra_id_1> <extra_id_0> treatment <extra_id_5> 3 weeks after infusion with infliximab <extra_id_1> <extra_id_0> drug <extra_id_5> infliximab <extra_id_1> <extra_id_0> route <extra_id_5> infusion <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 3 weeks <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> CD <extra_id_1> <extra_id_0> effect <extra_id_5> nodular sclerosing Hodgkin 's lymphoma <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> observed <extra_id_0> treatment <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> drug <extra_id_5> gemcitabine <extra_id_1> <extra_id_0> effect <extra_id_5> radiation recall <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> subject <extra_id_5> a patient <extra_id_1> <extra_id_0> treatment <extra_id_5> itraconazole <extra_id_1> <extra_id_0> drug <extra_id_5> itraconazole <extra_id_1> <extra_id_0> duration <extra_id_5> 24 weeks <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 24 weeks <extra_id_1> <extra_id_0> effect <extra_id_5> acute cytolytic hepatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> treatment <extra_id_0> subject <extra_id_5> patients with PTSD <extra_id_1> <extra_id_0> subject disorder <extra_id_5> PTSD <extra_id_1> <extra_id_0> treatment <extra_id_5> lithium <extra_id_1> <extra_id_0> drug <extra_id_5> lithium <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> PTSD <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> died <extra_id_0> subject <extra_id_5> She <extra_id_1> <extra_id_0> gender <extra_id_5> She <extra_id_1> <extra_id_0> treatment <extra_id_5> Adriamycin ( doxorubicin ) chemotherapy <extra_id_1> <extra_id_0> drug <extra_id_5> Adriamycin <extra_id_1> <extra_id_0> route <extra_id_5> chemotherapy <extra_id_1> <extra_id_0> time elapsed <extra_id_5> 6 months <extra_id_1> <extra_id_0> effect <extra_id_5> Adriamycin toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> under <extra_id_0> subject <extra_id_5> a postmenopausal woman <extra_id_1> <extra_id_0> gender <extra_id_5> woman <extra_id_1> <extra_id_0> treatment <extra_id_5> tamoxifen <extra_id_1> <extra_id_0> drug <extra_id_5> tamoxifen <extra_id_1> <extra_id_0> effect <extra_id_5> Ovarian cancer arising from an endometriotic cyst <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> induced <extra_id_0> treatment <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> drug <extra_id_5> L - asparaginase <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> leukemia <extra_id_1> <extra_id_0> effect <extra_id_5> pancreatitis <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> receiving <extra_id_0> subject <extra_id_5> An 89 - year - old man <extra_id_1> <extra_id_0> age <extra_id_5> 89 - year - old <extra_id_1> <extra_id_0> gender <extra_id_5> man <extra_id_1> <extra_id_0> treatment <extra_id_5> long - term anticoagulation with warfarin sodium ( total weekly dosage of 19 mg ) <extra_id_1> <extra_id_0> drug <extra_id_5> warfarin sodium <extra_id_1> <extra_id_0> dosage <extra_id_5> 19 mg <extra_id_1> <extra_id_0> frequency <extra_id_5> weekly <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> anticoagulation <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> potential therapeutic event <extra_id_5> had <extra_id_0> subject <extra_id_5> patients with severe sepsis and high INR <extra_id_1> <extra_id_0> subject disorder <extra_id_5> high INR <extra_id_1> <extra_id_0> subject disorder <extra_id_5> severe sepsis <extra_id_1> <extra_id_0> treatment <extra_id_5> Treatment with tifacogin <extra_id_1> <extra_id_0> drug <extra_id_5> tifacogin <extra_id_1> <extra_id_0> treatment disorder <extra_id_5> severe sepsis <extra_id_1> <extra_id_0> effect <extra_id_5> no effect on all - cause mortality <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> related <extra_id_0> subject <extra_id_5> three patients <extra_id_1> <extra_id_0> population <extra_id_5> three <extra_id_1> <extra_id_0> treatment <extra_id_5> CCNU <extra_id_1> <extra_id_0> drug <extra_id_5> CCNU <extra_id_1> <extra_id_0> effect <extra_id_5> pulmonary toxicity <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> enhance <extra_id_0> treatment <extra_id_5> Clarithromycin or other potent inhibitors of CYP3A4 with repaglinide <extra_id_1> <extra_id_0> drug <extra_id_5> clarithromycin <extra_id_1> <extra_id_0> drug <extra_id_5> repaglinide <extra_id_1> <extra_id_0> combination drug <extra_id_5> clarithromycin <extra_id_1> <extra_id_0> combination drug <extra_id_5> repaglinide <extra_id_1> <extra_id_0> effect <extra_id_5> blood glucose - lowering effect and increase the risk of hypoglycemia <extra_id_1> <extra_id_1> <extra_id_1>
<extra_id_0> <extra_id_0> adverse event <extra_id_5> due <extra_id_0> treatment <extra_id_5> diltiazem <extra_id_1> <extra_id_0> drug <extra_id_5> diltiazem <extra_id_1> <extra_id_0> effect <extra_id_5> fever <extra_id_1> <extra_id_1> <extra_id_1>